<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S022352342100413X</prism:url><dc:identifier>doi:10.1016/j.ejmech.2021.113564</dc:identifier><eid>1-s2.0-S022352342100413X</eid><prism:doi>10.1016/j.ejmech.2021.113564</prism:doi><pii>S0223-5234(21)00413-X</pii><dc:title>Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>222</prism:volume><prism:startingPage>113564</prism:startingpage><prism:pageRange>113564</prism:pagerange><articleNumber>113564</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2021-10-15</prism:coverdate><prism:coverDisplayDate>15 October 2021</prism:coverdisplaydate><prism:copyright>© 2021 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Fan, Xiaohong</dc:creator><dc:creator>Li, Junfang</dc:creator><dc:creator>Long, Lin</dc:creator><dc:creator>Shi, Tao</dc:creator><dc:creator>Liu, Dan</dc:creator><dc:creator>Tan, Wen</dc:creator><dc:creator>Zhang, Honghua</dc:creator><dc:creator>Wu, Xiaoyan</dc:creator><dc:creator>Lei, Xiaoyong</dc:creator><dc:creator>Wang, Zhen</dc:creator><dc:description>
                  COX-2 and STAT3 are two key culprits in the glioma microenvironment. Herein, to inhibit COX-2 and block STAT3 signaling, we disclosed 27 N-anthraniloyl tryptamine compounds based on the combination of melatonin derivatives and N-substituted anthranilic acid derivatives. Among them, NP16 showed the best antiproliferative activity and moderate COX-2 inhibition. Of note, NP16 decreased the level of p-JAK2 and p-STAT3, and blocked the nuclear translocation of STAT3 in GBM cell lines. Moreover, NP16 downregulated the MMP-9 expression of BV2 cells in a co-culture system of BV2 and C6 glioma cells, abrogated the proliferative/invasive/migratory abilities of GBM cells, induced apoptosis by ROS and the Bcl-2-regulated apoptotic pathway, and induced obvious G2/M arrest in glioma cells in vitro. Furthermore, NP16 displayed favorable pharmacokinetic profiles covering long half-life (11.43 ± 0.43 h) and high blood-brain barrier permeability. Finally, NP16 effectively inhibited tumor growth, promoted the survival rate, increased the expression of E-cadherin and reduced overproduction of PGE2, MMP-9, VEGF-A and the level of p-STAT3 in tumor tissue, and improved the anxiety-like behavior in C6 glioma model. All these evidences demonstrated N-anthraniloyl tryptamine derivatives as multifunctional anti-glioma agents with high potency could drain the swamp to beat glioma.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Glioma</dcterms:subject><dcterms:subject>Tryptamine</dcterms:subject><dcterms:subject>COX-2</dcterms:subject><dcterms:subject>STAT3</dcterms:subject><dcterms:subject>Structure-activity relationship</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S022352342100413X" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S022352342100413X" rel="scidir"/></link></coredata><objects><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="542" height="598" size="91019">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="800" height="478" size="114056">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="800" height="466" size="60676">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="623" height="597" size="112849">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="800" height="610" size="149066">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="800" height="484" size="72263">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="800" height="352" size="66318">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="800" height="458" size="89349">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="ga1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="125" size="28488">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-ga1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="801" height="592" size="170187">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="800" height="760" size="163444">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="800" height="520" size="136664">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="800" height="650" size="217580">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr11.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="711" height="595" size="145609">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-sc3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="623" height="641" size="92871">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="148" height="163" size="7580">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="131" size="10624">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="128" size="5326">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="14237">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="215" height="164" size="18940">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="133" size="4845">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="96" size="11324">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="125" size="13211">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="ga1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="55" size="5783">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-ga1.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="162" size="15842">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="163" size="16582">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="142" size="16379">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="202" height="164" size="20361">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr11.sml?httpAccept=%2A%2F%2A</object><object ref="sc3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="196" height="164" size="8609">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-sc3.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="159" height="164" size="8370">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2402" height="2652" size="756128">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3544" height="2118" size="773134">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3544" height="2064" size="416870">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2758" height="2641" size="909813">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3543" height="2702" size="1210572">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3543" height="2144" size="526183">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3543" height="1557" size="503453">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3543" height="2028" size="691276">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="ga1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="553" size="192823">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-ga1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3545" height="2619" size="1036135">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3544" height="3367" size="1297975">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3541" height="2303" size="1182518">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3544" height="2881" size="1892170">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3150" height="2636" size="1083556">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-sc3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2757" height="2836" size="751225">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="8052234">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-mmc1.pdf?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="10353633">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100413X-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85107275400</scopus-id><scopus-eid>2-s2.0-85107275400</scopus-eid><link href="https://api.elsevier.com/content/abstract/scopus_id/85107275400" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20210529">2021-05-29</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20210529">2021-05-29</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20210603">2021-06-03</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20210603">2021-06-03</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-06-03T03:37:38</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S022352342100413X</xocs:eid>
      <xocs:pii-formatted>S0223-5234(21)00413-X</xocs:pii-formatted>
      <xocs:pii-unformatted>S022352342100413X</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2021.113564</xocs:doi>
      <xocs:item-stage>S250</xocs:item-stage>
      <xocs:item-version-number>S250.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523421X00116</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210626">2021-06-26T02:03:27.197185Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20211015</xocs:date-search-begin>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1622334904">2021-05-30T00:35:04.072125Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>222</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>222</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 222</xocs:vol-iss-suppl-text>
      <xocs:sort-order>3</xocs:sort-order>
      <xocs:first-fp>113564</xocs:first-fp>
      <xocs:article-number>113564</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>113564</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20211015</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>15 October 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-10-15</xocs:cover-date-start>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2021 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DESIGNSYNTHESISBIOLOGICALEVALUATIONNANTHRANILOYLTRYPTAMINEDERIVATIVESPLEIOTROPICMOLECULESFORTHERAPYMALIGNANTGLIOMA</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>FAN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>X</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Result</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biology</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Antiproliferative activity and COX-2 inhibition <ce:italic>in vitro</ce:italic>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>NP4, NP15 and NP16 decreased MMP-9 production in BV2 cells when cocultured with C6 glioma cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound NP16 down-regulated the expression of COX-2, <ce:italic>p</ce:italic>-JAK2 and <ce:italic>p</ce:italic>-STAT3, and inhibited the nuclear translocation of STAT3 in human glioma cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Antiproliferative activity of NP16 in human glioma cells determined by plate clone formation assay and EdU assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>G<ce:inf loc="post">2</ce:inf>/M phase cell-cycle arrest and apoptosis induction of NP16 in human glioma cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Apoptosis induction of NP16 in U251 and U87MG cells <ce:italic>via</ce:italic> downregulating the ratio of Bcl-2/Bax and enhancing the production of ROS in U251 and U87MG cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Anti-migration and anti-invasion effects of NP16 in U251 and U87MG cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Acute toxicity assay, preliminary pharmacokinetic study and the blood brain barrier permeability assay of NP16</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>NP16 inhibited tumor growth in a rat C6 glioma orthotopic model, without significant toxicity on rats in blank control group, when treated twice a day (50 mg/kg, i.p.)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>NP16 improved anxiety-like behavior, the angiogenesis and invasion in C6 glioma orthotopic model when treated twice a day (50 mg/kg, i.p.)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experiment procedure</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>General procedures</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>HPLC analysis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>General procedure for the preparation of compounds</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((2-fluorophenyl)amino)benzamide <ce:bold>(NP1)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((2-iodophenyl)amino)benzamide <ce:bold>(NP2)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-(o-tolylamino)benzamide <ce:bold>(NP3)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((2-aminophenyl)amino)benzamide <ce:bold>(NP4)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((3-fluorophenyl)amino)benzamide <ce:bold>(NP5)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((3-chlorophenyl)amino)benzamide <ce:bold>(NP6)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((3-bromophenyl)amino)benzamide <ce:bold>(NP7)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-(m-tolylamino)benzamide <ce:bold>(NP8)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((4-fluorophenyl)amino)benzamide <ce:bold>(NP9)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((4-chlorophenyl)amino)benzamide <ce:bold>(NP10)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.11</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((4-bromophenyl)amino)benzamide <ce:bold>(NP11)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.12</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-(p-tolylamino)benzamide <ce:bold>(NP12)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.13</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((4-methoxyphenyl)amino)benzamide <ce:bold>(NP13)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.14</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((4-(trifluoromethyl)phenyl)amino)benzamide <ce:bold>(NP14)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.15</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((4-(dimethylamino)phenyl)amino)benzamide (<ce:bold>NP15</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.16</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((3,4,5-trimethoxyphenyl)amino)benzamide <ce:bold>(NP16)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.17</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((2-chlorophenyl)amino)benzamide <ce:bold>(NP17)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.18</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((2-bromophenyl)amino)benzamide <ce:bold>(NP18)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.19</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((4-butylphenyl)amino)benzamide <ce:bold>(NP20)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.20</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-(pyridin-3-ylamino)benzamide <ce:bold>(NZ1)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.21</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((2-methylpyridin-3-yl)amino)benzamide <ce:bold>(NZ2)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.22</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((6-methylpyridin-3-yl)amino)benzamide <ce:bold>(NZ3)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.23</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((6-chloropyridin-3-yl)amino)benzamide <ce:bold>(NZ4)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.24</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((5-methylpyridin-3-yl)amino)benzamide <ce:bold>(NZ5)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.25</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-((5-bromopyridin-3-yl)amino)benzamide <ce:bold>(NZ6)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.26</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-(quinoxalin-6-ylamino)benzamide <ce:bold>(NZ7)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.3.27</xocs:item-toc-label>
                  <xocs:item-toc-section-title>N-(2-(1H-indol-3-yl)ethyl)-2-(quinolin-8-ylamino)benzamide <ce:bold>(NZ8)</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological evaluation</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell culture</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell viability assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>COX-2 inhibition assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Colony formation assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Ethynyl-20-deoxyuridine (EdU) incorporation assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell cycle analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell apoptosis assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Measurement of intracellular ROS generation</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>In vitro</ce:italic> cell invasion and migration assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.11</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Fluorescence confocal imaging</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.4.12</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Co-cultures assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Animal experiments</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.5.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Acute toxicity study</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.5.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Pharmacokinetics</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.5.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Blood-brain barrier permeability qualification of NP16 <ce:italic>in vivo</ce:italic>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.5.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>C6 orthotopic glioma model construction, dosing, recording survival time and weight</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.5.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Tumor volume and tumor weight measurement in C6 orthotopic glioma model</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.5.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Open-field test of rats with C6 glioma</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.5.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Tumor volume measurement by MRI test in C6 glioma rats</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.5.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Tumor tissue collection and processing</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.5.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Immunostaining of MMP-9 in C6 glioma rats</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Statistical analysis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-section-title>Abbreviations</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>HUSE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>59</xocs:ref-first-fp>
            <xocs:ref-last-lp>70</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>LOUIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>803</xocs:ref-first-fp>
            <xocs:ref-last-lp>820</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>MAHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>1311</xocs:ref-first-fp>
            <xocs:ref-last-lp>1333</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>VERHAAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>98</xocs:ref-first-fp>
            <xocs:ref-last-lp>110</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>THAKKAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1985</xocs:ref-first-fp>
            <xocs:ref-last-lp>1996</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>OSTROM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>x1</xocs:ref-first-fp>
            <xocs:ref-last-lp>x36</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>OSTROM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1254</xocs:ref-first-fp>
            <xocs:ref-last-lp>1262</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>VANLINDE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>183</xocs:ref-first-fp>
            <xocs:ref-last-lp>192</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>VOLLMANNZWERENZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>GRITSENKO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>DEGOOIJER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>763</xocs:ref-first-fp>
            <xocs:ref-last-lp>780</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>CUDDAPAH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>455</xocs:ref-first-fp>
            <xocs:ref-last-lp>465</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>42</xocs:ref-first-fp>
            <xocs:ref-last-lp>56</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>VANTELLINGEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>12</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>BROEKMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>482</xocs:ref-first-fp>
            <xocs:ref-last-lp>495</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>FERRER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1542</xocs:ref-first-fp>
            <xocs:ref-last-lp>1565</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>61</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>QIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1680</xocs:ref-first-fp>
            <xocs:ref-last-lp>1699</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>TIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>6327</xocs:ref-first-fp>
            <xocs:ref-last-lp>6337</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>OCHS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1142</xocs:ref-first-fp>
            <xocs:ref-last-lp>1154</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>JIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>360</xocs:ref-first-fp>
            <xocs:ref-last-lp>367</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>PALUMBO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>167</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>TADAHISASHONO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>4375</xocs:ref-first-fp>
            <xocs:ref-last-lp>4381</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>COOK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1379</xocs:ref-first-fp>
            <xocs:ref-last-lp>1389</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>GREENHOUGH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>377</xocs:ref-first-fp>
            <xocs:ref-last-lp>386</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>ZELENAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1257</xocs:ref-first-fp>
            <xocs:ref-last-lp>1270</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>MEGANWU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>82217</xocs:ref-first-fp>
            <xocs:ref-last-lp>82230</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>CHIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>118</xocs:ref-first-fp>
            <xocs:ref-last-lp>129</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>QIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>148</xocs:ref-first-fp>
            <xocs:ref-last-lp>156</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>MARCOTAFANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>32</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>JIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>1436</xocs:ref-first-fp>
            <xocs:ref-last-lp>1446</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>SEVER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>179</xocs:ref-first-fp>
            <xocs:ref-last-lp>186</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>93</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>XING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1655</xocs:ref-first-fp>
            <xocs:ref-last-lp>1670</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>JIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>75</xocs:ref-first-fp>
            <xocs:ref-last-lp>78</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>TUETTENBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>31</xocs:ref-first-fp>
            <xocs:ref-last-lp>40</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>SANTOSHKESARI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>300</xocs:ref-first-fp>
            <xocs:ref-last-lp>308</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>MULLARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>895</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>LUWOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>907</xocs:ref-first-fp>
            <xocs:ref-last-lp>911</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>IWAMARU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>2435</xocs:ref-first-fp>
            <xocs:ref-last-lp>2444</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>HUYNH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>82</xocs:ref-first-fp>
            <xocs:ref-last-lp>96</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>TAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>3601</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>HU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>29</xocs:ref-first-fp>
            <xocs:ref-last-lp>40</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>DALWADI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>7674</xocs:ref-first-fp>
            <xocs:ref-last-lp>7682</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>LO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>232</xocs:ref-first-fp>
            <xocs:ref-last-lp>245</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>KOPPIKAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>670</xocs:ref-first-fp>
            <xocs:ref-last-lp>672</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>BAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>511</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>MAITRA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>527</xocs:ref-first-fp>
            <xocs:ref-last-lp>541</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>208</xocs:ref-first-fp>
            <xocs:ref-last-lp>217</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>113027</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>FAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>112217</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>HAGMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>4360</xocs:ref-first-fp>
            <xocs:ref-last-lp>4369</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>HAMBARDZUMYAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>20</xocs:ref-first-fp>
            <xocs:ref-last-lp>27</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>958</xocs:ref-first-fp>
            <xocs:ref-last-lp>978</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>MARINARI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>1779990</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>YIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>2978</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>GE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>590941</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>QIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1381</xocs:ref-first-fp>
            <xocs:ref-last-lp>1393</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>PEDROJREAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>7611</xocs:ref-first-fp>
            <xocs:ref-last-lp>7618</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>LALIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>4999</xocs:ref-first-fp>
            <xocs:ref-last-lp>5009</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>GORRINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>931</xocs:ref-first-fp>
            <xocs:ref-last-lp>947</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>HAMBARDZUMYAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>252</xocs:ref-first-fp>
            <xocs:ref-last-lp>265</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>XIAOMINGRONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>83976</xocs:ref-first-fp>
            <xocs:ref-last-lp>83986</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>TONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>23</xocs:ref-first-fp>
            <xocs:ref-last-lp>32</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>OCALLAGHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>5239</xocs:ref-first-fp>
            <xocs:ref-last-lp>5250</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>TABOURET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1174</xocs:ref-first-fp>
            <xocs:ref-last-lp>1176</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>1168</xocs:ref-first-fp>
            <xocs:ref-last-lp>1177</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>APPOLLONI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1991</xocs:ref-first-fp>
            <xocs:ref-last-lp>2002</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref69">
            <xocs:ref-normalized-surname>SITARZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>475</xocs:ref-first-fp>
            <xocs:ref-last-lp>485</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref70">
            <xocs:ref-normalized-surname>JUNYANGLIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>645</xocs:ref-first-fp>
            <xocs:ref-last-lp>659</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref71">
            <xocs:ref-normalized-surname>GORADEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>56</xocs:ref-first-fp>
            <xocs:ref-last-lp>63</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref72">
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>TESTNO425ACUTEORALTOXICITYUPANDDOWNPROCEDURE</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>FANX2021X113564</xocs:refkey3>
         <xocs:refkey4ai>FANX2021X113564XX</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2023-06-03T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2023-06-03T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2021 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2021-05-21T04:30:00.573Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(21)00413-X</xocs:pii-formatted>
         <xocs:pii-unformatted>S022352342100413X</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S022352342100413X</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2021.113564</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-06-26T02:03:27.197185Z</xocs:timestamp>
         <xocs:cover-date-start>2021-10-15</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/MAIN/application/pdf/273e5a07c8f0839193288689e0af71ff/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>6730252</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>23</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S022352342100413X-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/PREVIEW/image/png/7570379586f10ff3b10f08ad2b7c5cf3/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>59565</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/sc1/DOWNSAMPLED/image/jpeg/24c4100598fd98e942e10f4c1f94f3cd/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>91019</xocs:filesize>
               <xocs:pixel-height>598</xocs:pixel-height>
               <xocs:pixel-width>542</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr6/DOWNSAMPLED/image/jpeg/a8bc5cfa46e97b54b7ee8bf01d4f1198/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>114056</xocs:filesize>
               <xocs:pixel-height>478</xocs:pixel-height>
               <xocs:pixel-width>800</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr9/DOWNSAMPLED/image/jpeg/92483da81a991506d0b80ca9b13dcaa6/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>60676</xocs:filesize>
               <xocs:pixel-height>466</xocs:pixel-height>
               <xocs:pixel-width>800</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr2/DOWNSAMPLED/image/jpeg/0bc57f7d5016e89244268c92f9b763bf/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>112849</xocs:filesize>
               <xocs:pixel-height>597</xocs:pixel-height>
               <xocs:pixel-width>623</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr1/DOWNSAMPLED/image/jpeg/31039c2e4a09e651c7c88a6569483549/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>149066</xocs:filesize>
               <xocs:pixel-height>610</xocs:pixel-height>
               <xocs:pixel-width>800</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/sc2/DOWNSAMPLED/image/jpeg/9047aa3eeb5a43bb4803db6faf77ffa1/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>72263</xocs:filesize>
               <xocs:pixel-height>484</xocs:pixel-height>
               <xocs:pixel-width>800</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr7/DOWNSAMPLED/image/jpeg/0597e0fdb2380f5c904fb65dff407dd9/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>66318</xocs:filesize>
               <xocs:pixel-height>352</xocs:pixel-height>
               <xocs:pixel-width>800</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr3/DOWNSAMPLED/image/jpeg/575a7b241431609ca548e9d49746010e/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>89349</xocs:filesize>
               <xocs:pixel-height>458</xocs:pixel-height>
               <xocs:pixel-width>800</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-ga1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/ga1/DOWNSAMPLED/image/jpeg/555ee429031197706083a72d9c9b967a/ga1.jpg</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>28488</xocs:filesize>
               <xocs:pixel-height>125</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr4/DOWNSAMPLED/image/jpeg/3ab60d120837256b453ad288cfe8d711/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>170187</xocs:filesize>
               <xocs:pixel-height>592</xocs:pixel-height>
               <xocs:pixel-width>801</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr10/DOWNSAMPLED/image/jpeg/efb404fdfe33da3c0c8f04f4f7fe8358/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>163444</xocs:filesize>
               <xocs:pixel-height>760</xocs:pixel-height>
               <xocs:pixel-width>800</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr8/DOWNSAMPLED/image/jpeg/45a0102828884f86cdd6e94904c42c17/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>136664</xocs:filesize>
               <xocs:pixel-height>520</xocs:pixel-height>
               <xocs:pixel-width>800</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr11/DOWNSAMPLED/image/jpeg/e7089ce38925346e52078e121b2fdecb/gr11.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>217580</xocs:filesize>
               <xocs:pixel-height>650</xocs:pixel-height>
               <xocs:pixel-width>800</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-sc3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/sc3/DOWNSAMPLED/image/jpeg/f25f69d9b1917cfef1f44dfbb0965705/sc3.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>145609</xocs:filesize>
               <xocs:pixel-height>595</xocs:pixel-height>
               <xocs:pixel-width>711</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr5/DOWNSAMPLED/image/jpeg/5e43534906145bdab4afa0be78357b47/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>92871</xocs:filesize>
               <xocs:pixel-height>641</xocs:pixel-height>
               <xocs:pixel-width>623</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/sc1/THUMBNAIL/image/gif/111d2bc8d0f31bec3ee82fb2564d7b1a/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7580</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>148</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr6/THUMBNAIL/image/gif/a499194649fd5404f580402d04288275/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10624</xocs:filesize>
               <xocs:pixel-height>131</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr9/THUMBNAIL/image/gif/528bf7c9f92971384b46f58cd1108f1c/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5326</xocs:filesize>
               <xocs:pixel-height>128</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr2/THUMBNAIL/image/gif/d5ab2e0cadef82aca5605c9d64b6c5af/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14237</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr1/THUMBNAIL/image/gif/f415d18ec713299de4caaee4e9a42caf/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>18940</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>215</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/sc2/THUMBNAIL/image/gif/ba9b88a1c635da8d83bb96ec96b9e122/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4845</xocs:filesize>
               <xocs:pixel-height>133</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr7/THUMBNAIL/image/gif/2758e46c71e7bc8d9ac201fe439ac5f3/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11324</xocs:filesize>
               <xocs:pixel-height>96</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr3/THUMBNAIL/image/gif/eeebb19effd53ba55831ba05de7b08d6/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13211</xocs:filesize>
               <xocs:pixel-height>125</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-ga1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/ga1/THUMBNAIL/image/gif/473bb4ffac0b5c0bea5dcb2528ee6379/ga1.sml</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5783</xocs:filesize>
               <xocs:pixel-height>55</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr4/THUMBNAIL/image/gif/80ac485fed7a169a553caf1e10f74cab/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>15842</xocs:filesize>
               <xocs:pixel-height>162</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr10/THUMBNAIL/image/gif/28ed2c727976ee5e26f03d8b0f9cbc39/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16582</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr8/THUMBNAIL/image/gif/1ab27d8e1ae5608bc50710828bc5ca66/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16379</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr11/THUMBNAIL/image/gif/bb3943d7b4bff9877ad69b2fce4c2663/gr11.sml</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>20361</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>202</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-sc3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/sc3/THUMBNAIL/image/gif/6163ff33fc43032f4b1c832b0801a241/sc3.sml</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8609</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>196</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr5/THUMBNAIL/image/gif/992be5aa2d5e0c993fac8cac86ece9e2/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8370</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>159</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/sc1/HIGHRES/image/jpeg/d8cd8c3b758945f6ed2e308ded981653/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>756128</xocs:filesize>
               <xocs:pixel-height>2652</xocs:pixel-height>
               <xocs:pixel-width>2402</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr6/HIGHRES/image/jpeg/8703175b04d3c8b77e684fd2b6836904/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>773134</xocs:filesize>
               <xocs:pixel-height>2118</xocs:pixel-height>
               <xocs:pixel-width>3544</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr9/HIGHRES/image/jpeg/5e8bdc3d63f831aa921b27c499c1625f/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>416870</xocs:filesize>
               <xocs:pixel-height>2064</xocs:pixel-height>
               <xocs:pixel-width>3544</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr2/HIGHRES/image/jpeg/b5f264c00469665d884d39a6eca6f988/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>909813</xocs:filesize>
               <xocs:pixel-height>2641</xocs:pixel-height>
               <xocs:pixel-width>2758</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr1/HIGHRES/image/jpeg/aa4b8f11918636f9ca97f996887ffe5d/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1210572</xocs:filesize>
               <xocs:pixel-height>2702</xocs:pixel-height>
               <xocs:pixel-width>3543</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/sc2/HIGHRES/image/jpeg/c2f839ccba3377bbf58ce645f86b0685/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>526183</xocs:filesize>
               <xocs:pixel-height>2144</xocs:pixel-height>
               <xocs:pixel-width>3543</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr7/HIGHRES/image/jpeg/704ba4c74fa13d0e3816e94f95bd34a8/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>503453</xocs:filesize>
               <xocs:pixel-height>1557</xocs:pixel-height>
               <xocs:pixel-width>3543</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr3/HIGHRES/image/jpeg/44cbcba63989cf1dbc1a56dc948e6105/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>691276</xocs:filesize>
               <xocs:pixel-height>2028</xocs:pixel-height>
               <xocs:pixel-width>3543</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-ga1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/ga1/HIGHRES/image/jpeg/60d88821d89f53362252ed6d142f052f/ga1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>192823</xocs:filesize>
               <xocs:pixel-height>553</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr4/HIGHRES/image/jpeg/6cfda0b2cae2d9edaa6d4add90767918/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1036135</xocs:filesize>
               <xocs:pixel-height>2619</xocs:pixel-height>
               <xocs:pixel-width>3545</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr10/HIGHRES/image/jpeg/dc1df3b51fc583b8c2eacf8939896688/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1297975</xocs:filesize>
               <xocs:pixel-height>3367</xocs:pixel-height>
               <xocs:pixel-width>3544</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr8/HIGHRES/image/jpeg/d259b9a3dcc4040e9c6935115f1c9552/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1182518</xocs:filesize>
               <xocs:pixel-height>2303</xocs:pixel-height>
               <xocs:pixel-width>3541</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr11/HIGHRES/image/jpeg/8bfcf57e5989a5b406852a0004a3eeda/gr11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1892170</xocs:filesize>
               <xocs:pixel-height>2881</xocs:pixel-height>
               <xocs:pixel-width>3544</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-sc3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/sc3/HIGHRES/image/jpeg/a2e63151a6242cff7fb43897ef4a7553/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1083556</xocs:filesize>
               <xocs:pixel-height>2636</xocs:pixel-height>
               <xocs:pixel-width>3150</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/gr5/HIGHRES/image/jpeg/6f6011086589ccb793c535c966485b09/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>751225</xocs:filesize>
               <xocs:pixel-height>2836</xocs:pixel-height>
               <xocs:pixel-width>2757</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-mmc1.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100413X/mmc1/MAIN/application/pdf/0887bdf809be2e1bd025f0e1f8442c5d/mmc1.pdf</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>8052234</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100413X-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>10353633</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10JR36D9B08/MAIN/application/pdf/daeaf1c3edb11a5141570a12f2549f07/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>113564</aid>
            <ce:article-number>113564</ce:article-number>
            <ce:pii>S0223-5234(21)00413-X</ce:pii>
            <ce:doi>10.1016/j.ejmech.2021.113564</ce:doi>
            <ce:copyright type="full-transfer" year="2021">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">
                     <ce:bold>NP4, NP15</ce:bold> and <ce:bold>NP16</ce:bold> obviously reduced MMP-9 expression in BV2 cells when cocultured with C6 glioma cells. (A) Representative immunofluorescence images of MMP-9 in BV2 cells (Magnification × 40, scale bar = 20 μm). Before the coculture assay, MTT assay was performed to evaluate cytotoxicity of compound <ce:bold>NP4, NP15</ce:bold> and <ce:bold>NP16</ce:bold> on BV2 cell to shrug off the influence of cytotoxicity. (B) The cell viability of all tested compounds at the indicated concentrations (1, 2, 4, 8 and 16 μM) were more than 80% compared with control. (C) Diagram illustrating a transwell segregated microglia-glioma coculture setup. (D) MMP-9 expression of BV2 measured by immunofluorescence intensity. Each error bar represents the mean ± SD of five random field. <ce:sup loc="post">###</ce:sup>P < 0.001, when compared to the monoculture cells; ∗∗P < 0.01, when compared to the coculture cells.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S022352342100413X/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">
                     <ce:bold>NP16</ce:bold> down-regulated the expression of COX-2, <ce:italic>p</ce:italic>-JAK2 and <ce:italic>p</ce:italic>-STAT3, and inhibited the nuclear translocation of STAT3 in both U251 and U87MG cells. (A, B) western blot analysis of the expression of JAK2<ce:italic>, p-</ce:italic>JAK2<ce:italic>, p-</ce:italic>STAT3 and STAT3: the cells were exposed to <ce:bold>NP16</ce:bold> at concentrations of 0.25, 1 and 4 μM for 8 h; western blot analysis of the expression of COX<ce:italic>-</ce:italic>2: the cells were exposed to <ce:bold>NP16</ce:bold> at concentrations of 1, 2 and 4 μM for 24 h (C, D, E) Relative expression of the target protein in the cell lysate was calculated using the ImageJ image analysis software. Each error bar represents the mean ± SD of three independent experiments. ∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001 versus the DMSO group. (F, G) representative fluorescence microscopy images: the cells were exposed to <ce:bold>NP16</ce:bold> at concentrations of 4 μM for 8 h. Compound <ce:bold>NP16</ce:bold> inhibited nuclear translocation of STAT3 in both U251 and U87MG cells. (Magnification × 60, scale bar = 20 μm).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S022352342100413X/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">
                     <ce:bold>NP16</ce:bold> elicited markable antiproliferative activities in U251 and U87MG. (A–B) The concentration-response curve for treated U87MG and U251 cells at 24. (C) Representative images of plate clone formation assays of U87MG and U251 cells exposed to <ce:bold>NP16</ce:bold> (0.5, 1, 2 and 4 μM) or equivalent volume of DMSO. Cell clones stained with 1% crystal violet reagent before being counted. The statistical data of the relative cell colony ratio to DMSO groups in U87MG (D) and U251 (E) after treatment of <ce:bold>NP16</ce:bold> of indicated concentration. All statistical data are presented as the mean ± SD of three experiments. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared with the control group.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S022352342100413X/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">
                     <ce:bold>NP16</ce:bold> elicited anti-proliferative activities in U251 and U87MG detected by Hoechst (blue) and EdU (red) staining assay. (A, B) The represented fluorescence images of Hoechst and EdU double staining assay in U87MG (A) and U251 (B) after treated by <ce:bold>NP16</ce:bold> or DMSO at 36 h (magnification, × 20, scale bar = 200 μm). Cells-stained red were considered as positive for proliferation. (C, D) The statistical data of the EdU-positive cell ratio calculated by the ratio of relative EdU fluorescence intensity (red) to relative Hoechst fluorescence intensity (blue) of U87MG and U251 were measured by image J. All statistical data are presented as the mean ± SD pooled from five random fields of view. ∗∗P < 0.01, ∗∗∗P < 0.001 compared with DMSO group, which were treated by equal volume of DMSO.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S022352342100413X/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">
                     <ce:bold>NP16</ce:bold> induced G<ce:inf loc="post">2</ce:inf>/M cell cycle arrest in U251 and U87MG. (A) Flow cytometric analysis of DNA content determined by PI staining after treatment with <ce:bold>NP16</ce:bold> (2, 4, 8 μM) for 48 h in U87MG and U251. (B, C) Percentage of each cell phase was statistically analyzed after treatment with difference dosages of <ce:bold>NP16</ce:bold> in U251 cells and U87MG cells. Control groups were treated by DMSO of same volume for comparison.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S022352342100413X/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">
                     <ce:bold>NP16</ce:bold> induced apoptosis of U251 and U87MG cells at 2, 4, 8 μM for 48 h. U251 cells (A) and U87MG (B) were respectively treated with <ce:bold>NP16</ce:bold> calculated by flow cytometry using Annexin V/PI double staining. Control groups were treated by DMSO of same volume for comparison.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S022352342100413X/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">
                     <ce:bold>NP16</ce:bold> induces U87MG and U251 apoptosis and ROS generation at various concentrations (1, 2 and 4 μM). (A, B): images of apoptosis-related key protein (Bax, Bcl-2 and cytochrome <ce:italic>c</ce:italic>) expression levels of detected by western blotting method in U251 and U87MG cells. β-actin was used as an internal loading control. (C–F) Quantification of Bcl-2/Bax ratio and cytochrome <ce:italic>c</ce:italic> using ImageJ software. (G) Representative DCFH-DA fluorescence images of U251 and U87MG cells treated by <ce:bold>NP16</ce:bold> at 1, 2 and 4 μM (magnification, × 10, scale bar = 500 μm). (H–I) Reactive ROS generation ratio qualified by DCFH-DA fluorescence density in U251 and U87MG using image J. All data are expressed as the mean ± SD pooled from three independent experiments. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 when compared with the DMSO groups treated by equivalent amounts of DMSO.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S022352342100413X/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">
                     <ce:bold>NP16</ce:bold> attenuated migration and invasion capacities of U251 and U87MG as well as MMP-9 protein expressions in U251 and U87MG cells <ce:italic>in vitro</ce:italic>. (A) Represented images of migration and invasion assays after treated by <ce:bold>NP16</ce:bold> in U87MG (magnification × 200, scale bar = 200 μm). (B, C) The statistical data of the invasive and migrative U87MG cells counted by Image J. (D) Represented images of migration and invasion assays after treated by <ce:bold>NP16</ce:bold> in U251 cells (magnification × 200, scale bar = 200 μm). (E, F) The statistical data of the invasive and migrative U251 cells counted by Image J. Data are presented as the mean ± SD pooled from five random fields of view. ∗P < 0.05; ∗∗P < 0.01, ∗∗∗P < 0.001 compared with DMSO group, which were treated by equal volume of DMSO. (G, H) The qualification of protein expressions of MMP-9 in U87MG and U251 after treatment of <ce:bold>NP16</ce:bold> at 1, 2, 4 μM by Image J. Data are shown as mean ± SD, n = 3. ∗∗P < 0.01, ∗∗∗P < 0.001 compared with DMSO group, which were treated by equal volume of DMSO. (I, J) Western bolt analysis using anti-MMP-9 antibody of cell lysates treated with or without NP16. β-actin was used as an internal loading control.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S022352342100413X/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">The blood brain barrier permeability assay of <ce:bold>NP16.</ce:bold> (A) <ce:bold>NP16</ce:bold> as standard control in blank cerebrospinal fluid; (B) The representative LC-MS chromatogram of cerebrospinal fluid collected from a rat 2 h after dosing with <ce:bold>NP16</ce:bold> (60 mg/kg, i. p.) and tandem mass spectrometry of <ce:bold>NP16</ce:bold> (highlighted by M + H<ce:sup loc="post">+</ce:sup>, M + Na<ce:sup loc="post">+</ce:sup>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Fig. 9</ce:alt-text>
               <ce:link locator="gr9" xlink:href="pii:S022352342100413X/gr9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig. 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">
                     <ce:bold>NP16</ce:bold> suppressed the growth of tumor in a rat C6 glioma orthotopic model <ce:italic>in vivo</ce:italic>. All data are expressed as the mean ± SD of individual groups of rats (n = 5 per group). (A) Images of MRI of all tumors on day 12 after tumor cell implantation. (B) Image of dissected tumors from the brains on day 13 after tumor cell implantation. (C) Body weight variation curve for every rat was recorded every three days after modelling. <ce:sup loc="post">#</ce:sup>P < 0.05, <ce:sup loc="post">##</ce:sup>P < 0.01, <ce:sup loc="post">###</ce:sup>P < 0.001 vs Sham; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs C6 group. (D) The weights of dissected tumors on day 13 after tumor cell implantation. ∗P < 0.05 vs C6 group. (E) The volumes of peeled tumors on day 13 after tumor cell implantation. Tumor volume was calculated by length × width [<ce:cross-ref id="crosref0575" refid="bib2">2</ce:cross-ref>] × 0.50 using radial measurements performed with calipers. ∗P < 0.05, ∗∗P < 0.01 vs C6 group. (F) Tumor tissue lysates were analyzed by Western blot. (G) The quantification of protein expressions of <ce:italic>E</ce:italic>-cadherin, VEGF-A and <ce:italic>p</ce:italic>-STAT3 in tumor lysates by Image J. <ce:sup loc="post">##</ce:sup>P < 0.01 vs Sham; ∗∗P < 0.01, ∗∗∗P < 0.001 vs C6 group. (H) Effect of <ce:bold>NP16</ce:bold> on PGE<ce:inf loc="post">2</ce:inf> level in peeled tumors measured by ELISA. <ce:sup loc="post">##</ce:sup>P < 0.01 vs Sham; ∗P < 0.05 vs C6 group.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Fig. 10</ce:alt-text>
               <ce:link locator="gr10" xlink:href="pii:S022352342100413X/gr10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig11">
               <ce:label>Fig. 11</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">
                     <ce:bold>NP16</ce:bold> improved anxiety-like behavior of C6 glioma rats and suppressed the angiogenesis and tendency of invasion in C6 glioma orthotopic model. (A) Representative images of open field test. (B) Statistical data of time spent in the central part. All data are expressed as the mean ± SEM pooled from six rats. ∗P < 0.05 when compared with the C6 groups, <ce:sup loc="post">##</ce:sup>P < 0.01 when compared with the sham groups. (C) The statistical data of IntDen value of MMP-9. All data are expressed as the mean ± SD pooled from six rats. ∗P < 0.05, ∗∗∗P < 0.001 when compared with the C6 groups. <ce:sup loc="post">###</ce:sup>P < 0.001 when compared with the sham groups. (D) Representative images of hematoxylin-eosin staining (HE, magnification × 200, scale bar = 200 μm in first row) and immunohistochemical staining (ICH) of MMP-9 (magnification × 200, scale bar = 200 μm in second row). The black arrows highlighted vessels in the glioma, and yellow arrows indicate glioma cells that invade normal brain tissue.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Fig. 11</ce:alt-text>
               <ce:link locator="gr11" xlink:href="pii:S022352342100413X/gr11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">A. New COX-2 inhibitors or agents to interrupt COX-2-mediated signaling cascade of GBM. B. JAK2/STAT3 pathway inhibitors for treating GBM. C. Rational design of <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives based on the combination of melatonin derivatives and <ce:italic>N</ce:italic>-phenylanthranilic acid derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0075" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S022352342100413X/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="fspara0070" view="all">Synthetic routes to twenty-seven <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0080" role="short">Scheme 2</ce:alt-text>
               <ce:link locator="sc2" xlink:href="pii:S022352342100413X/sc2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch3">
               <ce:label>Scheme 3</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="fspara0075" view="all">Structure-activity relationships of twenty-seven <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives in antiproliferation assay assessed by CCK-8 method (A) and in COX-2 inhibition assay (B).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0085" role="short">Scheme 3</ce:alt-text>
               <ce:link locator="sc3" xlink:href="pii:S022352342100413X/sc3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="tspara0010" view="all">Antiproliferation activity against three glioma cell lines and COX-2 inhibitory effects.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0090" role="short">Table 1</ce:alt-text>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col5" namest="col2" role="colgroup">IC50 (μM) ± SD<cross-ref id="crosref0580" refid="tbl1fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">U87MG</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">U251</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">C6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">hCOX-2</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26.25 ± 0.69</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.23 ± 0.07</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">32.85 ± 0.65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30.51 ± 0.99</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP4</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.21 ± 0.17</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP5</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.37 ± 0.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP6</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.24 ± 0.44</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.97 ± 1.66</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.45 ± 3.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.30 ± 1.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30.96 ± 1.65</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.82 ± 0.73</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.11 ± 0.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.46 ± 0.12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP10</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.89 ± 0.82</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.98 ± 0.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.68 ± 0.06</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">34.71 ± 5.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.73 ± 1.26</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.96 ± 0.14</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">32.34 ± 3.37</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.21 ± 0.27</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP14</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">35.74 ± 5.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.30 ± 0.58</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.43 ± 0.12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP16</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.78 ± 0.78</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.87 ± 0.48</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.23 ± 0.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.29 ± 0.27</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14.77 ± 0.79</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21.37 ± 0.31</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.85 ± 1.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NP20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18.24 ± 0.73</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">33.71 ± 0.79</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NZ1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25.19 ± 0.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.67 ± 0.80</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NZ2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.87 ± 0.86</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.60 ± 0.75</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NZ3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.62 ± 0.96</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.96 ± 0.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NZ4</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.46 ± 0.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.13 ± 0.48</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.96 ± 0.21</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NZ5</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.45 ± 0.54</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.65 ± 0.86</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NZ6</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25.12 ± 0.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NZ7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>NZ8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Melatonin</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Celecoxib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.16 ± 0.05</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">IC<ce:inf loc="post">50</ce:inf> (μM), the concentrations of compounds producing 50% inhibition on Glioma cells U87MG, U251, C6 and on COX-2 <ce:italic>in vitro</ce:italic>. The IC<ce:inf loc="post">50</ce:inf> values for antiproliferation activity and COX-2 inhibition were determined by a dose-response inhibition curve with GraphPad PRISM. All assays were determined in triplicate.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0085">
                  <ce:simple-para id="tspara0015" view="all">Pharmacokinetic profiles of <ce:bold>NP16</ce:bold> after intraperitoneal injection of 60 mg/kg<ce:cross-ref id="crosref0585" refid="tbl2fna">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0095" role="short">Table 2</ce:alt-text>
               <tgroup cols="2">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Parameter</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Value</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t<inf loc="post">1/2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.43 ± 3.42 h</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">T<inf loc="post">max</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.42 ± 0.00 h</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">C<inf loc="post">max</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.15 ± 0.17 μg/mL</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AUC<inf loc="post">0-t</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.33 ± 2.20 μg/mL × h</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0020" view="all">Pharmacokinetic parameters were determined using four animals (male Sprague Dawley rats) per group following a single dose of 60 mg/kg by intraperitoneal injection. The analyze method was Linear Trapezoidal in a non-compartmental model using the PK solver 2.0 computer program. Data for <ce:bold>NP16</ce:bold> were shown as the mean ± SD (n = 4).</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:title id="title0010">Design, synthesis and biological evaluation of <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S022352342100413X-454b84fecb6fe71ba3bf4294f5869594">
                  <ce:given-name>Xiaohong</ce:given-name>
                  <ce:surname>Fan</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S022352342100413X-1cc0724a73ea2525a1919f7098280403">
                  <ce:given-name>Junfang</ce:given-name>
                  <ce:surname>Li</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S022352342100413X-c1b997893945c00c8420ce2e454dc8ce">
                  <ce:given-name>Lin</ce:given-name>
                  <ce:surname>Long</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0035" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" orcid="0000-0003-4118-8022" author-id="S022352342100413X-383d333bd8300b661b830d2d3c1f579e">
                  <ce:given-name>Tao</ce:given-name>
                  <ce:surname>Shi</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0045" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au5" author-id="S022352342100413X-b5147701866b90aca99fb1d64f5dc909">
                  <ce:given-name>Dan</ce:given-name>
                  <ce:surname>Liu</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S022352342100413X-8457044177cf5522aed5737c3ceb33a1">
                  <ce:given-name>Wen</ce:given-name>
                  <ce:surname>Tan</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S022352342100413X-b6fd6fd2375861481fc1af380d8b2ded">
                  <ce:given-name>Honghua</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0060" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S022352342100413X-bc130f392184e520e18504cd81f3b830">
                  <ce:given-name>Xiaoyan</ce:given-name>
                  <ce:surname>Wu</ce:surname>
                  <ce:cross-ref id="crosref0065" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S022352342100413X-20572eb8afeb36e54146bec136364951">
                  <ce:given-name>Xiaoyong</ce:given-name>
                  <ce:surname>Lei</ce:surname>
                  <ce:cross-ref id="crosref0070" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0075" refid="cor3">
                     <ce:sup loc="post">∗∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au10" orcid="0000-0003-4134-1779" author-id="S022352342100413X-d7b4725b7fb6a09ec1f4a957e6a32fca">
                  <ce:given-name>Zhen</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0080" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0085" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0090" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S022352342100413X-8dc9d947de8dc2970bc8dcbac86296bf">
                  <ce:label>a</ce:label>
                  <ce:textfn>School of Pharmaceutical Science, University of South China, Hengyang, 421001, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>School of Pharmaceutical Science</sa:organization>
                     <sa:organization>University of South China</sa:organization>
                     <sa:city>Hengyang</sa:city>
                     <sa:postal-code>421001</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">School of Pharmaceutical Science, University of South China, Hengyang, 421001, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S022352342100413X-71434b8afaee7bd00cca9f9f134b5d90">
                  <ce:label>b</ce:label>
                  <ce:textfn>School of Pharmacy, Lanzhou University, Lanzhou, 730000, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>School of Pharmacy</sa:organization>
                     <sa:organization>Lanzhou University</sa:organization>
                     <sa:city>Lanzhou</sa:city>
                     <sa:postal-code>730000</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">School of Pharmacy, Lanzhou University, Lanzhou, 730000, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author. School of Pharmaceutical Science, University of South China, Hengyang, 421001, China.</ce:text>
                  <sa:affiliation>
                     <sa:organization>School of Pharmaceutical Science</sa:organization>
                     <sa:organization>University of South China</sa:organization>
                     <sa:city>Hengyang</sa:city>
                     <sa:postal-code>421001</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.;</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor3">
                  <ce:label>∗∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contributed equally to the work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="4" month="3" year="2021"/></ce:date-received>
            <ce:date-revised day="4" month="5" year="2021"/></ce:date-revised>
            <ce:date-accepted day="11" month="5" year="2021"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">COX-2 and STAT3 are two key culprits in the glioma microenvironment. Herein, to inhibit COX-2 and block STAT3 signaling, we disclosed 27 <ce:italic>N-</ce:italic>anthraniloyl tryptamine compounds based on the combination of melatonin derivatives and <ce:italic>N</ce:italic>-substituted anthranilic acid derivatives. Among them, <ce:bold>NP16</ce:bold> showed the best antiproliferative activity and moderate COX-2 inhibition. Of note, <ce:bold>NP16</ce:bold> decreased the level of <ce:italic>p-</ce:italic>JAK2 and <ce:italic>p</ce:italic>-STAT3, and blocked the nuclear translocation of STAT3 in GBM cell lines. Moreover, <ce:bold>NP16</ce:bold> downregulated the MMP-9 expression of BV2 cells in a co-culture system of BV2 and C6 glioma cells, abrogated the proliferative/invasive/migratory abilities of GBM cells, induced apoptosis by ROS and the Bcl-2-regulated apoptotic pathway, and induced obvious G<ce:inf loc="post">2</ce:inf>/M arrest in glioma cells <ce:italic>in vitro.</ce:italic> Furthermore, <ce:bold>NP16</ce:bold> displayed favorable pharmacokinetic profiles covering long half-life (11.43 ± 0.43 h) and high blood-brain barrier permeability. Finally, <ce:bold>NP16</ce:bold> effectively inhibited tumor growth, promoted the survival rate, increased the expression of <ce:italic>E</ce:italic>-cadherin and reduced overproduction of PGE<ce:inf loc="post">2</ce:inf>, MMP-9, VEGF-A and the level of <ce:italic>p</ce:italic>-STAT3 in tumor tissue, and improved the anxiety-like behavior in C6 glioma model. All these evidences demonstrated <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives as multifunctional anti-glioma agents with high potency could drain the swamp to beat glioma.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="ga1" xlink:href="pii:S022352342100413X/ga1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Glioma</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Tryptamine</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>COX-2</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>STAT3</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Structure-activity relationship</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0035" view="all">Malignant tumors pose an increasing threat to humans and have since gradually developed into a major public health problem. More seriously, glioma, originating from the glial cells, is one of the most refractory primary tumors in the central nervous system [<ce:cross-ref id="crosref0095" refid="bib1">1</ce:cross-ref>]. Particularly, among four grades (I ∼ IV) ascending malignancy classified by WHO [<ce:cross-ref id="crosref0100" refid="bib2">2</ce:cross-ref>], glioblastoma multiforme (GBM) is the most malignant subtype of glioma featured by high invasiveness, rapid progression, easy relapse and poor prognosis [<ce:cross-refs id="crosrefs0010" refid="bib3 bib4 bib5">3–5</ce:cross-refs>]. Moreover, with highest incidence accounting for all brain tumors (approximately 30%) and high mortality (approximately 12.8%) [<ce:cross-ref id="crosref0105" refid="bib6">6</ce:cross-ref>], GBM has been received increasing attention. However, the current treatment for GBM relies on surgical resection followed by radiotherapy and chemotherapy, all of which exhibit a poor therapeutic outcome in GBM patients, and the median survival is only 12–15 months [<ce:cross-ref id="crosref0110" refid="bib7">7</ce:cross-ref>,<ce:cross-ref id="crosref0115" refid="bib8">8</ce:cross-ref>]. A major hurdle for GBM treatment is that all GBM subtypes share the outstanding characteristic of aggressive invasion into the surrounding brain parenchyma, which prevents complete surgical resection or evades radiotherapy and underlies an adverse prognosis [<ce:cross-refs id="crosrefs0015" refid="bib9 bib10 bib11 bib12 bib13">9–13</ce:cross-refs>]. Furthermore, another main reason for treatment failures is the blood–brain barrier (BBB) impairs the delivery of chemotherapeutics [<ce:cross-ref id="crosref0120" refid="bib13">13</ce:cross-ref>,<ce:cross-ref id="crosref0125" refid="bib14">14</ce:cross-ref>]. Therefore, the development of anti-GBM agents with good blood-brain barrier permeability and the ability to overcome the aggressiveness of GBM is urgently needed.</ce:para>
                  <ce:para id="p0040" view="all">The invasion of GBM and poor prognosis are facilitated by the tumor inflammatory microenvironment [<ce:cross-ref id="crosref0130" refid="bib15">15</ce:cross-ref>,<ce:cross-ref id="crosref0135" refid="bib16">16</ce:cross-ref>]. The cyclooxygenase-2 (COX-2) is a key mediator of inflammatory pathways and COX-2 induction or overexpression in gliomas contributes to invasion, angiogenesis, immune evasion and chemotherapy resistance by upregulating the expression of tumor promoting cytokines, chemokines and the extracellular matrix, including prostaglandin E<ce:inf loc="post">2</ce:inf> (PGE<ce:inf loc="post">2</ce:inf>), interleukin 1β (IL-1β), interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), B-cell lymphoma 2 (Bcl-2), tryptophan-2,3-dioxygenase (TDO) and matrix metallopeptidase (MMPs) [<ce:cross-refs id="crosrefs0020" refid="bib17 bib18 bib19 bib20 bib21 bib22">17–22</ce:cross-refs>]. More importantly, the expression of COX-2 correlates positively with tumor grade and negatively with prognosis in patients with high-grade gliomas [<ce:cross-ref id="crosref0140" refid="bib21">21</ce:cross-ref>,<ce:cross-refs id="crosrefs0025" refid="bib23 bib24 bib25 bib26">23–26</ce:cross-refs>]. Besides, it needs to be emphasized that the hypoxic microenvironment of GBM induces COX-2 overexpression, which exacerbate the invasive and migratory capacities of the glioma cells, partially leading to ineffective surgical resection and high risk of recurrence [<ce:cross-ref id="crosref0145" refid="bib24">24</ce:cross-ref>,<ce:cross-refs id="crosrefs0030" refid="bib27 bib28 bib29">27–29</ce:cross-refs>]. Based on this, numerous researches on novel COX-2 inhibitors and agents to interrupt COX-2-mediated signaling cascade for GBM has been becoming new hotspots of researches (<ce:cross-ref id="crosref0150" refid="sch1">Scheme 1</ce:cross-ref>
                     <ce:float-anchor refid="sch1"/></ce:float-anchor>) [<ce:cross-ref id="crosref0155" refid="bib22">22</ce:cross-ref>,<ce:cross-refs id="crosrefs0035" refid="bib30 bib31 bib32 bib33 bib34">30–34</ce:cross-refs>]. Delightedly, recent evidence showed that COX-2 inhibitors sensitized cancer cells in combination with various antitumor agents, leading to synergistic anti-invasion and improved therapeutic efficacy [<ce:cross-ref id="crosref0160" refid="bib29">29</ce:cross-ref>,<ce:cross-refs id="crosrefs0040" refid="bib35 bib36 bib37">35–37</ce:cross-refs>].</ce:para>
                  <ce:para id="p0045" view="all">Signal transducer and activator of transcription 3 (STAT3) is another attractive but challenging cancer target of GBM molecular therapy because of constitutive activation of STAT3 in high-grade gliomas [<ce:cross-ref id="crosref0165" refid="bib38">38</ce:cross-ref>]. Several preclinical studies have demonstrated that targeting JAK2/STAT3 signaling pathway could significantly improve the survival rate (<ce:cross-ref id="crosref0170" refid="sch1">Scheme 1</ce:cross-ref>)[<ce:cross-ref id="crosref0175" refid="bib39">39</ce:cross-ref>,<ce:cross-ref id="crosref0180" refid="bib40">40</ce:cross-ref>]. Activated STAT3 ultimately triggers the transcription of downstream oncogenes involved in promoting tumor proliferation, invasion, angiogenesis, host immunosuppression, including Survivin, Bcl-2, IL-8, MMPs, etc. [<ce:cross-ref id="crosref0185" refid="bib41">41</ce:cross-ref>] In tumor microenvironment (TME), a variety of inflammatory cytokines (including IL-6, prostaglandin E<ce:inf loc="post">2</ce:inf> and IL-10) overexpression led to enhanced JAK2/STAT3 activity [<ce:cross-ref id="crosref0190" refid="bib42">42</ce:cross-ref>]. STAT3 plays a pivotal role in shaping TME by enhancing the communication between cancer and immune cells [<ce:cross-ref id="crosref0195" refid="bib43">43</ce:cross-ref>]. Interestingly, when STAT3 interact with EGFR/EGFRvIII, COX-2 gene expression could be activated, suggesting the possible existence of positive feedforward loop between STAT3 and COX-2.[<ce:cross-ref id="crosref0200" refid="bib31">31</ce:cross-ref>, <ce:cross-ref id="crosref0205" refid="bib44">44</ce:cross-ref>, <ce:cross-ref id="crosref0210" refid="bib45">45</ce:cross-ref>]<ce:sup loc="post">.</ce:sup>Therefore, inhibiting both COX-2 and STAT3 pathways could effectively cut off the vicious connection of the tumor microenvironment so that avoid tumor progression. Considering none of STAT3 inhibitors have been approved for clinical therapy due to its “undruggable” feature [<ce:cross-ref id="crosref0215" refid="bib46">46</ce:cross-ref>,<ce:cross-ref id="crosref0220" refid="bib47">47</ce:cross-ref>], suppressing STAT3 pathway that show promise as an alternative strategy can combine with chemotherapies to improve therapeutic effectiveness. Melatonin was found to exert anti-tumor effects partially <ce:italic>via</ce:italic> inhibiting STAT3 signaling, and as a kind of neurotransmitters, it is equipped with favorable blood brain barrier penetration [<ce:cross-ref id="crosref0225" refid="bib48">48</ce:cross-ref>,<ce:cross-ref id="crosref0230" refid="bib49">49</ce:cross-ref>]. Moreover, previous work reported the application of melatonin derivatives as anti-cancer agents by targeting the main culprit STAT3 [<ce:cross-ref id="crosref0235" refid="bib50">50</ce:cross-ref>,<ce:cross-ref id="crosref0240" refid="bib51">51</ce:cross-ref>]. On the other hand, <ce:italic>N</ce:italic>-phenylanthranilic acid derivatives are a well-known class of COX inhibitors, but its poor liquid solubility greatly restricted BBB permeability. <ce:sup loc="post">29, 31</ce:sup>In this respect, we rationally designed a novel series of <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives <ce:italic>via</ce:italic> combination of <ce:italic>N</ce:italic>-phenylanthranilic acid derivatives with melatonin derivatives (<ce:cross-ref id="crosref0245" refid="sch1">Scheme 1</ce:cross-ref>). The subsequent structure modification, biological evaluation <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> shed a sight of designing new candidates for GBM.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Result</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Chemistry</ce:section-title>
                     <ce:para id="p0050" view="all">To explore the SAR of the <ce:italic>N</ce:italic>-phenyl ring, twenty-seven novel compounds composed of three kinds <ce:bold>NP1-NP20</ce:bold> (<ce:italic>N</ce:italic>-phenyl derivatives), <ce:bold>NZ1-NZ8</ce:bold> (<ce:italic>N</ce:italic>-heterocycle and <ce:italic>N</ce:italic>-benzoheterocycle derivatives) were synthesized simply and efficiently in two steps by Ullmann coupling reaction mediated by Cu, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> and condensation reaction using EDCI, HOBt, Et<ce:inf loc="post">3</ce:inf>N (<ce:cross-ref id="crosref0250" refid="sch2">Scheme 2</ce:cross-ref>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>). All compounds were well characterized by NMR and mass spectrometry. Purities (>95%) of them were confirmed by HPLC, which established solid foundation for further activity investigations.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Biology</ce:section-title>
                     <ce:section id="sec2.2.1" view="all">
                        <ce:label>2.2.1</ce:label>
                        <ce:section-title id="sectitle0050">Antiproliferative activity and COX-2 inhibition <ce:italic>in vitro</ce:italic>
                        </ce:section-title>
                        <ce:para id="p0055" view="all">To conduct SAR study and screen the lead compounds, the growth inhibitory activities of <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives were assayed against two human cancer cell lines U251, U87MG, and one rat cancer cell line C6 using CCK-8 method [<ce:cross-ref id="crosref0255" refid="bib33">33</ce:cross-ref>]. The results displayed in <ce:cross-ref id="crosref0260" refid="tbl1">Table 1</ce:cross-ref>
                           <ce:float-anchor refid="tbl1"/></ce:float-anchor> and <ce:cross-ref id="crosref0265" refid="sch3">Scheme 3</ce:cross-ref>
                           <ce:float-anchor refid="sch3"/></ce:float-anchor> indicated that most <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives we synthesized appeared in almost close antiproliferative activities. Particularly, one special compound featured by 3,4,5-tri-OMe in <ce:italic>N</ce:italic>-phenyl ring (<ce:bold>NP16</ce:bold>) was the most active among twenty-seven compounds, with IC<ce:inf loc="post">50</ce:inf> values of 1.87 ± 0.48 μM (in U251), 4.23 ± 0.61 μM (in rat glioma cell C6) and 4.78 ± 0.78 μM (in U87MG).</ce:para>
                        <ce:para id="p0060" view="all">In detail, in the series of <ce:italic>N</ce:italic>-phenyl-derivatives (<ce:bold>NP1</ce:bold>-<ce:bold>NP20</ce:bold>), no specific steric effect was observed in cell proliferation assay, but the electronic effect had influence——the electron-donating substituents are advantageous to anti-tumor activity, especially in <ce:italic>meta</ce:italic>-and <ce:italic>para</ce:italic>-position. For instance, in <ce:italic>meta</ce:italic>-position, <ce:bold>NP8</ce:bold> (3-Me) achieved a significantly improved anti-tumor activity versus <ce:bold>NP5</ce:bold> (3-F), <ce:bold>NP6</ce:bold> (3-Cl) and <ce:bold>NP7</ce:bold> (3-Br). Similarly, in <ce:italic>para</ce:italic>-position, a decreasing trend of activity was observed in C6 cells when electron-donating substituents Me (<ce:bold>NP12</ce:bold>), OMe (<ce:bold>NP13</ce:bold>), <ce:italic>n</ce:italic>-butyl (<ce:bold>NP20</ce:bold>) changed to electron-withdrawing substituents F (<ce:bold>NP9</ce:bold>), Cl (<ce:bold>NP10</ce:bold>), Br (<ce:bold>NP11</ce:bold>) which verified the cruciality of electron effects. Differently, this benefit of electron-donating substituents was not clear in <ce:italic>ortho</ce:italic>-position, (F ≈ Cl ≈ I ≈ Br ≈ Me). In an attempt to improve the electron-donating effects, we introduced 3, 4, 5-tri-OMe substituents in <ce:italic>para</ce:italic>- and <ce:italic>meta</ce:italic>-position into <ce:italic>N</ce:italic>-phenyl ring. Fortunately, we obtained the most active compound <ce:bold>NP16</ce:bold> in all tested glioma cell lines, possibly due to the electron-donating effects in <ce:italic>para</ce:italic>- and <ce:italic>meta</ce:italic>-position. Besides, the <ce:italic>N</ce:italic>-heterocycle derivatives showed that in pyridin-3-amine derivatives, most compounds showed comparable activity. Subsequently, the replacement of phenyl rings by quinoline and quinoxaline ring caused reduction of anti-proliferative activity (compounds <ce:bold>NZ7</ce:bold> and <ce:bold>NZ8</ce:bold>, IC<ce:inf loc="post">50</ce:inf> > 40 μM).</ce:para>
                        <ce:para id="p0065" view="all">Besides, the data of COX-2 inhibition were also summarized in <ce:cross-ref id="crosref0270" refid="tbl1">Table 1</ce:cross-ref> and <ce:cross-ref id="crosref0275" refid="sch3">Scheme 3</ce:cross-ref>. For <ce:italic>N</ce:italic>-phenyl derivatives (<ce:bold>NP1</ce:bold>-<ce:bold>NP20</ce:bold>): <ce:bold>A)</ce:bold> Firstly, when substituents in <ce:italic>ortho</ce:italic>-position, the steric hindrance and the proposed hydrogen bonding but not the electronic effect influence the activity obviously. To be specific, the small-size groups (F, <ce:bold>NP1</ce:bold>) favored for COX-2 inhibition than the large-size groups (I, <ce:bold>NP2</ce:bold>). Besides, in the electron-withdrawing halogen substituents, the COX-2 inhibitory results showed that F-substituted compound in <ce:italic>ortho</ce:italic>-position had extremely higher COX-2 inhibition than Cl, Br, even I in the same position (<ce:bold>NP1</ce:bold> ≫ <ce:bold>NP2</ce:bold> ≈ <ce:bold>NP17</ce:bold> ≈ <ce:bold>NP18</ce:bold>), and the fact that the higher H-bonding capacities of F than Cl, Br, even I may explain the great difference in COX-2 inhibition of <ce:bold>NP1</ce:bold> (R<ce:inf loc="post">1</ce:inf> = F), <ce:bold>NP2</ce:bold> (R<ce:inf loc="post">1</ce:inf> = I), <ce:bold>NP17</ce:bold> (R<ce:inf loc="post">1</ce:inf> = Cl) and <ce:bold>NP18</ce:bold> (R<ce:inf loc="post">1</ce:inf> = Br). Likewise, in the electron-donating substituents, NH<ce:inf loc="post">2</ce:inf>-substituted compound in <ce:italic>ortho</ce:italic>-position also showed far better COX-2 inhibition than Me in the same position probably due to the easiness of forming hydrogen bonds in NH<ce:inf loc="post">2</ce:inf> than in Me (<ce:bold>NP4</ce:bold> ≫ <ce:bold>NP3</ce:bold>). <ce:bold>B)</ce:bold> Secondly, when moving the substituent to the <ce:italic>meta</ce:italic>-position, the electron effect is the most essential to the COX-2 inhibition activity. In detail, a dramatic increase in inhibitory activity was observed when the electron-withdrawing substituents (F, Cl, Br) changed to the electron-donating substituent (Me) (Me ≫ F ≈ Cl ≈ Br; <ce:bold>NP8</ce:bold> ≫ <ce:bold>NP5</ce:bold> ≈ <ce:bold>NP6</ce:bold> ≈ <ce:bold>NP7</ce:bold>). <ce:bold>C)</ce:bold> Thirdly, in the <ce:italic>para</ce:italic>-position, the electron effect and hydrogen bonding interaction may be the major factor that influencing the COX-2 inhibitory activity. In the activity order of NMe<ce:inf loc="post">2</ce:inf> > F > Cl > Br > Me > OMe ≫ CF<ce:inf loc="post">3</ce:inf> ≈ <ce:italic>n</ce:italic>-butyl (<ce:bold>NP15</ce:bold> > <ce:bold>NP9</ce:bold> > <ce:bold>NP10</ce:bold> > <ce:bold>NP11</ce:bold> > <ce:bold>NP12</ce:bold> > <ce:bold>NP13</ce:bold> > <ce:bold>NP14</ce:bold> ≈ <ce:bold>NP20</ce:bold>), electron-withdrawing substituted compounds (Cl, Br) showed slightly better COX-2 inhibitory activity than the electron-donating substituted compounds (Me, OMe, NMe<ce:inf loc="post">2</ce:inf>). The special activity results of NMe<ce:inf loc="post">2</ce:inf> and F-substituted compounds in <ce:italic>ortho</ce:italic>-position is probably due to the easiness of forming hydrogen bonding. Besides, CF<ce:inf loc="post">3</ce:inf> group is an exception with very weak COX-inhibition effect (IC<ce:inf loc="post">50</ce:inf> > 40 μM), suggesting the particularity of CF<ce:inf loc="post">3</ce:inf> [<ce:cross-ref id="crosref0280" refid="bib52">52</ce:cross-ref>]. Especially, adding multi-substituent 3,4,5-tri-OMe into N-phenyl ring (<ce:bold>NP16</ce:bold>, IC<ce:inf loc="post">50</ce:inf> = 8.28 ± 0.27 μM) led to a slight reduction of activity compared with 3-OMe-substitued phenyl rings (<ce:bold>NP13,</ce:bold> IC<ce:inf loc="post">50</ce:inf> = 6.21 ± 0.27 μM). Interestingly, it was found that the IC<ce:inf loc="post">50</ce:inf> values of COX-2 inhibition after introducing substituents in the <ce:italic>para</ce:italic>-position of N-phenyl ring were significantly better than the introduction of the same substituents at <ce:italic>ortho</ce:italic>- or <ce:italic>meta</ce:italic>-positions, indicating that reducing steric hindrance between N-phenyl ring and amide-phenyl ring is conducive to binding to COX-2 (<ce:bold>NP9</ce:bold> > <ce:bold>NP1</ce:bold> and <ce:bold>NP5</ce:bold>; <ce:bold>NP10</ce:bold> > <ce:bold>NP6</ce:bold> and <ce:bold>NP17</ce:bold>; <ce:bold>NP11</ce:bold> > <ce:bold>NP7</ce:bold> and <ce:bold>NP18</ce:bold>; <ce:bold>NP12</ce:bold> > <ce:bold>NP3</ce:bold> and <ce:bold>NP8</ce:bold>).</ce:para>
                        <ce:para id="p0070" view="all">Subsequently, the replacement of phenyl rings by pyridine rings (<ce:bold>NZ1</ce:bold>, IC<ce:inf loc="post">50</ce:inf> = 23.67 ± 0.80 μM) caused reduction of activity. In addition, introducing substituent in 4-position but not in other positions is obviously benefit for the activity. For instance, <ce:bold>NZ3</ce:bold> and <ce:bold>NZ4</ce:bold> were better than <ce:bold>NZ1</ce:bold> on COX-2 inhibition (4-Me ≈ 4-Cl ≫ 4-H; <ce:bold>NZ3</ce:bold> ≈ <ce:bold>NZ4</ce:bold> ≫ <ce:bold>NZ1</ce:bold>). In contrast, no obvious change or even decrease in activity were seen on introduction of substituents in 2- or 5-position of pyridine rings compared with non-substituted <ce:italic>N</ce:italic>-pyridine derivatives (4-H ≈ 2-Me ≈ 5-Me > 5-Br; <ce:bold>NZ1</ce:bold> ≈ <ce:bold>NZ2</ce:bold> ≈ <ce:bold>NZ5</ce:bold> ><ce:bold>NZ6</ce:bold>). Moreover, replacement of pyridine group with benzoheterocycle is devoid of activity (<ce:bold>NZ7</ce:bold>, <ce:bold>NZ8</ce:bold>: IC<ce:inf loc="post">50</ce:inf> > 40 μM), indicating that lager-size ring system disfavored for COX-2 inhibition activity (<ce:bold>NZ1</ce:bold> ≫ <ce:bold>NZ7</ce:bold> ≈ <ce:bold>NZ8</ce:bold>).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.2" view="all">
                        <ce:label>2.2.2</ce:label>
                        <ce:section-title id="sectitle0055">NP4, NP15 and NP16 decreased MMP-9 production in BV2 cells when cocultured with C6 glioma cells</ce:section-title>
                        <ce:para id="p0075" view="all">Glioma tissue consists of tumor cells and up to 30–50% of glioma-associated microglia/macrophages (GAMs) and negatively correlates with patient survival [<ce:cross-ref id="crosref0285" refid="bib53">53</ce:cross-ref>]. Recently, an increasing number of evidence suggesting that microglia is a key event in the progression and infiltration of glioma [<ce:cross-ref id="crosref0290" refid="bib54">54</ce:cross-ref>,<ce:cross-ref id="crosref0295" refid="bib55">55</ce:cross-ref>]. In detail, M2 phenotype tumor-reprogrammed microglial which infiltrated gliomas secreted immunosuppressive cytokines and chemokines to assist glioma invasion [<ce:cross-ref id="crosref0300" refid="bib56">56</ce:cross-ref>]. Mechanistically, COX-2 in GAMs induces MMP-9 expression and facilitate tumor cells invasion [<ce:cross-ref id="crosref0305" refid="bib57">57</ce:cross-ref>]. <ce:bold>NP4</ce:bold> and <ce:bold>NP15</ce:bold> show most COX-2 inhibitory action among twenty-seven compounds as demonstrated in <ce:cross-ref id="crosref0310" refid="tbl1">Table 1</ce:cross-ref>. Therefore, we evaluated compound <ce:bold>NP4</ce:bold>, <ce:bold>NP15</ce:bold> and <ce:bold>NP16</ce:bold> suppress the MMP-9 production in BV2 cells which was induced by C6 cells. According to the result, MMP-9 expression of BV2 was elevated significantly when cocultured with C6 cells, while after 2 μM of <ce:bold>NP4</ce:bold>, <ce:bold>NP15</ce:bold> and <ce:bold>NP16</ce:bold> treatment<ce:bold>,</ce:bold> MMP-9 expression was obviously decreased and these compounds exerted comparable activity (<ce:cross-ref id="crosref0315" refid="fig1">Fig. 1</ce:cross-ref>
                           <ce:float-anchor refid="fig1"/></ce:float-anchor>). Besides, owing to the best anti-proliferative activity on three glioma cell lines and favorable inhibition on MMP-9 production of <ce:bold>NP16</ce:bold>, it was chosen for in subsequent experiments.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.3" view="all">
                        <ce:label>2.2.3</ce:label>
                        <ce:section-title id="sectitle0060">Compound NP16 down-regulated the expression of COX-2, <ce:italic>p</ce:italic>-JAK2 and <ce:italic>p</ce:italic>-STAT3, and inhibited the nuclear translocation of STAT3 in human glioma cells</ce:section-title>
                        <ce:para id="p0080" view="all">Studies reported that PGE<ce:inf loc="post">2</ce:inf>/COX2 prompts STAT3 activation in many cancers, especially in GBM[<ce:cross-ref id="crosref0320" refid="bib31">31</ce:cross-ref>]. In turn, when STAT3 interact with EGFR/EGFRvIII, COX-2 gene expression could be activated [<ce:cross-ref id="crosref0325" refid="bib45">45</ce:cross-ref>], suggesting that co-inhibiting COX-2/STAT3 may block the positive loop thereby prompt the anti-glioma effects. To preliminarily explore the possible mechanism of action against anti-glioma of <ce:bold>NP16</ce:bold>, the expression of <ce:italic>p</ce:italic>-JAK2, JAK2, <ce:italic>p</ce:italic>-STAT3, STAT3 and COX-2 was evaluated by western blot assay and the nuclear translocation of STAT3 was accessed by immunofluorescence assay. The results showed that <ce:bold>NP16</ce:bold> displayed a concentration dependently decrease on the expression of phosphorylated JAK2 and STAT3, and consequently inhibited the nuclear translocation of STAT3 in U251 cells and U87MG cells (<ce:cross-ref id="crosref0330" refid="fig2">Fig. 2</ce:cross-ref>
                           <ce:float-anchor refid="fig2"/></ce:float-anchor>). Moreover, COX-2 expression was markedly down-regulated after exposure to 2 and 4 μM of <ce:bold>NP16</ce:bold> for 24 h.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.4" view="all">
                        <ce:label>2.2.4</ce:label>
                        <ce:section-title id="sectitle0065">Antiproliferative activity of NP16 in human glioma cells determined by plate clone formation assay and EdU assay</ce:section-title>
                        <ce:para id="p0085" view="all">To verify the antiproliferative activity of <ce:bold>NP16</ce:bold> in human glioma cells, plate clone formation assay and EdU assay were performed. Of note, over eighty percent of U87MG cells and U251 cells survived after <ce:bold>NP16</ce:bold> treatment at the concentration less than 4 μM at 24 h, indicating that the treatment condition of this time points and concentration is suitable for other assays, including migration and invasion assays which require no obvious cytotoxic treatments (<ce:cross-ref id="crosref0335" refid="fig8">Fig. 8</ce:cross-ref>). We examined the suppression effects of <ce:bold>NP16</ce:bold> on infinite proliferative capability of individual U251 and U87MG cells <ce:italic>via</ce:italic> plate clone formation assay. As indicated in <ce:cross-ref id="crosref0340" refid="fig3">Fig. 3</ce:cross-ref>
                           <ce:float-anchor refid="fig3"/></ce:float-anchor> 
                           <ce:bold>C-E</ce:bold>, <ce:bold>NP16</ce:bold> dose-dependently suppressed colony formation of U87MG and U251 at the tested concentrations. To be specific, after exposure to 4 μM of <ce:bold>NP16</ce:bold> for 14 days, the relative colony formation ratios of U251 and U87MG were 0 and 5.33%, respectively.</ce:para>
                        <ce:para id="p0090" view="all">Furthermore, in order to establish an intuitive and dynamic evaluation of <ce:bold>NP16</ce:bold> in antiproliferative respects, 5-ethynyl-2′-deoxyuridine (EdU) assay as a powerful tool to determine cell proliferative kinetics were carried out [<ce:cross-ref id="crosref0345" refid="bib58">58</ce:cross-ref>]. Consistently, as shown in <ce:cross-ref id="crosref0350" refid="fig4">Fig. 4</ce:cross-ref>
                           <ce:float-anchor refid="fig4"/></ce:float-anchor>, EdU assay revealed <ce:bold>NP16</ce:bold> caused obvious decreases in proliferation of U87MG and U251 cells at 2 and 4 μM qualified by EdU-positive cells ratios of them when compared with the control groups (P < 0.05). All results mentioned above clearly demonstrated that <ce:bold>NP16</ce:bold> had a potent anti-proliferative effect on glioma cells, which warranted further investigation on the antiproliferative mechanism.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.5" view="all">
                        <ce:label>2.2.5</ce:label>
                        <ce:section-title id="sectitle0070">G<ce:inf loc="post">2</ce:inf>/M phase cell-cycle arrest and apoptosis induction of NP16 in human glioma cells</ce:section-title>
                        <ce:para id="p0095" view="all">To further understand the anti-proliferative mechanism of <ce:bold>NP16</ce:bold>, we examined its effects on disturbing cell cycle and inducing apoptosis in U251 and U87MG cells. As shown in <ce:cross-ref id="crosref0355" refid="fig5">Fig. 5</ce:cross-ref>
                           <ce:float-anchor refid="fig5"/></ce:float-anchor>, G<ce:inf loc="post">2</ce:inf>/M arrest of U251 and U87MG were observed after a 48 h-exposure to <ce:bold>NP16</ce:bold>. In addition, the arrests were in a trend of dose-dependent change. To be concrete, after treating with <ce:bold>NP16</ce:bold> at 8 μM for 48 h, the ratios in the G<ce:inf loc="post">2</ce:inf>/M phase of the cell cycle were 63.7% in U251 and 68.2% in U87MG, respectively. In contrast, the ratios of untreated U251 cells and U87MG in G<ce:inf loc="post">2</ce:inf>/M cell cycle were 11.9% and 8.0%, respectively, which were significantly lower than those in the <ce:bold>NP16</ce:bold> treatment groups. Thus, <ce:bold>NP16</ce:bold> could significantly arrest the U251 and U87MG cell cycle at the G<ce:inf loc="post">2</ce:inf>/M phase. In view that most NSAIDs displayed G<ce:inf loc="post">0</ce:inf>/G<ce:inf loc="post">1</ce:inf> arrest on glioma cells, the observation of G<ce:inf loc="post">2</ce:inf>/M arrest of <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives implied the subtle difference between classical NSAIDs drugs and our synthesized compounds.</ce:para>
                        <ce:para id="p0100" view="all">Then the apoptosis induction of <ce:bold>NP16</ce:bold> was investigated. As illustrated in <ce:cross-ref id="crosref0360" refid="fig6">Fig. 6</ce:cross-ref>
                           <ce:float-anchor refid="fig6"/></ce:float-anchor>, <ce:bold>NP16</ce:bold> caused significant apoptosis of U251 and U87MG cells, particular at higher doses, while the percentage of apoptotic cells in the DMSO group was very low (no more that 4% in U251 cells and no more than 2% in U87MG cells). Interestingly, after 2, 4, 8 μM of <ce:bold>NP16</ce:bold> treatments for 48 h, both U251 and U87MG cells in late apoptosis were more than in early apoptosis. In summary, <ce:bold>NP16</ce:bold> could induce apoptosis and G<ce:inf loc="post">2</ce:inf>/M arrest to restrict rapid proliferation of glioma cells <ce:italic>in vitro</ce:italic>.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.6" view="all">
                        <ce:label>2.2.6</ce:label>
                        <ce:section-title id="sectitle0075">Apoptosis induction of NP16 in U251 and U87MG cells <ce:italic>via</ce:italic> downregulating the ratio of Bcl-2/Bax and enhancing the production of ROS in U251 and U87MG cells</ce:section-title>
                        <ce:para id="p0105" view="all">It is reported that the overexpression of Bcl-2 (antiapoptotic protein) in tumor cells is regulated by the constitutively active STAT3 and COX-2 [<ce:cross-ref id="crosref0365" refid="bib59">59</ce:cross-ref>,<ce:cross-ref id="crosref0370" refid="bib60">60</ce:cross-ref>]. To further verify the molecular mechanisms of apoptotic induction of <ce:bold>NP16</ce:bold>, we examined the expressions of Bcl-2, Bax (proapoptotic proteins) and cytochrome <ce:italic>c</ce:italic> in U251 and U87MG cells by western blotting. As shown in <ce:cross-ref id="crosref0375" refid="fig7">Fig. 7</ce:cross-ref>
                           <ce:float-anchor refid="fig7"/></ce:float-anchor>
                           <ce:float-anchor refid="fig8"/></ce:float-anchor> (A-F), the results showed that treatment of cells with 1, 2 and 4 μM of <ce:bold>NP16</ce:bold> caused mitochondrial apoptosis. Specifically, the drastic decreases of Bcl-2/Bax ratios in U87MG and U251 after treated by 2 and 4 μM of <ce:bold>NP16</ce:bold> were observed compared with control group, elucidating that <ce:bold>NP16</ce:bold> promoted the mitochondrial permeability and the mitochondrial release of cytochrome <ce:italic>c</ce:italic>. Subsequently, <ce:bold>NP16</ce:bold> could also remarkably enhances the levels of cytochrome <ce:italic>c</ce:italic> at 1, 2, 4 μM in U87MG and U251, suggesting that cytochrome <ce:italic>c</ce:italic> was released from the intermembrane space of mitochondria into cytoplasm to trigger a rapid apoptotic mechanism involving Apaf-1–mediated caspase activation after <ce:bold>NP16</ce:bold> treatment. Taken together, <ce:bold>NP16</ce:bold> induced the apoptosis by the dramatic reduction of Bcl-2/Bax ratio and evident increase on the expression of cytochrome <ce:italic>c</ce:italic>.</ce:para>
                        <ce:para id="p0110" view="all">ROS activation has been reported to induce apoptosis in cancer cells [<ce:cross-ref id="crosref0380" refid="bib61">61</ce:cross-ref>]. As anticipated, <ce:bold>NP16</ce:bold> treatment dose-dependently boosted ROS generation in U87MG and U251 at 1, 2 and 4 μM in <ce:cross-ref id="crosref0385" refid="fig7">Fig. 7</ce:cross-ref> (G-I) when compared with corresponding DMSO groups. This result may indicate that <ce:bold>NP16</ce:bold>-induce apoptosis partly <ce:italic>via</ce:italic> promoting ROS generation.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.7" view="all">
                        <ce:label>2.2.7</ce:label>
                        <ce:section-title id="sectitle0080">Anti-migration and anti-invasion effects of NP16 in U251 and U87MG cells</ce:section-title>
                        <ce:para id="p0115" view="all">GBM is featured by highly invasion and infiltration of surrounding brain tissue which contributes to tumor recurrence and surgical failure[<ce:cross-ref id="crosref0390" refid="bib62">62</ce:cross-ref>]. Notably, COX-2 is highly associated with migration and invasion capacity mediated by PGE<ce:inf loc="post">2</ce:inf> [<ce:cross-ref id="crosref0395" refid="bib28">28</ce:cross-ref>,<ce:cross-refs id="crosrefs0045" refid="bib63 bib64 bib65">63–65</ce:cross-refs>]. Moreover, STAT3 as critical transcription factors could promote migration and invasion capacity. Herein, to explore whether <ce:bold>NP16</ce:bold> can suppress the migration and invasion of U251 and U87MG is worth considering. As depicted in <ce:cross-ref id="crosref0400" refid="fig8">Fig. 8</ce:cross-ref>, <ce:bold>NP16</ce:bold> exerted dose-dependently obvious anti-migratory and anti-invasive properties of U251 and U87MG. Additionally, the inhibitory effects of <ce:bold>NP16</ce:bold> on invasion were apparently weaker than that on migration at the corresponding concentrations. The possible reason is that the invasion process is more complicated due to matrix degradation involved. Specifically, the implementation of matrix degradation is conducted by two major components of matrix metalloproteinases family, MMP-9 and MMP-2 [<ce:cross-ref id="crosref0405" refid="bib66">66</ce:cross-ref>]. As shown in <ce:cross-ref id="crosref0410" refid="fig8">Fig. 8</ce:cross-ref>, <ce:bold>NP16</ce:bold> dose-dependently reduced the protein expressions of MMP-9 in U251 and U87MG cells at 2 and 4 μM, partially explaining the positive results of invasion assays. All the <ce:italic>in-vitro</ce:italic> data demonstrated that <ce:bold>NP16</ce:bold> elicited outstanding antiproliferative capacities, remarkable anti-migratory and anti-invasive properties at very low doses (less than 4 μM), thus implying its potential and rationality to perform in-<ce:italic>vivo</ce:italic> experiments.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.8" view="all">
                        <ce:label>2.2.8</ce:label>
                        <ce:section-title id="sectitle0085">Acute toxicity assay, preliminary pharmacokinetic study and the blood brain barrier permeability assay of NP16</ce:section-title>
                        <ce:para id="p0120" view="all">In order to evaluate <ce:italic>in vivo</ce:italic> toxicity of <ce:bold>NP16</ce:bold> and provide reference for administered dose <ce:italic>in vivo</ce:italic>, the acute toxicity assay in Kunming mice was performed. The results showed that <ce:bold>NP16</ce:bold> was safe by intraperitoneal administration as high as 1000 mg/kg body weight, causing no mortality and no obvious behavioral change during 14 days of observation.</ce:para>
                        <ce:para id="p0125" view="all">Moreover, to investigate whether pharmacokinetic profile of <ce:bold>NP16</ce:bold> is compactable with administration <ce:italic>in vivo</ce:italic>, preliminary pharmacokinetic study on <ce:bold>NP16</ce:bold> was conducted by LC/MS qualification. To our delight, selected compound <ce:bold>NP16</ce:bold> displayed an acceptable pharmacological profile. As outlined in <ce:cross-ref id="crosref0415" refid="tbl2">Table 2</ce:cross-ref>
                           <ce:float-anchor refid="tbl2"/></ce:float-anchor> and <ce:cross-ref id="crosref0420" refid="appsec1">Figure S1</ce:cross-ref>, after intraperitoneal injection, <ce:bold>NP16</ce:bold> was quickly absorbed into systemic circulation and reached a peak value of 1.15 ± 0.17 μg/mL at 0.42 h. Then the concentration of <ce:bold>NP16</ce:bold> in plasma was reduced fast from that time point to 9 h. Subsequently, the plasma concentration was maintained at approximately 0.20 μg/mL up to 24 h, in concert with that the long half-life (11.43 ± 3.42 h) of <ce:bold>NP16</ce:bold>. In a word, the acceptable safety profile and pharmacological properties of <ce:bold>NP16</ce:bold> supported the studies of <ce:bold>NP16</ce:bold> in an orthotopic rat model of GBM.</ce:para>
                        <ce:para id="p0130" view="all">Moreover, the blood brain barrier (BBB) poses significant impediments to the treatment of malignant glioma of the brain. Herein, the blood brain barrier permeability is the key to ensuring the <ce:italic>in</ce:italic>-<ce:italic>vivo</ce:italic> efficacy of anti-glioma agents. Fortunately, after intraperitoneally injecting 60 mg/kg of <ce:bold>NP16,</ce:bold> the cerebrospinal fluid (CSF) was removed for determining the BBB permeability of <ce:bold>NP16</ce:bold>. As shown in <ce:cross-ref id="crosref0425" refid="fig9">Fig. 9</ce:cross-ref>
                           <ce:float-anchor refid="fig9"/></ce:float-anchor>, 2 h after intraperitoneal injection, the concentration of <ce:bold>NP16</ce:bold> in CSF was 0.20 ± 0.07 μg/mL (mean ± SD), simultaneously in the plasma was 0.52 ± 0.27 μg/mL (mean ± SD), and the calculated brain/blood ratio is 0.38:1, implying that <ce:bold>NP16</ce:bold> exerted favorable BBB permeability and afforded the viable evidence of glioma orthotopic model <ce:italic>in vivo</ce:italic>.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.9" view="all">
                        <ce:label>2.2.9</ce:label>
                        <ce:section-title id="sectitle0090">NP16 inhibited tumor growth in a rat C6 glioma orthotopic model, without significant toxicity on rats in blank control group, when treated twice a day (50 mg/kg, i.p.)</ce:section-title>
                        <ce:para id="p0135" view="all">On the basis of its acceptable pharmacokinetic profile, <ce:bold>NP16</ce:bold> was chosen to evaluate the antitumor effect <ce:italic>in vivo via</ce:italic> the C6 glioma orthotopic model. Combined with the result of the single-dose acute toxicity test, we employed 50 mg/kg as intraperitoneal injection doses corresponding to 1/20th of the MTD (1000 mg/kg). Firstly, a preliminary <ce:italic>in vivo</ce:italic> antitumor activity and a repeated dose toxicity study of compound <ce:bold>NP16</ce:bold> was conducted. As shown in <ce:cross-ref id="crosref0430" refid="appsec1">Figure S2</ce:cross-ref>, after 25 days of continuous intraperitoneal administration (50 mg/kg, twice a day), <ce:bold>NP16</ce:bold> significantly increased the survival rate of glioma rats (P < 0.05). To be specific, consistent with the established literature, most of SD rats in the C6 group died during the perioperative period (within the first postoperative day) and the survival rate is only 16% within 25 days after tumor cell implantation, while the survival rate in sham group is 100%, suggesting that glioma models were successfully established. However, in the <ce:bold>NP16</ce:bold>-treated group, only two rats died within 25 days; and the survival rate was 66% at the end of the trial, which is much higher than that in C6 group (16%) at the same time. Besides, in a repeated dose toxicity study, no significant toxicity was observed in rats when continuously administered <ce:bold>NP16</ce:bold> up to 50 mg/kg for 25 days (<ce:cross-ref id="crosref0435" refid="appsec1">Figure S3</ce:cross-ref>).</ce:para>
                        <ce:para id="p0140" view="all">To further evaluate the <ce:italic>in</ce:italic>-<ce:italic>vivo</ce:italic> antitumor effects of <ce:bold>NP16</ce:bold>, a rat C6 glioma orthotopic model was employed [<ce:cross-ref id="crosref0440" refid="bib67">67</ce:cross-ref>]. For the second modelling, male SD rats were intracranially injected with 5–7 × 10<ce:sup loc="post">4</ce:sup> C6 cells per rat. After three days, rats were randomly divided into four groups (five rats per group), including sham group (injected with saline and treated with equivalent volume of the solvent), C6 group (injected with C6 cells and treated with equivalent volume of the solvent), positive control group (injected with C6 cells and treated with Temozolomide, TMZ, 50 mg/kg, bid) and <ce:bold>NP16</ce:bold> group (injected with C6 cells and treated with <ce:bold>NP16</ce:bold>, 50 mg/kg, bid, i. p.). Simultaneously, the changes in body weight were measured every three days after modelling. As shown in <ce:cross-ref id="crosref0445" refid="fig10">Fig. 10</ce:cross-ref>
                           <ce:float-anchor refid="fig10"/></ce:float-anchor> (A-B, D-E), <ce:bold>NP16</ce:bold> and TMZ significantly reduced tumor weight and volume, and the tumor growth inhibition rate (TGI) for <ce:bold>NP16</ce:bold> and TMZ group were 66.01% and 54.83%, respectively.</ce:para>
                        <ce:para id="p0145" view="all">Besides, the infiltrative behavior of gliomas is one of their main hallmarks and cadherins act as vital participators in the process of cell migration and adhesion. Loss of <ce:italic>E</ce:italic>-cadherin expression has been associated with glioma progression and metastasis [<ce:cross-ref id="crosref0450" refid="bib68">68</ce:cross-ref>]. Of note, the mRNA and protein levels of <ce:italic>E</ce:italic>-cadherin could be up-regulated by COX-2 inhibitors [<ce:cross-ref id="crosref0455" refid="bib69">69</ce:cross-ref>]. In this rat C6 glioma orthotopic model, the expression of <ce:italic>E</ce:italic>-cadherin in peeled tumors of C6 group remarkedly decreased, while the level of PGE<ce:inf loc="post">2</ce:inf>, VEGF-A and <ce:italic>p</ce:italic>-STAT3 significantly increased compared with brain tissue of the sham group at the same site. After administrating compound <ce:bold>NP16</ce:bold> at a dose of 50 mg/kg by intraperitoneal injection, the expression of <ce:italic>E</ce:italic>-cadherin remarkedly increased and the level of PGE<ce:inf loc="post">2</ce:inf>, VEGF-A and <ce:italic>p</ce:italic>-STAT3 significantly (p < 0.05) reduced compared with the C6 group (<ce:cross-ref id="crosref0460" refid="fig10">Fig. 10</ce:cross-ref>F–H), which confirmed the target engagement of <ce:bold>NP16</ce:bold>. Meanwhile, TMZ also suppresses the level of VEGF-A. Besides, <ce:bold>NP16</ce:bold> had no obvious effects on body weight, indicating that <ce:bold>NP16</ce:bold> had no severe toxicity effect to the treated rats (<ce:cross-ref id="crosref0465" refid="fig10">Fig. 10</ce:cross-ref>, C). By contrast, TMZ treatment led to serve loss of weight after administration for five days (50 mg/kg, bid) (<ce:cross-ref id="crosref0470" refid="fig10">Fig. 10</ce:cross-ref>, C), suggesting that <ce:bold>NP16</ce:bold> was potentially safer than TMZ when used at high doses.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.10" view="all">
                        <ce:label>2.2.10</ce:label>
                        <ce:section-title id="sectitle0095">NP16 improved anxiety-like behavior, the angiogenesis and invasion in C6 glioma orthotopic model when treated twice a day (50 mg/kg, i.p.)</ce:section-title>
                        <ce:para id="p0150" view="all">Due to the abnormal behavioral symptoms induced by glioma, on third modelling of C6 glioma orthotopic model in rats (intracranially injected with 5–7 × 10<ce:sup loc="post">4</ce:sup> C6 cells per rat), the classical behavioral experiments (open field test) were further conducted on 10th day to evaluate the effectiveness of <ce:bold>NP16</ce:bold> 
                           <ce:italic>in vivo</ce:italic> [<ce:cross-ref id="crosref0475" refid="bib70">70</ce:cross-ref>]. Firstly, the open-field test is used to evaluate anxiety-like behavior in rodents. By recording the traveled speed over time to assess autonomous motors, as well as the amount of time a rat spending in the center of the field versus the edges, the anxiety-like behavior was recognized when a rat spends more time near the edges of the arena. As shown in <ce:cross-ref id="crosref0480" refid="fig11">Fig. 11</ce:cross-ref>
                           <ce:float-anchor refid="fig11"/></ce:float-anchor> (A, B), we found significantly longer time spent in the central part in sham group and TMZ group than that of C6 group (P < 0.05), implying the success of modelling supported by the less anxiety-like behaviors in sham group or TMZ group. Similarly, after treatment of <ce:bold>NP16</ce:bold>, the time spent in the central part has a remarkable increase compared with the C6 group (P < 0.05), demonstrating that <ce:bold>NP16</ce:bold> obviously decreased anxiety behavior of SD rats with glioma. Besides, no significant difference in traveled speed was observed between C6 group and <ce:bold>NP16</ce:bold> group (<ce:cross-ref id="crosref0485" refid="appsec1">Figure S4</ce:cross-ref>), indicating that <ce:bold>NP16</ce:bold> did not affect the autonomic movement of rats and supporting the validation of the test results.</ce:para>
                        <ce:para id="p0155" view="all">Additionally, 4 days after the behavior test, the brain tumor size of rats were evaluated by MRI. The next day, rats were sacrificed for routine blood test and microscopic observation examinations. Delightedly, no significant change was observed in simple routine blood test between <ce:bold>NP16</ce:bold> group and C6 group (<ce:cross-ref id="crosref0490" refid="appsec1">Table S1</ce:cross-ref>). Besides, as illustrated in <ce:cross-ref id="crosref0495" refid="fig11">Fig. 11</ce:cross-ref> D, results of both hematoxylin-eosin staining (HE) and immunohistochemical staining (ICH) for MMP-9 revealed that <ce:bold>NP16</ce:bold> obviously suppressed the tendency of glioma cells to invade the surrounding brain tissue and inhibited tumor angiogenesis compared with the C6 group. To be concrete, <ce:cross-ref id="crosref0500" refid="fig11">Fig. 11</ce:cross-ref> D (HE staining) displayed that glioma tissues characterized by significant atypia and mitotic activity had proliferated and migrated from the injected point to the surrounding area (marked by yellow arrows), along with massive formation of new blood vessels (marked by black arrows) in C6 model group. By contrast, when treated by <ce:bold>NP16</ce:bold>, massive tumor necrosis and low density of new blood vessels was observed, indicating that <ce:bold>NP16</ce:bold> promoted tumor necrosis possibly by occluding tumor vasculature. Besides, plenty of previous studies demonstrated that inhibiting COX-2 or STAT3 could attenuate angiogenesis in malignant disease mainly <ce:italic>via</ce:italic> reducing vascular endothelial growth factor (VEGF) expression, which was consistent with our results and suggested the anti-angiogenesis effects of <ce:bold>NP16</ce:bold> may be related to the downregulation of VEGF-A (<ce:cross-ref id="crosref0505" refid="fig10">Fig. 10</ce:cross-ref> G).</ce:para>
                        <ce:para id="p0160" view="all">Furthermore, glioma grow infiltratively <ce:italic>via</ce:italic> diffusion which leads to rare cure and a poor outcome globally. To our delight, <ce:bold>NP16</ce:bold> markedly attenuated the invasiveness of glioma in rats featured by clear boundaries with normal brain tissue compared with C6 group where the tumor growth is evidently invasive with an obscure boundary (marked by yellow arrows). Previous researches proved that COX-2 and STAT3 play a pivotal role in glioma invasion relies on upregulation of matrix metalloproteinase (including MMP-2, MMP-9) to destroy local tissue and enhance tumor angiogenesis, thereby accelerating glioma invasion and migration. Delightedly, in <ce:cross-ref id="crosref0510" refid="fig11">Fig. 11</ce:cross-ref> D, the results of immunohistochemical staining for MMP-9 disclosed that <ce:bold>NP16</ce:bold> remarkably suppressed the expression of MMP-9 in comparison with that in C6 group (P < 0.05).</ce:para>
                        <ce:para id="p0165" view="all">Taken together, <ce:bold>NP16</ce:bold> displayed potency and efficacy in a rat C6 glioma orthotopic model demonstrated by mounting evidence, including the increased survival rate, improved anxiety-like behavior, and more importantly, anti-proliferation, anti-angiogenesis and anti-invasion effects, all of which provided the strong evidence for <ce:bold>NP16</ce:bold> applied in glioma therapy.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0100">Conclusion</ce:section-title>
                  <ce:para id="p0170" view="all">GBM is the most refractory and palindromic CNS neoplasm with the poor clinical treatment effect and currently no definitely cure has been found. The main reasons for the refractoriness of GBM are partially due to the highly infiltrative and invasive properties of glioma tumors which are tightly correlative with the overexpression of COX-2 and STAT3 in GBM microenvironment [<ce:cross-ref id="crosref0515" refid="bib11">11</ce:cross-ref>,<ce:cross-ref id="crosref0520" refid="bib49">49</ce:cross-ref>]. It is reported that melatonin as a kind of neurotransmitter featured by favorable blood brain barrier penetration, of which anti-inflammatory and anti-tumor effects are related to the inhibition of STAT3 pathway [<ce:cross-ref id="crosref0525" refid="bib48">48</ce:cross-ref>,<ce:cross-ref id="crosref0530" refid="bib49">49</ce:cross-ref>,<ce:cross-ref id="crosref0535" refid="bib71">71</ce:cross-ref>]. Therefore, we combined a classical kind of COX-2 inhibitor——<ce:italic>N</ce:italic>-phenylanthranilic acid derivatives with melatonin derivatives. Moreover, <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives have been reported as COX-2 inhibitors and displayed remarkable anti-neuroinflammation and anti-tumor effects <ce:italic>in vivo</ce:italic> and <ce:italic>in vitro</ce:italic> thereby suggested its possible application for intracranial diseases. Herein, we designed a new series of <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives and found that the most of <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives inhibited glioblastoma cell growth and inhibited COX-2 obviously. The systemic SAR study showed that most of <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives we synthesized appeared in almost close antiproliferative activity, but in <ce:italic>meta</ce:italic>- and <ce:italic>para</ce:italic>-position the electron-donating substituents are advantageous to anti-tumor activity, especially one special compound featured by 3,4,5-tri-OMe in <ce:italic>meta</ce:italic>- and <ce:italic>para</ce:italic>-position (<ce:bold>NP16</ce:bold>) was the most active among twenty-seven compounds, with IC<ce:inf loc="post">50</ce:inf> ranging from 1.87 ± 0.48 μM (in U251) to 4.23 ± 0.61 μM (in rat glioma cell C6) and4.78 ± 0.78 μM (in U87MG). To further verify the mechanism of compound <ce:bold>NP16</ce:bold>, western blot and immunofluorescence assay were performed. The results display that <ce:bold>NP16</ce:bold> obviously decreases the expression of COX-2, <ce:italic>p</ce:italic>-JAK2 and <ce:italic>p</ce:italic>-STAT3, and inhibits the nuclear translocation of STAT3 in U251 cells and U87MG cells. <ce:bold>NP16</ce:bold> decreased the expression of MMP-9 in BV2 cells following coculture with glioma cells.</ce:para>
                  <ce:para id="p0175" view="all">A series of proliferation-related assays in U251 and U87MG (colony formation, EdU assay and cell cycle assay) collectively proved that <ce:bold>NP16</ce:bold> strikingly suppressed rapid proliferation of U251 and U87MG cells, and caused G<ce:inf loc="post">2</ce:inf>/M phase arrest. Flow cytometry assay demonstrated that <ce:bold>NP16</ce:bold> notably induced the apoptosis of U251 and U87MG detected by Annexin V-FITC/PI double-staining. Western blotting assay revealed that <ce:bold>NP16</ce:bold> induced the apoptosis by reducing the ratio of Bcl-2/Bax ratio and evidently increasing on the expression of cytochrome <ce:italic>c</ce:italic>, which also was supported by the results of the increased ROS production by DCF-H staining. Of note, <ce:bold>NP16</ce:bold> exerted dose-dependently anti-migratory and anti-invasive effects in U251 and U87MG, in accordance with the dramatic reduction of MMP-9 expression in those two human cell lines. The verified inhibition of STAT3 signaling, anti-proliferation, G<ce:inf loc="post">2</ce:inf>/M phase arrest, anti-migration and anti-invasion effects of <ce:bold>NP16</ce:bold> lay a solid basis for <ce:italic>in</ce:italic>-<ce:italic>vivo</ce:italic> research.</ce:para>
                  <ce:para id="p0180" view="all">Due to existence of blood brain barrier, plenty of anti-tumor agents were resisted to be applied for GBM. Fortunately, <ce:bold>NP16</ce:bold> was equipped with favorable blood brain barrier permeability with the brain/blood ratio of 0.38:1, indicating the potential of <ce:bold>NP16</ce:bold> for GBM. Besides, long half-lives (11.43 ± 3.42 h), acceptable C<ce:inf loc="post">max</ce:inf> value (1.15 ± 0.17 μg/mL), along with low acute toxicity (LD<ce:inf loc="post">50</ce:inf> < 1000 mg/kg) collectively revealed that <ce:bold>NP16</ce:bold> has the further potential therapeutic value <ce:italic>in vivo</ce:italic>. To our delight, in a rat C6 glioma orthotopic model, <ce:bold>NP16</ce:bold> significantly promoted the survival rate and reduced the volume and weight of tumor (TGI = 66.01%), increased the expression of <ce:italic>E</ce:italic>-cadherin and reduced overproduction of PGE<ce:inf loc="post">2</ce:inf>, MMP-9, VEGF-A and the level of <ce:italic>p</ce:italic>-STAT3 in tumor tissue, markedly improved anxiety-like behavior, and obviously suppressed angiogenesis and the invasion ability compared with the C6 group. Additionally, TMZ treatment led to serve loss of weight after administration for five days (50 mg/kg, bid) while <ce:bold>NP16</ce:bold> did not, suggesting that <ce:bold>NP16</ce:bold> was potentially safer than TMZ when used at high doses. All evidences <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> demonstrated the effectiveness of <ce:bold>NP16</ce:bold> for glioma therapy.</ce:para>
                  <ce:para id="p0185" view="all">To date, current chemotherapy drugs for GBM is mainly consistent of alkylating agents (temozolomide, carmustine, lomustine) [<ce:cross-ref id="crosref0540" refid="bib56">56</ce:cross-ref>], which bring out obvious toxicity but unfortunately did not prolong the survival times. In this regard, we designed a novel series of <ce:italic>N</ce:italic>-anthraniloyl tryptamine derivatives, unprecedentedly applied them for GBM, and provided compelling evidences <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> to demonstrate their effectiveness and safety for GBM treatment.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0105">Experiment procedure</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0110">General procedures</ce:section-title>
                     <ce:para id="p0190" view="all">All chemicals used were of reagent grade. Proton (<ce:sup loc="post">1</ce:sup>H) and carbon (<ce:sup loc="post">13</ce:sup>C) NMR spectra (400 or 300 MHz for <ce:sup loc="post">1</ce:sup>HNMR; 101 MHz or 75 MHZ for <ce:sup loc="post">13</ce:sup>CNMR) were recorded on a Bruker spectrometer (Bruker Company, Germany). Chemical shifts (δ) were referenced to internal tetramethylsilane or to solvent peaks (CDCl<ce:inf loc="post">3</ce:inf> at 7.26 ppm, DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> at 2.50 ppm, (CD<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">2</ce:inf>CO- at 2.05 ppm for <ce:sup loc="post">1</ce:sup>HNMR; CDCl<ce:inf loc="post">3</ce:inf> at 77.00 ppm, DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> at 39.96 ppm, (CD<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">2</ce:inf>CO at 29.70 ppm for <ce:sup loc="post">13</ce:sup>CNMR). The values of the chemical shifts are expressed in ppm and the coupling constants (<ce:italic>J</ce:italic>) in hertz. The following abbreviations were used to designate multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet, br = broad. High-resolution mass spectrometry (HRMS) analysis was performed using an Agilent UPLC-IM-QTOF spectrometer (Agilent 6560, USA). Purity of all final compounds was more than 95% (Agilent 1260 Infinity II; USA).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0115">HPLC analysis</ce:section-title>
                     <ce:para id="p0195" view="all">The purity was determined by HPLC. Purity of compounds NP1-NP18, NP20, NZ1-NZ8 was more than 95% (Agilent 1260 Infinity II; USA). The column (Eclipse Plus C18,4.6 × 250 mm, 4 μm) was used for separation. Chromatographic conditions of compounds NP1-NP18, NP20, NZ1-NZ8: 0–7 min, MeOH: H<ce:inf loc="post">2</ce:inf>O = 20:80; 7–25 min MeOH: H<ce:inf loc="post">2</ce:inf>O = 95:5, Wavelength: 254 nm; Column temperature: 25 °C; Flow rate of 0.5 mL/min.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0120">General procedure for the preparation of compounds</ce:section-title>
                     <ce:para id="p0200" view="all">A mixture of K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (1.0 mmol, 1.0 eq), amine (1.2 mmol, 1.2 eq), <ce:italic>ortho</ce:italic>-iodo benzoic acid (1.0 mmol, 1.0 eq) and DMF (2.0 mL) and copper powder (0.001 mmol, 0.1% eq) were stirred in the schlenk tube for 12 h at 100 °C under argon condition, and stopped heat and cooled to 25 °C. The solid (bottle green) was diluted with water, acidified with 2.0 N HCl until pH 2 was adjusted. The black solid was precipitated and filtered. The filter cake was washed with an excess of water to remove the excess amine, dissolved in dichloromethane. The dichloromethan was concentrated by rotary evaporation under reduced pressure and dried over Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. The crude compounds, o-aminobenzoic acid derivatives, were obtained. Then o-aminobenzoic acid derivatives (1.0 eq), tryptamine (1.0 eq), EDCI·HCl (1.2 eq), HOBT (1.1 eq) were dissolved in dichloromethane (3 mL), and Et<ce:inf loc="post">3</ce:inf>N (2.5 eq) was added at room temperature and stirred for 8 h. After completion of the reaction detected by TLC, the reaction liquid was concentrated by rotary evaporation under reduced pressure. Then the resulting residue was purified by silica gel flash column chromatography to afford the desired product as a solid and the total yield was 49–95%.</ce:para>
                     <ce:section id="sec4.3.1" view="all">
                        <ce:label>4.3.1</ce:label>
                        <ce:section-title id="sectitle0125">N-(2-(1H-indol-3-yl)ethyl)-2-((2-fluorophenyl)amino)benzamide <ce:bold>(NP1)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0205" view="all">white solid (78% yield), mp 118.3–120.0 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.34 (s, 1H), 8.20 (s, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.37–7.31 (m, 2H), 7.24 (dd, <ce:italic>J</ce:italic> = 8.3, 1.3 Hz, 1H), 7.22–7.19 (m, 2H), 7.18–7.15 (m, 1H), 7.12–7.06 (m, 2H), 7.06–7.01 (m, 1H), 6.99–6.96 (m, 1H), 6.96–6.91 (m, 1H), 6.71–6.65 (m, 1H), 6.28 (t, <ce:italic>J</ce:italic> = 4.8 Hz, 1H), 3.73 (q, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 3.04 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.3, 154.9 (d, <ce:italic>J</ce:italic> = 244.9 Hz), 144.4, 136.3, 132.0, 129.6 (d, <ce:italic>J</ce:italic> = 11.3 Hz), 127.4, 127.1, 124.1 (d, <ce:italic>J</ce:italic> = 3.7 Hz), 122.8 (d, <ce:italic>J</ce:italic> = 7.4 Hz), 122.2, 122.1, 121.2 (d, <ce:italic>J</ce:italic> = 1.7 Hz), 119.4, 119.1, 118.6, 118.5, 116.0 (d, <ce:italic>J</ce:italic> = 19.5 Hz), 115.4, 112.6, 111.3, 40.0, 25.1. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>FNaN<ce:inf loc="post">3</ce:inf>O [M+Na]<ce:sup loc="post">+</ce:sup> 396.1482, found 396.1489. The purity was 98.6% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.2" view="all">
                        <ce:label>4.3.2</ce:label>
                        <ce:section-title id="sectitle0130">N-(2-(1H-indol-3-yl)ethyl)-2-((2-iodophenyl)amino)benzamide <ce:bold>(NP2)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0210" view="all">white solid (80% yield), mp 118.2–119.1 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, Acetone <ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 10.05 (s, 1H), 9.89 (s, 1H), 7.98 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 7.89 (dd, <ce:italic>J</ce:italic> = 7.9, 1.4 Hz, 1H), 7.66 (s, 1H), 7.65–7.63 (m, 1H), 7.42–7.36 (m, 2H), 7.35–7.28 (m, 2H), 7.28–7.23 (m, 1H), 7.23–7.21 (m, 1H), 7.12–7.07 (m, 1H), 7.03–6.98 (m, 1H), 6.85–6.80 (m, 1H), 6.77 (td, <ce:italic>J</ce:italic> = 7.8, 1.5 Hz, 1H), 3.72 (q, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 3.10 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, Acetone <ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 169.5, 145.0, 144.1, 140.7, 137.5, 132.3, 129.7, 129.0, 128.4, 124.4, 123.2, 121.9, 120.8, 120.2, 119.6, 119.3, 119.2, 116.6, 113.2, 112.0, 92.3, 41.1, 25.9. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>INaN<ce:inf loc="post">3</ce:inf>O [M+Na]<ce:sup loc="post">+</ce:sup> 504.0543, found 504.0543. The purity was 98.0% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.3" view="all">
                        <ce:label>4.3.3</ce:label>
                        <ce:section-title id="sectitle0135">N-(2-(1H-indol-3-yl)ethyl)-2-(o-tolylamino)benzamide <ce:bold>(NP3)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0215" view="all">white solid (89% yield), mp 155.7–157.0 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.21 (s, 1H), 8.09 (s, 1H), 7.64 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.37 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.31 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.25–7.23 (m, 1H), 7.23–7.21 (m, 2H), 7.20–7.16 (m, 2H), 7.16–7.13 (m, 1H), 7.12–7.07 (m, 1H), 7.05 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.99 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 6.67–6.60 (m, 1H), 6.26–6.19 (m, 1H), 3.77 (q, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.09 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 2.30 (s, 3H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.5, 146.0, 139.8, 136.3, 132.0, 131.0, 131.0, 127.3, 127.2, 126.4, 123.0, 122.3, 122.1, 120.9, 119.5, 118.7, 117.8, 117.3, 115.2, 112.8, 111.3, 39.9, 25.2, 18.1. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">23</ce:inf>NaN<ce:inf loc="post">3</ce:inf>O [M+Na]<ce:sup loc="post">+</ce:sup> 392.1733, found 392.1736. The purity was 96.4% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.4" view="all">
                        <ce:label>4.3.4</ce:label>
                        <ce:section-title id="sectitle0140">N-(2-(1H-indol-3-yl)ethyl)-2-((2-aminophenyl)amino)benzamide <ce:bold>(NP4)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0220" view="all">yellow solid (51% yield), mp 123.3–124.2 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 8.93 (s, 1H), 8.24 (s, 1H), 7.63 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.34 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.28–7.07 (m, 7H), 7.06–7.02 (m, 1H), 7.01 (s, 1H), 6.79–6.71 (m, 2H), 6.66 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H), 6.57 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 6.29 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 3.75 (q, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 3.07 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H).<ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.6, 147.4, 142.7, 136.3, 132.4, 127.1, 126.9, 126.5, 126.3, 122.2, 119.4, 118.7, 118.6, 116.7, 116.4, 115.9, 114.4, 112.7, 111.3, 39.9, 25.2. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">22</ce:inf>NaN<ce:inf loc="post">4</ce:inf>O [M+Na]<ce:sup loc="post">+</ce:sup> 393.1685, found 393.1695. The purity was 95.2% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.5" view="all">
                        <ce:label>4.3.5</ce:label>
                        <ce:section-title id="sectitle0145">N-(2-(1H-indol-3-yl)ethyl)-2-((3-fluorophenyl)amino)benzamide <ce:bold>(NP5)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0225" view="all">white solid (81% yield), mp 164.3–165.3 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 10.05 (s, 1H), 9.99 (s, 1H), 8.02 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 1H), 7.65 (dd, <ce:italic>J</ce:italic> = 7.9, 1.6 Hz, 2H), 7.45 (dd, <ce:italic>J</ce:italic> = 8.3, 0.9 Hz, 1H), 7.41–7.38 (m, 1H), 7.38–7.32 (m, 1H), 7.32–7.26 (m, 1H), 7.21 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.14–7.08 (m, 1H), 7.04–6.95 (m, 3H), 6.87–6.81 (m, 1H), 6.73–6.66 (m, 1H), 3.76–3.68 (m, 2H), 3.09 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 169.8, 164.3 (d, <ce:italic>J</ce:italic> = 242.6 Hz), 145.0 (d, <ce:italic>J</ce:italic> = 10.5 Hz), 144.6, 137.5, 132.5, 131.4 (d, <ce:italic>J</ce:italic> = 10.0 Hz), 129.1, 128.4, 123.2, 122.0, 120.8, 119.7, 119.3, 119.2, 116.8, 115.4 (d, <ce:italic>J</ce:italic> = 2.5 Hz), 113.2, 112.0, 108.3 (d, <ce:italic>J</ce:italic> = 21.5 Hz), 105.8 (d, <ce:italic>J</ce:italic> = 24.6 Hz), 41.1, 25.9. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>NaFN<ce:inf loc="post">3</ce:inf>O [M+Na]<ce:sup loc="post">+</ce:sup> 396.1482, found 396.1486. The purity was 97.7% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.6" view="all">
                        <ce:label>4.3.6</ce:label>
                        <ce:section-title id="sectitle0150">N-(2-(1H-indol-3-yl)ethyl)-2-((3-chlorophenyl)amino)benzamide <ce:bold>(NP6)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0230" view="all">white solid (80% yield), mp 149.1–150.1 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 10.05 (s, 1H), 9.96 (s, 1H), 8.03 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 7.68–7.62 (m, 2H), 7.44–7.39 (m, 1H), 7.38–7.37 (m, 1H), 7.36–7.32 (m, 1H), 7.29 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.23 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.21 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.15–7.07 (m, 2H), 7.01 (td, <ce:italic>J</ce:italic> = 7.5, 0.9 Hz, 1H), 6.97–6.94 (m, 1H), 6.87–6.81 (m, 1H), 3.74–3.67 (m, 2H), 3.08 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 169.7, 144.6, 144.5, 137.5, 135.1, 132.5, 131.4, 129.1, 128.4, 123.2, 122.0, 121.7, 120.9, 119.8, 119.3, 119.2, 119.0, 118.0, 116.7, 113.2, 112.0, 41.1, 25.9. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>NaClN<ce:inf loc="post">3</ce:inf>O [M+Na]<ce:sup loc="post">+</ce:sup> 412.1187, found 412.1193. The purity was 99.3% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.7" view="all">
                        <ce:label>4.3.7</ce:label>
                        <ce:section-title id="sectitle0155">N-(2-(1H-indol-3-yl)ethyl)-2-((3-bromophenyl)amino)benzamide <ce:bold>(NP7)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0235" view="all">white solid (78% yield), mp 154.9–155.7 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 10.05 (s, 1H), 9.95 (s, 1H), 8.06–7.99 (m, 1H), 7.68–7.61 (m, 2H), 7.43–7.33 (m, 4H), 7.27–7.23 (m, 1H), 7.22–7.20 (m, 1H), 7.20–7.16 (m, 1H), 7.12–7.10 (m, 1H), 7.10–7.07 (m, 1H), 7.04–6.98 (m, 1H), 6.87–6.81 (m, 1H), 3.70 (q, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 3.08 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 169.7, 144.7, 144.5, 137.5, 132.5, 131.7, 129.1, 128.4, 124.7, 123.2, 121.9, 121.9, 120.9, 119.8, 119.3, 119.2, 118.4, 116.7, 113.2, 112.0, 41.1, 25.9. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf> NaBrN<ce:inf loc="post">3</ce:inf>O [M+Na]<ce:sup loc="post">+</ce:sup> 456.0682, found 456.0683. The purity was 95.4% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.8" view="all">
                        <ce:label>4.3.8</ce:label>
                        <ce:section-title id="sectitle0160">N-(2-(1H-indol-3-yl)ethyl)-2-(m-tolylamino)benzamide <ce:bold>(NP8)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0240" view="all">white solid (86% yield), mp 164.1–165.2 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.23 (s, 1H), 8.17 (s, 1H), 7.62 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.37–7.30 (m, 2H), 7.22 (dd, <ce:italic>J</ce:italic> = 6.8, 3.2 Hz, 2H), 7.19 (d, <ce:italic>J</ce:italic> = 3.5 Hz, 1H), 7.18–7.14 (m, 1H), 7.12 (dd, <ce:italic>J</ce:italic> = 11.0, 3.9 Hz, 1H), 6.98 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 3H), 6.81 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 6.65 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 1H), 6.25 (s, 1H), 3.73 (q, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.05 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 2.30 (s, 3H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.5, 145.1, 141.5, 139.1, 136.3, 131.9, 129.0, 127.4, 127.2, 123.0, 122.2, 122.1, 121.2, 119.4, 118.7, 118.6, 117.8, 117.3, 115.6, 112.7, 111.3, 39.9, 25.1, 21.4. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">23</ce:inf>NaN<ce:inf loc="post">3</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 392.1733, found 392.1743. The purity was 95.1% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.9" view="all">
                        <ce:label>4.3.9</ce:label>
                        <ce:section-title id="sectitle0165">N-(2-(1H-indol-3-yl)ethyl)-2-((4-fluorophenyl)amino)benzamide <ce:bold>(NP9)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0245" view="all">white solid (73% yield), mp 162.1–163.3 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, <ce:bold>Acetone</ce:bold>
                           <ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 10.06 (s, 1H), 9.88 (s, 1H), 8.01–7.94 (m, 1H), 7.68–7.60 (m, 2H), 7.38 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.29 (dd, <ce:italic>J</ce:italic> = 8.4, 1.4 Hz, 1H), 7.25 (dd, <ce:italic>J</ce:italic> = 5.6, 3.5 Hz, 2H), 7.21 (dd, <ce:italic>J</ce:italic> = 10.4, 1.9 Hz, 2H), 7.14–7.10 (m, 2H), 7.10–7.07 (m, 1H), 7.04–6.98 (m, 1H), 6.76–6.70 (m, 1H), 3.74–3.67 (m, 2H), 3.08 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 169.9, 159.1 (d, <ce:italic>J</ce:italic> = 239.1 Hz), 146.6, 138.9 (d, <ce:italic>J</ce:italic> = 2.5 Hz), 137.5, 132.6, 129.0, 128.4, 123.3 (d, <ce:italic>J</ce:italic> = 8.0 Hz), 123.2, 122.0, 119.3, 119.2, 119.0, 118.3, 116.5 (d, <ce:italic>J</ce:italic> = 22.6 Hz), 114.9, 113.2, 112.0, 41.0, 26.0. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>NaFN<ce:inf loc="post">3</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 396.1482, found 396.1488. The purity was 98.1% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.10" view="all">
                        <ce:label>4.3.10</ce:label>
                        <ce:section-title id="sectitle0170">N-(2-(1H-indol-3-yl)ethyl)-2-((4-chlorophenyl)amino)benzamide <ce:bold>(NP10)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0250" view="all">white solid (75% yield), mp 159.1–160.5 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 10.05 (s, 1H), 9.95 (s, 1H), 8.00 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 7.68–7.61 (m, 2H), 7.39 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.37–7.32 (m, 2H), 7.32–7.28 (m, 2H), 7.23–7.18 (m, 3H), 7.14–7.08 (m, 1H), 7.05–6.99 (m, 1H), 6.82–6.76 (m, 1H), 3.75–3.68 (m, 2H), 3.09 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 169.8, 145.2, 141.7, 137.5, 132.5, 129.9, 129.1, 128.4, 126.4, 123.2, 122.0, 121.6, 120.1, 119.3, 119.2, 115.9, 113.2, 112.0, 41.0, 25.9. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>NaClN<ce:inf loc="post">3</ce:inf>O [M+Na]<ce:sup loc="post">+</ce:sup> 412.1187, found 412.1195. The purity was 96.9% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.11" view="all">
                        <ce:label>4.3.11</ce:label>
                        <ce:section-title id="sectitle0175">N-(2-(1H-indol-3-yl)ethyl)-2-((4-bromophenyl)amino)benzamide <ce:bold>(NP11)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0255" view="all">white solid (76% yield), mp 135.6–136.3 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 10.05 (s, 1H), 9.94 (s, 1H), 8.00 (t, <ce:italic>J</ce:italic> = 4.8 Hz, 1H), 7.69–7.60 (m, 2H), 7.45–7.41 (m, 2H), 7.41–7.35 (m, 2H), 7.34–7.29 (m, 1H), 7.21 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.17–7.13 (m, 2H), 7.13–7.07 (m, 1H), 7.05–6.99 (m, 1H), 6.83–6.77 (m, 1H), 3.72 (q, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 3.09 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H).<ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 169.8, 145.0, 142.1, 137.5, 132.8, 132.5, 129.1, 128.4, 123.2, 122.0, 121.8, 120.3, 119.3, 119.3, 119.2, 116.0, 113.6, 113.2, 112.0, 41.0, 25.9. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>NaBrN<ce:inf loc="post">3</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 456.0682, found 456.0691. The purity was 95.2% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.12" view="all">
                        <ce:label>4.3.12</ce:label>
                        <ce:section-title id="sectitle0180">N-(2-(1H-indol-3-yl)ethyl)-2-(p-tolylamino)benzamide <ce:bold>(NP12)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0260" view="all">pale yellow solid (88% yield), mp 146.6–147.5 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.23 (s, 1H), 8.22 (s, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.30 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.22 (dd, <ce:italic>J</ce:italic> = 8.7, 1.1 Hz, 1H), 7.20–7.14 (m, 3H), 7.10 (dd, <ce:italic>J</ce:italic> = 7.9, 0.7 Hz, 1H), 7.08–7.03 (m, 4H), 6.93 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.63–6.56 (m, 1H), 6.28 (t, <ce:italic>J</ce:italic> = 5.5 Hz, 1H), 3.70 (q, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.02 (t, <ce:italic>J</ce:italic> = 6.7 Hz, 2H), 2.29 (s, 3H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.5, 145.8, 138.6, 136.3, 132.1, 132.0, 129.7, 127.4, 127.1, 122.1, 122.1, 121.3, 119.3, 118.6, 117.8, 117.3, 114.8, 112.6, 111.3, 39.9, 25.1, 20.7. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">23</ce:inf>NaN<ce:inf loc="post">3</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 392.1733, found 392.1740. The purity was 96.7% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.13" view="all">
                        <ce:label>4.3.13</ce:label>
                        <ce:section-title id="sectitle0185">N-(2-(1H-indol-3-yl)ethyl)-2-((4-methoxyphenyl)amino)benzamide <ce:bold>(NP13)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0265" view="all">yellow solid (89% yield), mp 134.8–135.8 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.20 (s, 1H), 8.19 (s, 1H), 7.63 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.35 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.24–7.19 (m, 1H), 7.19–7.15 (m, 2H), 7.14–7.10 (m, 3H), 7.07–7.03 (m, 1H), 7.01 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.89–6.82 (m, 2H), 6.60–6.54 (m, 1H), 6.25 (t, <ce:italic>J</ce:italic> = 5.3 Hz, 1H), 3.78 (s, 3H), 3.74 (q, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 3.07 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.6, 155.8, 147.1, 136.3, 134.2, 132.1, 127.3, 127.2, 124.3, 122.2, 122.1, 119.5, 118.7, 116.8, 116.7, 114.5, 114.1, 112.8, 111.3, 55.4, 39.9, 25.2. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">23</ce:inf>NaN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> [M + Na]<ce:sup loc="post">+</ce:sup> 408.1682, found 408.1687. The purity was 98.1% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.14" view="all">
                        <ce:label>4.3.14</ce:label>
                        <ce:section-title id="sectitle0190">N-(2-(1H-indol-3-yl)ethyl)-2-((4-(trifluoromethyl)phenyl)amino)benzamide <ce:bold>(NP14)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0270" view="all">white solid (72% yield), mp 121.1–122.8 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.50 (s, 1H), 8.09 (s, 1H), 7.63 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.49 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 7.46–7.40 (m, 1H), 7.40–7.35 (m, 1H), 7.30 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.26–7.21 (m, 2H), 7.21–7.17 (m, 2H), 7.13 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 7.05 (s, 1H), 6.79 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 6.24 (t, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 3.76 (q, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 3.09 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (75 MHz, CDCl3) δ 169.2, 145.1, 143.2, 136.4, 132.0, 127.6, 127.2, 126.5 (q, <ce:italic>J</ce:italic> = 3.7 Hz), 124.5 (q, <ce:italic>J</ce:italic> = 270.9 Hz), 122.8 (d, <ce:italic>J</ce:italic> = 32.8 Hz), 122.3, 122.1, 120.6, 119.7, 119.6, 118.6, 118.0, 116.9, 112.7, 111.3, 40.1, 25.1. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">20</ce:inf>NaF<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">3</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 446.1451, found 446.1467. The purity was 97.7% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.15" view="all">
                        <ce:label>4.3.15</ce:label>
                        <ce:section-title id="sectitle0195">N-(2-(1H-indol-3-yl)ethyl)-2-((4-(dimethylamino)phenyl)amino)benzamide (<ce:bold>NP15</ce:bold>)</ce:section-title>
                        <ce:para id="p0275" view="all">white solid (70% yield), mp 131.1–132.5 °C.<ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.12 (s, 1H), 8.14 (s, 1H), 7.66 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.38 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.25–7.20 (m, 1H), 7.19–7.10 (m, 5H), 7.06 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.02 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 6.79–6.72 (m, 2H), 6.59–6.52 (m, 1H), 6.23 (t, <ce:italic>J</ce:italic> = 5.0 Hz, 1H), 3.77 (q, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 3.10 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 2.94 (s, 6H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.7, 148.0, 147.7, 136.4, 132.1, 130.9, 127.3, 127.2, 124.9, 122.2, 122.1, 119.5, 118.7, 116.4, 116.1, 114.1, 113.7, 113.0, 111.3, 41.1, 39.9, 25.3. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">26</ce:inf>NaN<ce:inf loc="post">4</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 421.1999, found 421.2004. The purity was 98.6% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.16" view="all">
                        <ce:label>4.3.16</ce:label>
                        <ce:section-title id="sectitle0200">N-(2-(1H-indol-3-yl)ethyl)-2-((3,4,5-trimethoxyphenyl)amino)benzamide <ce:bold>(NP16)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0280" view="all">yellow solid (86% yield), mp 166.7–167.4 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.31 (s, 1H), 8.29 (s, 1H), 7.63 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.37 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.29 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 7.24–7.18 (m, 3H), 7.12 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 7.06–7.03 (m, 1H), 6.65 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 6.42 (s, 2H), 6.28 (t, <ce:italic>J</ce:italic> = 5.3 Hz, 1H), 3.82 (s, 3H), 3.78 (s, 6H), 3.76–3.72 (m, 2H), 3.08 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.5, 153.6, 145.7, 137.5, 136.4, 133.4, 132.1, 127.4, 127.1, 122.2, 122.2, 119.5, 118.6, 118.1, 117.6, 115.2, 112.7, 111.3, 98.6, 61.0, 56.0, 40.0, 25.2. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">27</ce:inf>NaN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf> [M + Na]<ce:sup loc="post">+</ce:sup> 468.1894, found 468.1900. The purity was 95.8% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.17" view="all">
                        <ce:label>4.3.17</ce:label>
                        <ce:section-title id="sectitle0205">N-(2-(1H-indol-3-yl)ethyl)-2-((2-chlorophenyl)amino)benzamide <ce:bold>(NP17)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0285" view="all">white solid (78% yield), mp 135.3–136.5 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 10.11 (s, 1H), 10.07 (s, 1H), 8.08–7.99 (m, 1H), 7.65 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 7.54–7.48 (m, 1H), 7.48–7.44 (m, 1H), 7.41–7.36 (m, 2H), 7.36–7.31 (m, 1H), 7.28–7.24 (m, 1H), 7.23–7.21 (m, 1H), 7.12–7.06 (m, 1H), 7.01 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1H), 6.99–6.92 (m, 1H), 6.89–6.82 (m, 1H), 3.77–3.68 (m, 2H), 3.09 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 169.6, 144.2, 139.7, 137.5, 132.3, 130.7, 129.1, 128.4, 128.2, 124.7, 123.2, 122.8, 121.9, 121.3, 119.9, 119.2, 119.1, 119.1, 116.7, 113.2, 112.0, 41.1, 25.9. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>NaClN<ce:inf loc="post">3</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 412.1187, found 412.1190. The purity was 96.9% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.18" view="all">
                        <ce:label>4.3.18</ce:label>
                        <ce:section-title id="sectitle0210">N-(2-(1H-indol-3-yl)ethyl)-2-((2-bromophenyl)amino)benzamide <ce:bold>(NP18)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0290" view="all">white solid (79% yield), mp 147.9–148.5 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 10.07 (s, 1H), 10.03 (s, 1H), 8.06–7.98 (m, 1H), 7.68–7.61 (m, 3H), 7.51–7.45 (m, 1H), 7.40–7.37 (m, 1H), 7.36–7.32 (m, 2H), 7.32–7.26 (m, 1H), 7.22 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.14–7.05 (m, 1H), 7.00 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 1H), 6.92–6.88 (m, 1H), 6.89–6.80 (m, 1H), 3.72 (q, <ce:italic>J</ce:italic> = 7.0 Hz, 2H), 3.09 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 169.5, 144.3, 141.1, 137.5, 134.0, 132.3, 129.1, 128.8, 128.4, 123.3, 123.2, 121.9, 121.3, 119.8, 119.5, 119.2, 119.2, 116.7, 115.3, 113.2, 112.0, 41.1, 25.9. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">20</ce:inf>NaBrN<ce:inf loc="post">3</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 456.0682, found 456.0687. The purity was 95.6% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.19" view="all">
                        <ce:label>4.3.19</ce:label>
                        <ce:section-title id="sectitle0215">N-(2-(1H-indol-3-yl)ethyl)-2-((4-butylphenyl)amino)benzamide <ce:bold>(NP20)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0295" view="all">white solid (70% yield), mp 143.9–144.2 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.22 (s, 1H), 8.15 (s, 1H), 7.61 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.33–7.30 (m, 1H), 7.26–7.23 (m, 1H), 7.20–7.16 (m, 3H), 7.13–7.08 (m, 5H), 6.96 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 6.63–6.58 (m, 1H), 6.25 (t, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 3.72 (q, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.04 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 2.58–2.54 (m, 2H), 1.62–1.54 (m, 2H), 1.40–1.31 (m, 2H), 0.93 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.5, 145.9, 139.0, 137.2, 136.4, 132.0, 129.1, 127.4, 127.2, 122.1, 122.1, 121.2, 119.4, 118.6, 118.0, 117.4, 115.1, 112.8, 111.3, 40.0, 35.0, 33.7, 25.2, 22.3, 13.9. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">30</ce:inf>N<ce:inf loc="post">3</ce:inf>O [M + H]<ce:sup loc="post">+</ce:sup> 412.2383, found 412.2389. The purity was 97.1% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.20" view="all">
                        <ce:label>4.3.20</ce:label>
                        <ce:section-title id="sectitle0220">N-(2-(1H-indol-3-yl)ethyl)-2-(pyridin-3-ylamino)benzamide <ce:bold>(NZ1)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0300" view="all">white solid (68% yield), mp 163.3–164.1 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.82 (s, 1H), 9.73 (s, 1H), 8.72 (t, <ce:italic>J</ce:italic> = 5.4 Hz, 1H), 8.44 (s, 1H), 8.24–8.07 (m, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.62–7.54 (m, 2H), 7.38–7.26 (m, 4H), 7.21–7.17 (m, 1H), 7.06 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 6.97 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 6.94–6.85 (m, 1H), 3.54 (q, <ce:italic>J</ce:italic> = 6.7 Hz, 2H), 2.96 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 169.0, 143.8, 142.8, 141.9, 136.7, 132.3, 129.3, 129.1, 127.7, 125.9, 124.4, 123.1, 121.4, 120.6, 119.5, 118.7, 118.7, 115.8, 112.3, 111.8, 40.6, 25.4. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">20</ce:inf>NaN<ce:inf loc="post">4</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 379.1529, found 379.1537. The purity was 95.7% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.21" view="all">
                        <ce:label>4.3.21</ce:label>
                        <ce:section-title id="sectitle0225">N-(2-(1H-indol-3-yl)ethyl)-2-((2-methylpyridin-3-yl)amino)benzamide <ce:bold>(NZ2)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0305" view="all">white solid (74% yield), mp 162.4–163.8 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 10.09 (s, 1H), 9.92 (s, 1H), 8.13 (dd, <ce:italic>J</ce:italic> = 4.7, 1.3 Hz, 1H), 8.08–8.01 (m, 1H), 7.69–7.67 (m, 1H), 7.66–7.59 (m, 1H), 7.63 (s, 1H), 7.40–7.36 (m, 1H), 7.36–7.26 (m, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.18–7.15 (m, 1H), 7.14–7.11 (m, 1H), 7.10–7.06 (m, 1H), 7.04–6.97 (m, 1H), 6.82–6.76 (m, 1H), 3.76–3.69 (m, 2H), 3.10 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 2.50 (s, 3H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, Acetone<ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 169.9, 151.3, 145.7, 143.2, 137.5, 136.9, 132.6, 129.1, 128.4, 126.3, 123.2, 122.2, 121.9, 119.7, 119.3, 119.2, 118.9, 115.5, 113.2, 112.0, 41.1, 25.9, 21.2. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">23</ce:inf> N<ce:inf loc="post">4</ce:inf>O [M + H]<ce:sup loc="post">+</ce:sup> 371.1866, found 371.1872. The purity was 98.4% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.22" view="all">
                        <ce:label>4.3.22</ce:label>
                        <ce:section-title id="sectitle0230">N-(2-(1H-indol-3-yl)ethyl)-2-((6-methylpyridin-3-yl)amino)benzamide <ce:bold>(NZ3)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0310" view="all">yellow solid (69% yield), mp 143.9–144.7 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.39 (s, 1H), 8.36 (d, <ce:italic>J</ce:italic> = 17.0 Hz, 2H), 7.65 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.45–7.36 (m, 2H), 7.25–7.19 (m, 3H), 7.19–7.12 (m, 2H), 7.12–7.07 (m, 2H), 6.69 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 6.33 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 1H), 3.77 (q, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 3.11 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 2.52 (s, 3H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.4, 152.0, 145.3, 142.5, 136.4, 135.5, 129.0, 127.5, 127.2, 123.4, 122.3, 122.1, 119.5, 118.7, 118.3, 118.2, 114.6, 112.8, 111.8, 111.3, 40.0, 25.2, 23.6. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">4</ce:inf>O [M + H]<ce:sup loc="post">+</ce:sup> 371.1866, found 371.1874. The purity was 99.0% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.23" view="all">
                        <ce:label>4.3.23</ce:label>
                        <ce:section-title id="sectitle0235">N-(2-(1H-indol-3-yl)ethyl)-2-((6-chloropyridin-3-yl)amino)benzamide <ce:bold>(NZ4)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0315" view="all">pale yellow solid (62% yield), mp 162.1–162.5 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.52 (s, 1H), 8.25 (s, 1H), 8.22 (d, <ce:italic>J</ce:italic> = 2.7 Hz, 1H), 7.64 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.45 (dd, <ce:italic>J</ce:italic> = 8.5, 2.8 Hz, 1H), 7.38 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.32–7.26 (m, 1H), 7.25–7.17 (m, 4H), 7.13 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 7.09–7.06 (m, 1H), 6.76 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 6.35 (t, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 3.77 (q, <ce:italic>J</ce:italic> = 6.3 Hz, 2H), 3.10 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.2, 143.9, 143.3, 141.6, 137.5, 136.4, 132.3, 129.7, 127.6, 127.1, 124.2, 122.3, 122.1, 119.6, 119.3, 119.3, 118.6, 115.1, 112.7, 111.3, 40.1, 25.1. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">19</ce:inf>NaClN<ce:inf loc="post">4</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 413.1139, found 413.1143. The purity was 98.1% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.24" view="all">
                        <ce:label>4.3.24</ce:label>
                        <ce:section-title id="sectitle0240">N-(2-(1H-indol-3-yl)ethyl)-2-((5-methylpyridin-3-yl)amino)benzamide <ce:bold>(NZ5)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0320" view="all">yellow solid (67% yield), mp 106.2–107.3 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.39 (s, 1H), 8.50 (d, <ce:italic>J</ce:italic> = 11.9 Hz, 1H), 8.31–8.25 (m, 1H), 8.04 (s, 1H), 7.63 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.37 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.29 (s, 1H), 7.27 (d, <ce:italic>J</ce:italic> = 1.9 Hz, 1H), 7.25 (s, 1H), 7.24–7.21 (m, 1H), 7.21–7.18 (m, 1H), 7.15–7.09 (m, 1H), 7.06 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.75–6.70 (m, 1H), 6.51–6.41 (m, 1H), 3.76 (q, <ce:italic>J</ce:italic> = 6.5 Hz, 2H), 3.10 (t, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 2.28 (s, 3H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.3, 144.4, 143.6, 139.6, 137.9, 136.4, 133.5, 132.1, 127.6, 127.5, 127.2, 122.2, 119.5, 119.1, 118.7, 118.6, 115.3, 112.7, 111.3, 40.1, 25.1, 18.3. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">4</ce:inf>O [M + H]<ce:sup loc="post">+</ce:sup> 371.1866, found 371.1878. The purity was 98.9% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.25" view="all">
                        <ce:label>4.3.25</ce:label>
                        <ce:section-title id="sectitle0245">N-(2-(1H-indol-3-yl)ethyl)-2-((5-bromopyridin-3-yl)amino)benzamide <ce:bold>(NZ6)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0325" view="all">yellow solid (69% yield), mp 138.0–138.9 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, <ce:bold>Acetone</ce:bold>
                           <ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 10.06 (s, 1H), 10.01 (s, 1H), 8.44 (d, <ce:italic>J</ce:italic> = 1.9 Hz, 1H), 8.23–8.18 (m, 1H), 8.13–8.06 (m, 1H), 7.79 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.70–7.66 (m, 1H), 7.63 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.46–7.41 (m, 1H), 7.40–7.38 (m, 1H), 7.38–7.36 (m, 1H), 7.21 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.12–7.07 (m, 1H), 7.02–6.97 (m, 1H), 6.94–6.89 (m, 1H), 3.71 (q, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 3.08 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, <ce:bold>Acetone</ce:bold>
                           <ce:italic>-d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) δ 169.5, 143.6, 143.1, 141.0, 140.3, 137.5, 132.6, 129.2, 128.4, 127.2, 123.3, 121.9, 121.6, 120.7, 119.3, 119.1, 116.9, 113.1, 112.0, 41.1, 25.9. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">19</ce:inf>BrNaN<ce:inf loc="post">4</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 457.0634, found 457.0641. The purity was 95.1% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.26" view="all">
                        <ce:label>4.3.26</ce:label>
                        <ce:section-title id="sectitle0250">N-(2-(1H-indol-3-yl)ethyl)-2-(quinoxalin-6-ylamino)benzamide <ce:bold>(NZ7)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0330" view="all">yellow solid (76% yield), mp 117.4–118.3 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 9.82 (s, 1H), 8.65 (s, 1H), 8.59–8.51 (m, 2H), 7.93 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 1H), 7.76 (s, 1H), 7.63 (dd, <ce:italic>J</ce:italic> = 12.9, 8.2 Hz, 2H), 7.51–7.45 (m, 1H), 7.34 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.32–7.26 (m, 2H), 7.19 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 7.10 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 7.04 (s, 1H), 6.80 (t, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 6.56–6.44 (m, 1H), 3.76 (q, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 3.09 (t, <ce:italic>J</ce:italic> = 6.5 Hz, 2H). <ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, CDCl<ce:inf loc="post">3</ce:inf>) δ 169.2, 145.0, 144.5, 143.7, 142.5, 141.9, 139.2, 136.3, 132.0, 130.2, 127.6, 127.1, 125.2, 122.2, 122.1, 120.9, 120.3, 119.4, 118.6, 117.4, 112.5, 111.3, 110.7, 40.1, 25.0. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">21</ce:inf>NaN<ce:inf loc="post">5</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 430.1638, found 430.1641. The purity was 97.7% by HPLC analysis.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.3.27" view="all">
                        <ce:label>4.3.27</ce:label>
                        <ce:section-title id="sectitle0255">N-(2-(1H-indol-3-yl)ethyl)-2-(quinolin-8-ylamino)benzamide <ce:bold>(NZ8)</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0335" view="all">yellow solid (77% yield), mp 195.4–196.4 °C. <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>H NMR</ce:bold> (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ10.84 (s, 1H), 10.79 (s, 1H), 8.91 (dd, <ce:italic>J</ce:italic> = 4.2, 1.6 Hz, 1H), 8.70 (t, <ce:italic>J</ce:italic> = 5.6 Hz, 1H), 8.30 (dd, <ce:italic>J</ce:italic> = 8.3, 1.6 Hz, 1H), 7.76 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.66–7.61 (m, 2H), 7.60–7.55 (m, 2H), 7.50–7.41 (m, 2H), 7.41–7.34 (m, 2H), 7.21 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.10–7.04 (m, 1H), 6.99–6.93 (m, 2H), 3.58 (q, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 2.99 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 2H).<ce:sup loc="post">
                              <ce:bold>13</ce:bold>
                           </ce:sup>
                           <ce:bold>C NMR</ce:bold> (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 168.8, 148.7, 139.5, 139.1, 136.7, 136.7, 131.8, 129.4, 129.2, 127.8, 127.5, 123.6, 123.1, 122.5, 121.4, 120.1, 118.7, 118.7, 118.4, 117.5, 112.4, 111.8, 110.0, 40.6, 25.4. <ce:bold>HRMS (ESI-TOF)</ce:bold> Calcd for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">22</ce:inf>NaN<ce:inf loc="post">4</ce:inf>O [M + Na]<ce:sup loc="post">+</ce:sup> 429.1686, found 429.1698. The purity was 97.7% by HPLC analysis.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0260">Biological evaluation</ce:section-title>
                     <ce:section id="sec4.4.1" view="all">
                        <ce:label>4.4.1</ce:label>
                        <ce:section-title id="sectitle0265">Cell culture</ce:section-title>
                        <ce:para id="p0340" view="all">Rat C6, and human U251 glioma cells were grown in Dulbecco's modified Eagle's medium (DMEM) and the U87MG cells were grown in MEM, both media contains 10% FBS (fetal bovine serum, Gemini Foundational), 100 U/mL penicillin and 100 μg/mL streptomycin, and all cell lines were maintained at 37 °C and in a humidified environment containing 95% air and 5% CO<ce:inf loc="post">2</ce:inf>.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.2" view="all">
                        <ce:label>4.4.2</ce:label>
                        <ce:section-title id="sectitle0270">Cell viability assay</ce:section-title>
                        <ce:para id="p0345" view="all">C6 (2–5 × 10<ce:sup loc="post">3</ce:sup> cells/mL), U87MG (2–5 × 10<ce:sup loc="post">3</ce:sup> cells/mL) and U251 (2–5 × 10<ce:sup loc="post">3</ce:sup> cells/mL) glioma cells were separately added into 96-well microplate at 37 °C in 5% CO<ce:inf loc="post">2</ce:inf> for overnight, and then were treated with various concentrations (100, 50, 25, 12.5, 6.25 μM) of most compound except for <ce:bold>NP16</ce:bold> (8, 4, 2, 1, 0.5 μM). After incubating for 72 h (anti-proliferation assay) or 24 h (growth curve assay), the cellular viability was measured by a Cell Counting Kit-8 (CCK-8) kit (Solarbio, China, lot: CA1210). The absorbance value (OD) was determined using a microplate reader (TECAN, spark, Switzerland) at 450 nm. The IC<ce:inf loc="post">50</ce:inf> values for antiproliferation activity were measured by a dose-response inhibition curve using GraphPad PRISM. All assays were in triplicate and represented in mean ± SD values.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.3" view="all">
                        <ce:label>4.4.3</ce:label>
                        <ce:section-title id="sectitle0275">COX-2 inhibition assay</ce:section-title>
                        <ce:para id="p0350" view="all">The COX-2 inhibition of all compounds was assessed by human COX-2 inhibitory screening assay kit COX-2 (Beyotime, China, lot: S0168. The test concentrations of all compounds except for celecoxib were 0.625, 1.25, 2.5, 5, 10, 20 and 40 μM, while the concentrations of celecoxib were 0.08, 0.16, 0.32, 0.64, 1.28 μM. The fluorescence value for the assay was then determined at (Ex560 nm/Em590 nm) using a microplate reader (TECAN, spark, Switzerland). IC<ce:inf loc="post">50</ce:inf> values were assessed by dose-response inhibition curve (GraphPad software).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.4" view="all">
                        <ce:label>4.4.4</ce:label>
                        <ce:section-title id="sectitle0280">Colony formation assay</ce:section-title>
                        <ce:para id="p0355" view="all">U251 (5–10 × 10<ce:sup loc="post">2</ce:sup> cells/well) and U87MG (5–10 × 10<ce:sup loc="post">2</ce:sup> cells/well) glioma cells were plated into 6-well plate and cultured 12 h at 37 °C in 5% CO<ce:inf loc="post">2</ce:inf>. After the cells attached, <ce:bold>NP16</ce:bold> at indicated concentrations was added into medium and incubated for 14 days. Then the cells were fixed with 4% paraformaldehyd for 5 min and stained with 1% crystal violet for 10 min. Colonies of ≥50 cells were considered as colonies and counted. All data are expressed as the mean ± SD pooled from three independent experiments.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.5" view="all">
                        <ce:label>4.4.5</ce:label>
                        <ce:section-title id="sectitle0285">5-Ethynyl-20-deoxyuridine (EdU) incorporation assay</ce:section-title>
                        <ce:para id="p0360" view="all">U251 and U87MG glioma cells were seeded at a density of 1 × 10<ce:sup loc="post">3</ce:sup> cells/well onto 96-well plates and incubated until the cells attached, then treated with different various of <ce:bold>NP16</ce:bold> (0, 1, 2 and 4 μM). After 36 h, containing 50 μM/100 μL of EdU medium was added and cultured for another 4 h (U87MG) or 2 h (U251) at 37 °C in 5% CO<ce:inf loc="post">2</ce:inf>. Then, removed EdU medium, and added 4% paraformaldehyde (pH 7.4) into the plates for 30 min. Then EdU staining and following Hoechst 33,342 staining was determined according to the manufacture’ instructions. The observation was conducted under a fluorescence microscope (Motic, China). All data are expressed as the mean ± SD pooled from five random fields of view.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.6" view="all">
                        <ce:label>4.4.6</ce:label>
                        <ce:section-title id="sectitle0290">Cell cycle analysis</ce:section-title>
                        <ce:para id="p0365" view="all">The cell cycle of U87MG and U251 cells was determined by flow cytometric analysis. In detail, U87MG and U251 cells at a density of 2–5 × 10<ce:sup loc="post">5</ce:sup> cells/mL were respectively seeded into 6-well plates and cultured until the cells attached, then treated with <ce:bold>NP16</ce:bold> at 2, 4, 8 μM for 48 h. Then the cells were harvested and fixed with 70% pre-cooled ethanol at 4 °C for overnight. After removing ethanol by centrifugation, the fixed cells were resuspended in PBS and treated with RNase A followed by staining with PI for 10 min. The cell cycle analysis was determined by Flow cytometry (Becton Dickinson, USA). Data were analyzed by Modfit software.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.7" view="all">
                        <ce:label>4.4.7</ce:label>
                        <ce:section-title id="sectitle0295">Cell apoptosis assay</ce:section-title>
                        <ce:para id="p0370" view="all">U251 (2–5 × 10<ce:sup loc="post">4</ce:sup> cells/mL) and U87MG (2–5 × 10<ce:sup loc="post">4</ce:sup> cells/mL) glioma cells were plated into 6-well plates and cultured until the cell attached, then treated with <ce:bold>NP16</ce:bold> at 2, 4, 8 μM for 48 h. After that, the cells were collected, washed with PBS, and stained with PI and FITC-Annexin-V for 0.5 h in the dark. Then, the flow cytometry (BD Bioscience, USA) was used for determined the percentages of apoptotic cells. Data were analyzed by Flow J software.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.8" view="all">
                        <ce:label>4.4.8</ce:label>
                        <ce:section-title id="sectitle0300">Measurement of intracellular ROS generation</ce:section-title>
                        <ce:para id="p0375" view="all">U251 (2–5 × 10<ce:sup loc="post">4</ce:sup> cells/well) and U87MG (2–5 × 10<ce:sup loc="post">4</ce:sup> cells/well) glioma cells were seeded into 6-well plates. Twelve hours later, those cells were incubated with the <ce:bold>NP16</ce:bold> (1, 2 and 4 μM) for 12 h. After treatment, the intracellular ROS generation was determined as described previously[<ce:cross-ref id="crosref0545" refid="bib51">51</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.9" view="all">
                        <ce:label>4.4.9</ce:label>
                        <ce:section-title id="sectitle0305">Western blot analysis</ce:section-title>
                        <ce:para id="p0380" view="all">U251 (2–5 × 10<ce:sup loc="post">5</ce:sup> cells/mL) and U87MG (2–5 × 10<ce:sup loc="post">5</ce:sup> cells/mL) glioma cells were separately placed into 6-well plate and cultured for 24 h, then treated with <ce:bold>NP16</ce:bold> at 2, 4, 8 μM for 8 h (<ce:italic>p</ce:italic>-JAK2, JAK2 and β-tubulin) or 24 h (COX-2, MMP9 and β-actin) or 48 h (Bcl-2, Bax, Cytochrome <ce:italic>c</ce:italic> and β-actin). Collecting and washing the cells with pre-cold PBS. To analyze the expression of VEGF-A and <ce:italic>p</ce:italic>-STAT3 in gliomas in rats, the tumor tissue was prepared tissue homogenate on ice, weighed and extracted with 10 mg/100 μL RIPA buffer (Solarbio, Cat.#: R0010, China) supplemented with protease inhibitor cocktail for general use (Beyotime, Cat.#: P1005, China) per 10 mg of tissues on ice for 2 h, the cell were lysed in RIPA buffer on ice for 30 min. The protein concentrations were estimated using a BCA Protein Assay Kit (Beyotime, Cat.#: P0010S). The protein samples (30 μg) were mixed with 4ⅹloading buffer (Solarbio, Cat.#: P1015),were run by 10% SDS-PAGE (Solarbio, Cat.#: P1200) for separation, and transferred to polyvinylidene difluoride membrane (PVDF) of 0.45 μm (Beyotime, Cat.#: FFP32). Membranes were incubated with 5% BSA in TBST buffer for 2 h on shaker at room temperature and then incubated with appropriate diluted (1:1000–1:5000) primary Bcl-2 antibody (Affinity, Bioscience, USA, Cat.#: AF6139), β-actin antibody (Affinity, Bioscience, USA, Cat.#: AF7018), Bax antibody (Affinity, Bioscience, USA, Cat.#: AF0120), Cytochrome <ce:italic>c</ce:italic> antibody (Affinity, Bioscience, USA, Cat.#:BF0714), MMP-9 (Affinity, Bioscience, USA, Cat.#: AF5228), JAK-2 (Affinity, Bioscience, USA, Cat.#: AF6022), <ce:italic>p</ce:italic>-JAK-2 antibody (Affinity, Bioscience, USA, Cat.#: AF3024), COX-2 (D5H5) XP® Rabbit antibody (Cell signaling, USA, Cat.#12282), VEGF-A antibody (Affinity, Bioscience, USA, Cat.#: AF5131), <ce:italic>p</ce:italic>-STAT3 antibody (Affinity, Bioscience, USA, Cat.# AF3293) and β-tubulin antibody (Affinity, Bioscience, USA, Cat.#: AF7010) at 4 °C overnight on shaker. Afterwards, membranes were washed with TBST buffer (1 × ) three times, probed with goat anti-rabbit IgG H + L (Affinity, Bioscience, USA, Cat.#: HRP-S0001) for Bcl-2, β-actin, Bax, VEGF-A, COX-2, MMP-9, JAK-2 and <ce:italic>p</ce:italic>-JAK-2, STAT3 and <ce:italic>p</ce:italic>-STAT3 or goat anti-mouse IgG H + L (Affinity, Bioscience, USA, Cat.#: HRP-S0002) for Cytochrome <ce:italic>c</ce:italic> as secondary antibody at room temperature on shaker for 2 h. After washing by TBST buffer, targeted protein blots were developed using the Affinity ECL kit (Affinity, Bioscience, USA, Cat.#:KF001). The imaging system (FUSION SOLO6S.EDGE, France) was used for WB visualization. Each blotting membrane was calculated by ImageJ software. The relative density of each band were normalized to anti-β-actin antibody and anti-phosphoprotein antibodies were normalized to with anti-total protein antibodies.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.10" view="all">
                        <ce:label>4.4.10</ce:label>
                        <ce:section-title id="sectitle0310">
                           <ce:italic>In vitro</ce:italic> cell invasion and migration assays</ce:section-title>
                        <ce:para id="p0385" view="all">The cell migration and invasion assay were performed with the upper chamber with or without Matrigel (BD) of a 24-well Transwell plate (Costar, Cambridge, MA). Cells suspended with FBS-free medium at a density of 5 × 10<ce:sup loc="post">4</ce:sup>/mL were added into the upper chamber and the outer chamber contained 700 μL medium (15% FBS). At the same time, the various concentrations of <ce:bold>NP16</ce:bold> (1, 2 and 4 μM) were added into the chambers and incubated at 37 °C for 24 h. At the end, cells in upper chamber were removed with cotton swabs. Invaded and migrated cells adhered to the outer surface of the chamber, were fixed with 4% paraformaldehyd for 3 min and stained with crystal violet (0.1%). Five random views were chosen for cell counting (magnification × 200).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.11" view="all">
                        <ce:label>4.4.11</ce:label>
                        <ce:section-title id="sectitle0315">Fluorescence confocal imaging</ce:section-title>
                        <ce:para id="p0390" view="all">U87MG and U251 cells was culture on confocal glass slides until cells attached and were treated with <ce:bold>NP16</ce:bold> of 4 μM for 24 h. Afterwards, medium was replaced, cells were fixed with 1 mL of 4% paraformaldehyde for 10 min then, 4% paraformaldehyde was removed and cells were washed with PBS, and incubated for 45 min with the penetrating solution (5% BSA and 0.3% Triton x-100 diluted in PBS) at room temperature. Then, the primary STAT3 (Affinity, Bioscience, USA, Cat.#: AF6294) antibody (diluted in the penetrating solution at the rate of 1:100) was added into the slides, and subsequently incubated at 4 °C for 12 h. After washed three times with TBST, cells were incubated with Goat Anti-Rabbit (IgG) secondary antibody (Invitrogen, USA, Cat.#: A11011.1:200 dilution in penetrating solution) for 1 h at room temperature in dark place. After washed three times with PBS, cells were stained with Hoechst 33,342 (Solarbio) diluted in PBS at a concentration of 1 μg/mL for 3 min, followed washed with water. Fluorescent images were recorded with a confocal laser microscope (Zeiss LSM700, Switzerland).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.4.12" view="all">
                        <ce:label>4.4.12</ce:label>
                        <ce:section-title id="sectitle0320">Co-cultures assay</ce:section-title>
                        <ce:para id="p0395" view="all">BV2 cells (1 × 10<ce:sup loc="post">4</ce:sup> cells/mL) were plated in the outer wells of 24-well Transwell plate (Costar, Cambridge, MA, 8.0 μm pore size) and cultured at 37 °C and cells were attached. Dissociated C6 cells (5 × 10<ce:sup loc="post">4</ce:sup> cells/mL) in 200 μL serum-free F12K were seeded into upper chambers of the plate. After incubating with <ce:bold>NP4</ce:bold>, <ce:bold>NP15</ce:bold> and <ce:bold>NP16</ce:bold> (2 μM) at 37 °C for 24 h, the expression of MMP-9 in BV2 cells were determined according to “4.4.11” methods.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.5" view="all">
                     <ce:label>4.5</ce:label>
                     <ce:section-title id="sectitle0325">Animal experiments</ce:section-title>
                     <ce:para id="p0400" view="all">The <ce:italic>vivo</ce:italic> study was performed according to the Institutional Animal Care and Use Committee (IACUC) guidelines and was approved by the Institutional Animal Ethics Committee of Lanzhou University. SD rats at the age 7–8 weeks and Kunming mice at the age of 8 weeks were obtained from Lanzhou University. Mice and rats were kept at 25 °C under 12 h of alternating light and dark. All experiments were in compliance with ARRIVE guidelines.</ce:para>
                     <ce:section id="sec4.5.1" view="all">
                        <ce:label>4.5.1</ce:label>
                        <ce:section-title id="sectitle0330">Acute toxicity study</ce:section-title>
                        <ce:para id="p0405" view="all">According to OECD Test Guidelines, the study was performed [<ce:cross-ref id="crosref0550" refid="bib72">72</ce:cross-ref>]. Briefly, four male and four female mice (Kunming) weighing from 18 to 22 g (7–8 weeks of age) were randomly divided into two groups (n = 4, two female and two male mice per group), one group is treated with <ce:bold>NP16</ce:bold> (1000 mg/kg), the other group is treated with equal solvent served as a control. In <ce:bold>NP16</ce:bold> group, <ce:bold>NP16</ce:bold> was dissolved in 20 μL of DMSO, then mixed with saline containing 5% polyoxyethylated castor oil (Sigma, St. Louis, MO, USA, cat. # 238,470) and 5% HS-15 (Meilun Biotechnology Co., Ltd., China, cat. # MB1809) as co-solvent agent. Each mouse was treated with 0.2 mL of diluted <ce:bold>NP16</ce:bold> by intraperitoneal injection at a dose of 1000 mg/kg. Then 14-days continuous observation were performed in terms of states, behavior and death rate.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.5.2" view="all">
                        <ce:label>4.5.2</ce:label>
                        <ce:section-title id="sectitle0335">Pharmacokinetics</ce:section-title>
                        <ce:para id="p0410" view="all">Five SD male adult rats weighing from 180 to 220 g (7–8 weeks of age) were intraperitoneal injected compound <ce:bold>NP16</ce:bold> at 60 mg/kg. Afterwards, rats were anesthetized, then blood was collected from posterior orbital venous plexus at the time points of 0.08, 0.42, 1.42, 3.42, 5.42, 7.42, 9.42 and 24 h after injection. Next, serum sample was separated by centrifugation at 4 °C (2500 rpm, 10 min). Then, the separated serum was mixed vigorously with twice the volume of cold methanol for 1 min. The sample was filtrated using microfiltration membrane (0.22 μm), following were determined by LC-MS and the method was described same as “4.2”. The concentrations of compound <ce:bold>NP16</ce:bold> were calculated by the standard curve, and the formula was y = 453564x+38,167 (r = 0.9934). The pharmacokinetic curve was depicted using Graphpad Prism 8.0. Subsequently, pharmacokinetic parameters were calculated with Pksolver2.0, using the linear trapezoidal method to conduct non-compartmental analysis [<ce:cross-ref id="crosref0555" refid="bib58">58</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec4.5.3" view="all">
                        <ce:label>4.5.3</ce:label>
                        <ce:section-title id="sectitle0340">Blood-brain barrier permeability qualification of NP16 <ce:italic>in vivo</ce:italic>
                        </ce:section-title>
                        <ce:para id="p0415" view="all">Three male adult SD rats (200–220 g) were treated with <ce:bold>NP16</ce:bold> at a dose of 60 mg/kg by intraperitoneally injected. After 2 h, animals were anesthetized and cerebrospinal fluid (50–100 μL) was collected from the cerebellomedullary cistern. The sample preparation method was same as that in pharmacokinetics study. The LC-MS chromatography conditions for qualification were same as mentioned above (4.5.2 Pharmacokinetics study). The brain-to-blood ratio was calculated by the formula: C<ce:inf loc="post">brain</ce:inf>/C<ce:inf loc="post">blood</ce:inf>. C<ce:inf loc="post">brain</ce:inf> and C<ce:inf loc="post">blood</ce:inf> represents the mean concentration in cerebrospinal fluid and serum respectively.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.5.4" view="all">
                        <ce:label>4.5.4</ce:label>
                        <ce:section-title id="sectitle0345">C6 orthotopic glioma model construction, dosing, recording survival time and weight</ce:section-title>
                        <ce:para id="p0420" view="all">Animals were anesthetized and fixed on a stereotactic frame. Following the parietal bone was exposed and drilled a burr hole (diameter = 1 mm) in the right 3 mm and posterior 1 mm of the bregma. C6 glioma cells suspension (5–7 × 10<ce:sup loc="post">4</ce:sup> cells/5 μL) were slowly injected into the rat's cranial cavity vertically at the depth of 4 mm (The needle was advanced to a depth of 5 mm followed by 1 mm withdrawal later from the dura mater) at an injected rate of 1 μL/min. After injection, the injection needle maintained for 5 min and slowly pulled out. The wound was disinfected using iodophor solution and the skin was sutured. In the sham group, 5 μL of PBS as an alternative was injected slowly. After modelling, rats were divided into two groups randomly, including the model group (n = 6), <ce:bold>NP16</ce:bold> treated group (n = 6). The sham group was divided with six rats with sham operation performed previously. The rats in <ce:bold>NP16</ce:bold> group were treated by intraperitoneally injection at a dose of 50 mg/kg (2 mL/100g body weight, suspended in PBS containing 5% polyoxyethylated castor oil (Sigma, St. Louis, MO, USA, cat. # 238,470) and 5% HS-15 (Meilun Biotechnology Co., Ltd., China, cat. # MB1809) per day for 25 consecutive days, while the rats in the model group and sham group were injected with equivalent solvent in the same way. Mortality was recorded continuously for 25 days after C6 cell injection. From the day of modelling surgery, the weight of rats was recorded every three days and analyzed Survival curves by log-rank (Mantel-Cox) test in GraphPad Prism 8.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.5.5" view="all">
                        <ce:label>4.5.5</ce:label>
                        <ce:section-title id="sectitle0350">Tumor volume and tumor weight measurement in C6 orthotopic glioma model</ce:section-title>
                        <ce:para id="p0425" view="all">The modelling method is the same as above <ce:bold>(4.5.4)</ce:bold>. After modelling, rats were randomly divided into three groups, including the model group (n = 5), <ce:bold>NP16</ce:bold> treated group (n = 5), TMZ treated group (n = 5). The sham group was divided with five rats with sham operation performed previously. Tumors were isolated from rats immediately after sacrifice, followed by photographed, and weighed. Tumor volume was calculated by length × width [<ce:cross-ref id="crosref0560" refid="bib2">2</ce:cross-ref>] × 0.50 using radial measurements performed with calipers. The tumor growth inhibition rate (TGI) is calculated using the formula TGI (%) = (1 – TWt/TWc)ⅹ100, where TWt and TWc are the mean tumor weight of treated and C6 groups, respectively. All the results were calculated from five rats and represented as mean ± SD.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.5.6" view="all">
                        <ce:label>4.5.6</ce:label>
                        <ce:section-title id="sectitle0355">Open-field test of rats with C6 glioma</ce:section-title>
                        <ce:para id="p0430" view="all">The modelling method is the same as above <ce:bold>(4.5.4)</ce:bold>. After modelling, rats were randomly divided into three groups, including the model group (n = 6), <ce:bold>NP16</ce:bold> treated group (n = 6), TMZ treated group (n = 6). The sham group was divided with six rats with sham operation performed previously. On day 10 after modelling, the open-field test of rats was performed. In brief, the bottom of the open field (60 cm wide × 60 cm long × 40 cm high) was divided into 3 × 3 grids. The fifth grid in the center was defined as the central grid, and the surrounding grids was the remaining 8 grids around the central grid. Rats were placed in the center of the bottom for 5 min. Meanwhile, the camera recorded the trail of rats, cleaned up the inside of the test box with 75% alcohol after each experiment. The test rats were placed in the center of the box and trail of rats was recorded using a video-tracking system (Chengdu Tai League Software Co., Ltd., Chengdu, China). The residence time of rats in the central grid, and the mean of traveled speed was calculated to evaluate the test results. All the results were calculated from six rats and represented as mean ± SD.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.5.7" view="all">
                        <ce:label>4.5.7</ce:label>
                        <ce:section-title id="sectitle0360">Tumor volume measurement by MRI test in C6 glioma rats</ce:section-title>
                        <ce:para id="p0435" view="all">The twenty rats constructed of C6 orthotopic glioma model was used in Section <ce:cross-ref id="crosref0565" refid="sec4.5.6">4.5.6</ce:cross-ref>. On day 14, tumor volume was measured by MRI (XGY OPER 1.0.). Briefly, rats were anesthetized and positioned on an animal cradle with a rat coil. T2-weighted rapid acquisition was performed to assess tumor volume. The acquisition parameters were as follows: TE = 83.5 s, TR = 3000 ms, 13 image slices, 1.5 mm slice thickness, and 50 μm in-plane resolution.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.5.8" view="all">
                        <ce:label>4.5.8</ce:label>
                        <ce:section-title id="sectitle0365">Tumor tissue collection and processing</ce:section-title>
                        <ce:para id="p0440" view="all">The twenty rats constructed of C6 orthotopic glioma model was used in Section <ce:cross-ref id="crosref0570" refid="sec4.5.6">4.5.6</ce:cross-ref>. After anesthesia, serum samples in C6 and <ce:bold>NP16</ce:bold> group were respectively collected for routine blood test. Then rats were sacrificed for adequate cardiac perfusion with saline (20 mL) followed by 4% paraformaldehyde (20 mL). The whole brains were fixed in 4% paraformaldehyde at 4 °C for more than 24 h and dehydrated in high concentrations of sucrose at 4 °C, embedded in OCT and cut at 5 μm for hematoxylin and eosin staining or immunohistochemistry. The pathological or immunohistochemistry images were recorded by microscope (Motic, China).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.5.9" view="all">
                        <ce:label>4.5.9</ce:label>
                        <ce:section-title id="sectitle0370">Immunostaining of MMP-9 in C6 glioma rats</ce:section-title>
                        <ce:para id="p0445" view="all">The brain tissue section was permeabilized in 0.3% Triton X-100 in TBS and blocked in 5% BSA. After incubation with primary antibody of MMP-9 (Affinity, Bioscience, USA, Cat.#: AF5228) diluted in TBST at 4 °C overnight, Sections were washed three times carefully with 1ⅹTBST and incubated with HRP-conjugated secondary antibody (1:500, diluted in TBST) for 1 h at room temperature. Chromogen detection was carried out with the DAB chromogen kit (Solarbio, cat# DA1015). Section was washed and probed with hematoxylin for nuclear staining. All the results were calculated from six rats and represented as mean ± SD.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.6" view="all">
                     <ce:label>4.6</ce:label>
                     <ce:section-title id="sectitle0375">Statistical analysis</ce:section-title>
                     <ce:para id="p0450" view="all">The data was given as the mean ± SEM/SD and determined for statistical significance by analysis of variance (ANOVA). P values of less than 0.05 were considered significant.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0380">Declaration of competing interest</ce:section-title>
               <ce:para id="p0455" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0385">Acknowledgements</ce:section-title>
               <ce:para id="p0460" view="all">We thank Prof. Qingfeng Wu and Dr. Boyi Yu for MRI measurement. This work was technically supported by <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100009020" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">University of South China</ce:grant-sponsor> and <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/100012899" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Lanzhou University</ce:grant-sponsor>, <ce:grant-sponsor id="gs3" sponsor-id="https://doi.org/10.13039/501100002338" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Ministry of Education of China</ce:grant-sponsor>. This work was financially supported by the <ce:grant-sponsor id="gs6" sponsor-id="https://doi.org/10.13039/501100010871" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Recruitment Program of Global Experts</ce:grant-sponsor> (1000 Talents Plan), the <ce:grant-sponsor id="gs7" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Gansu Province Science Foundation for Distinguished Young Scholars</ce:grant-sponsor> (<ce:grant-number refid="gs7">20JR5RA304</ce:grant-number>), and the <ce:grant-sponsor id="gs8" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Fundamental Research Funds for the Central Universities</ce:grant-sponsor> (<ce:grant-number refid="gs8">lzujbky-2019-ct08</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="all">
                  <ce:section-title id="sectitle0390">Abbreviations</ce:section-title>
                  <ce:para id="p0465" view="all">
                     <ce:def-list id="dlist0010">
                        <ce:def-term id="d0010">GBM</ce:def-term>
                        <ce:def-description id="defdis0010">
                           <ce:para id="p0470" view="all">Glioblastoma multiforme</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0015">COX-2</ce:def-term>
                        <ce:def-description id="defdis0015">
                           <ce:para id="p0475" view="all">Cyclooxygenase-2</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0020">CNS</ce:def-term>
                        <ce:def-description id="defdis0020">
                           <ce:para id="p0480" view="all">Central nervous system</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0025">FBS</ce:def-term>
                        <ce:def-description id="defdis0025">
                           <ce:para id="p0485" view="all">fetal bovine serum</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0030">m</ce:def-term>
                        <ce:def-description id="defdis0030">
                           <ce:para id="p0490" view="all">multiplet (spectral)</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0035">IC<ce:inf loc="post">50</ce:inf>
                        </ce:def-term>
                        <ce:def-description id="defdis0035">
                           <ce:para id="p0495" view="all">half-maximum inhibitory concentration</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0040">SD</ce:def-term>
                        <ce:def-description id="defdis0040">
                           <ce:para id="p0500" view="all">Standard deviation</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0045">i.p</ce:def-term>
                        <ce:def-description id="defdis0045">
                           <ce:para id="p0505" view="all">Intraperitoneally</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0050">MMP-9</ce:def-term>
                        <ce:def-description id="defdis0050">
                           <ce:para id="p0510" view="all">matrix metalloproteinase-9</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0055">DCFH-DA</ce:def-term>
                        <ce:def-description id="defdis0055">
                           <ce:para id="p0515" view="all">2′,7′-dichlorodi-hydrofluorescein</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0060">LD<ce:inf loc="post">50</ce:inf>
                        </ce:def-term>
                        <ce:def-description id="defdis0060">
                           <ce:para id="p0520" view="all">dose that is lethal in 50% of test subjects</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0065">HOBt</ce:def-term>
                        <ce:def-description id="defdis0065">
                           <ce:para id="p0525" view="all">1-Hydroxybenzotriazole</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0070">EDCI</ce:def-term>
                        <ce:def-description id="defdis0070">
                           <ce:para id="p0530" view="all">1-ethyl-3(3-dimethylpropylamine) carbodiimide</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0075">AUC</ce:def-term>
                        <ce:def-description id="defdis0075">
                           <ce:para id="p0535" view="all">area under curve</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0080">DMSO</ce:def-term>
                        <ce:def-description id="defdis0080">
                           <ce:para id="p0540" view="all">dimethyl sulphoxide</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0085">SD</ce:def-term>
                        <ce:def-description id="defdis0085">
                           <ce:para id="p0545" view="all">standard deviation</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0090">SEM</ce:def-term>
                        <ce:def-description id="defdis0090">
                           <ce:para id="p0550" view="all">standard error of mean</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0095">PBS</ce:def-term>
                        <ce:def-description id="defdis0095">
                           <ce:para id="p0555" view="all">Phosphate-buffered saline</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0100">MRI</ce:def-term>
                        <ce:def-description id="defdis0100">
                           <ce:para id="p0560" view="all">magnetic resonance imaging</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0105">OFT</ce:def-term>
                        <ce:def-description id="defdis0105">
                           <ce:para id="p0565" view="all">open field test</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0110">OCT</ce:def-term>
                        <ce:def-description id="defdis0110">
                           <ce:para id="p0570" view="all">optimal cutting temperature compound</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0115">VEGF</ce:def-term>
                        <ce:def-description id="defdis0115">
                           <ce:para id="p0575" view="all">vascular endothelial growth factor</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0120">TMZ</ce:def-term>
                        <ce:def-description id="defdis0120">
                           <ce:para id="p0580" view="all">Temozolomide</ce:para>
                        </ce:def-description>
                     </ce:def-list>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0395">Supplementary data</ce:section-title>
                  <ce:para id="p0585" view="all">The following is the Supplementary data to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Multimedia component 1</ce:label>
                           <ce:alt-text id="alttext0015" role="short">Multimedia component 1</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S022352342100413X/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec3" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0400">Supplementary data</ce:section-title>
                  <ce:para id="p0590" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0010" xlink:href="https://doi.org/10.1016/j.ejmech.2021.113564" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2021.113564</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0405">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Huse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Holland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>DeAngelis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Glioblastoma: molecular analysis and clinical implications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu. Rev. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>64</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>59</sb:first-page>
                              <sb:last-page>70</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1146/annurev-med-100711-143028</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0020">Huse, J. T.; Holland, E.; DeAngelis, L. M., Glioblastoma: molecular analysis and clinical implications. Annu Rev Med 2013, 64, 59-70. DOI: 10.1146/annurev-med-100711-143028</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.N.</ce:given-name>
                                 <ce:surname>Louis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Perry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Reifenberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>von Deimling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Figarella-Branger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.K.</ce:given-name>
                                 <ce:surname>Cavenee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ohgaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.D.</ce:given-name>
                                 <ce:surname>Wiestler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kleihues</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Ellison</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The 2016 world health organization classification of tumors of the central nervous system: a summary</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Neuropathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>131</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>803</sb:first-page>
                              <sb:last-page>820</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s00401-016-1545-1</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">Louis, D. N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W. K.; Ohgaki, H.; Wiestler, O. D.; Kleihues, P.; Ellison, D. W., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016, 131 (6), 803-820. DOI: 10.1007/s00401-016-1545-1</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Maher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.B.</ce:given-name>
                                 <ce:surname>Furnari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Bachoo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Rowitch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.N.</ce:given-name>
                                 <ce:surname>Louis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.K.</ce:given-name>
                                 <ce:surname>Cavenee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>DePinho</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Malignant glioma: genetics and biology of a grave matter</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes Dev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1311</sb:first-page>
                              <sb:last-page>1333</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1101/gad.891601</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">Maher, E. A.; Furnari, F. B.; Bachoo, R. M.; Rowitch, D. H.; Louis, D. N.; Cavenee, W. K.; DePinho, R. A., Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001, 15 (11), 1311-1333. DOI: 10.1101/gad.891601</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.G.</ce:given-name>
                                 <ce:surname>Verhaak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Hoadley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Purdom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Wilkerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Golub</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Mesirov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Alexe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>O'Kelly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Tamayo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Weir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gabriel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Winckler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gupta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Jakkula</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Feiler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Hodgson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>James</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>Sarkaria</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Brennan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Spellman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.K.</ce:given-name>
                                 <ce:surname>Wilson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Speed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Meyerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Getz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Perou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.N.</ce:given-name>
                                 <ce:surname>Hayes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Cancer Genome Atlas Research</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>98</sb:first-page>
                              <sb:last-page>110</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ccr.2009.12.020</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">Verhaak, R. G.; Hoadley, K. A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M. D.; Miller, C. R.; Ding, L.; Golub, T.; Mesirov, J. P.; Alexe, G.; Lawrence, M.; O'Kelly, M.; Tamayo, P.; Weir, B. A.; Gabriel, S.; Winckler, W.; Gupta, S.; Jakkula, L.; Feiler, H. S.; Hodgson, J. G.; James, C. D.; Sarkaria, J. N.; Brennan, C.; Kahn, A.; Spellman, P. T.; Wilson, R. K.; Speed, T. P.; Gray, J. W.; Meyerson, M.; Getz, G.; Perou, C. M.; Hayes, D. N.; Cancer Genome Atlas Research, N., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17 (1), 98-110. DOI: 10.1016/j.ccr.2009.12.020</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Thakkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Dolecek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Horbinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.T.</ce:given-name>
                                 <ce:surname>Ostrom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Lightner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Barnholtz-Sloan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Villano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Epidemiologic and molecular prognostic review of glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Epidemiol. Biomark. Prev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1985</sb:first-page>
                              <sb:last-page>1996</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1055-9965.EPI-14-0275</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">Thakkar, J. P.; Dolecek, T. A.; Horbinski, C.; Ostrom, Q. T.; Lightner, D. D.; Barnholtz-Sloan, J. S.; Villano, J. L., Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev 2014, 23 (10), 1985-1996. DOI: 10.1158/1055-9965.EPI-14-0275</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.T.</ce:given-name>
                                 <ce:surname>Ostrom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>de Blank</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Kruchko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Petersen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Finlay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Stearns</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Wolff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wolinsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Letterio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Barnholtz-Sloan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Alex's lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuro Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>Suppl 10</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>x1</sb:first-page>
                              <sb:last-page>x36</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/neuonc/nou327</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">Ostrom, Q. T.; de Blank, P. M.; Kruchko, C.; Petersen, C. M.; Liao, P.; Finlay, J. L.; Stearns, D. S.; Wolff, J. E.; Wolinsky, Y.; Letterio, J. J.; Barnholtz-Sloan, J. S., Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro Oncol 2015, 16 Suppl 10, x1-x36. DOI: 10.1093/neuonc/nou327</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.T.</ce:given-name>
                                 <ce:surname>Ostrom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Cote</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ascha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Kruchko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Barnholtz-Sloan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JAMA Oncol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1254</sb:first-page>
                              <sb:last-page>1262</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1001/jamaoncol.2018.1789</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">Ostrom, Q. T.; Cote, D. J.; Ascha, M.; Kruchko, C.; Barnholtz-Sloan, J. S., Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. JAMA Oncol 2018, 4 (9), 1254-1262. DOI: 10.1001/jamaoncol.2018.1789</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>van Linde</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Brahm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>de Witt Hamer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Reijneveld</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.E.</ce:given-name>
                                 <ce:surname>Bruynzeel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.P.</ce:given-name>
                                 <ce:surname>Vandertop</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>van de Ven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wagemakers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>van der Weide</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.H.</ce:given-name>
                                 <ce:surname>Enting</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.E.</ce:given-name>
                                 <ce:surname>Walenkamp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.W.</ce:given-name>
                                 <ce:surname>Verheul</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Neuro Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>135</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>183</sb:first-page>
                              <sb:last-page>192</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s11060-017-2564-z</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">van Linde, M. E.; Brahm, C. G.; de Witt Hamer, P. C.; Reijneveld, J. C.; Bruynzeel, A. M. E.; Vandertop, W. P.; van de Ven, P. M.; Wagemakers, M.; van der Weide, H. L.; Enting, R. H.; Walenkamp, A. M. E.; Verheul, H. M. W., Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. J Neurooncol 2017, 135 (1), 183-192. DOI: 10.1007/s11060-017-2564-z</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Vollmann-Zwerenz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Leidgens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Feliciello</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Klein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Hau</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tumor cell invasion in glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <ce:doi>10.3390/ijms21061932</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">Vollmann-Zwerenz, A.; Leidgens, V.; Feliciello, G.; Klein, C. A.; Hau, P., Tumor Cell Invasion in Glioblastoma. Int J Mol Sci 2020, 21 (6). DOI: 10.3390/ijms21061932</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Gritsenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Friedl</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Adaptive adhesion systems mediate glioma cell invasion in complex environments</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cell Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>131</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>15</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <ce:doi>10.1242/jcs.216382</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">Gritsenko, P. G.; Friedl, P., Adaptive adhesion systems mediate glioma cell invasion in complex environments. J Cell Sci 2018, 131 (15). DOI: 10.1242/jcs.216382</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>de Gooijer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Guillen Navarro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bernards</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wurdinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>van Tellingen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An experimenter's guide to glioblastoma invasion pathways</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Mol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>763</sb:first-page>
                              <sb:last-page>780</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.molmed.2018.07.003</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">de Gooijer, M. C.; Guillen Navarro, M.; Bernards, R.; Wurdinger, T.; van Tellingen, O., An Experimenter's Guide to Glioblastoma Invasion Pathways. Trends Mol Med 2018, 24 (9), 763-780. DOI: 10.1016/j.molmed.2018.07.003</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.A.</ce:given-name>
                                 <ce:surname>Cuddapah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Robel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Watkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sontheimer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A neurocentric perspective on glioma invasion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>455</sb:first-page>
                              <sb:last-page>465</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrn3765</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">Cuddapah, V. A.; Robel, S.; Watkins, S.; Sontheimer, H., A neurocentric perspective on glioma invasion. Nat Rev Neurosci 2014, 15 (7), 455-465. DOI: 10.1038/nrn3765</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Squatrito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Scarpace</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>deCarvalho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lyu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Barthel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.H.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Satani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Martinez-Ledesma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Sauve</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Olar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.D.</ce:given-name>
                                 <ce:surname>Lan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Finocchiaro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Phillips</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Berger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Gabrusiewicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Eskilsson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mikkelsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>DePinho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Muller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Heimberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.P.</ce:given-name>
                                 <ce:surname>Sulman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Nam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.G.W.</ce:given-name>
                                 <ce:surname>Verhaak</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>42</sb:first-page>
                              <sb:last-page>56</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ccell.2017.06.003</ce:doi>
                        </sb:host>
                        <sb:comment>e6</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0080">Wang, Q.; Hu, B.; Hu, X.; Kim, H.; Squatrito, M.; Scarpace, L.; deCarvalho, A. C.; Lyu, S.; Li, P.; Li, Y.; Barthel, F.; Cho, H. J.; Lin, Y. H.; Satani, N.; Martinez-Ledesma, E.; Zheng, S.; Chang, E.; Sauve, C. G.; Olar, A.; Lan, Z. D.; Finocchiaro, G.; Phillips, J. J.; Berger, M. S.; Gabrusiewicz, K. R.; Wang, G.; Eskilsson, E.; Hu, J.; Mikkelsen, T.; DePinho, R. A.; Muller, F.; Heimberger, A. B.; Sulman, E. P.; Nam, D. H.; Verhaak, R. G. W., Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 2017, 32 (1), 42-56 e6. DOI: 10.1016/j.ccell.2017.06.003</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>van Tellingen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Yetkin-Arik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>de Gooijer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wesseling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wurdinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.E.</ce:given-name>
                                 <ce:surname>de Vries</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overcoming the blood-brain tumor barrier for effective glioblastoma treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Resist. Updates</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>12</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.drup.2015.02.002</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">van Tellingen, O.; Yetkin-Arik, B.; de Gooijer, M. C.; Wesseling, P.; Wurdinger, T.; de Vries, H. E., Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 2015, 19, 1-12. DOI: 10.1016/j.drup.2015.02.002</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Broekman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.N.</ce:given-name>
                                 <ce:surname>Maas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.R.</ce:given-name>
                                 <ce:surname>Abels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.R.</ce:given-name>
                                 <ce:surname>Mempel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Krichevsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.O.</ce:given-name>
                                 <ce:surname>Breakefield</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multidimensional communication in the microenvirons of glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Neurol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>482</sb:first-page>
                              <sb:last-page>495</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41582-018-0025-8</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">Broekman, M. L.; Maas, S. L. N.; Abels, E. R.; Mempel, T. R.; Krichevsky, A. M.; Breakefield, X. O., Multidimensional communication in the microenvirons of glioblastoma. Nat Rev Neurol 2018, 14 (8), 482-495. DOI: 10.1038/s41582-018-0025-8</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.P.</ce:given-name>
                                 <ce:surname>Ferrer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Moura Neto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mentlein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Glioma infiltration and extracellular matrix: key players and modulators</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Glia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1542</sb:first-page>
                              <sb:last-page>1565</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/glia.23309</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">Ferrer, V. P.; Moura Neto, V.; Mentlein, R., Glioma infiltration and extracellular matrix: key players and modulators. Glia 2018, 66 (8), 1542-1565. DOI: 10.1002/glia.23309</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Quercetin sensitizes glioblastoma to t-AUCB by dual inhibition of Hsp27 and COX-2 in vitro and in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>61</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1186/s13046-016-0331-1</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">Li, J.; Tang, C.; Li, L.; Li, R.; Fan, Y., Quercetin sensitizes glioblastoma to t-AUCB by dual inhibition of Hsp27 and COX-2 in vitro and in vivo. J Exp Clin Cancer Res 2016, 35, 61. DOI: 10.1186/s13046-016-0331-1</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Qiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Bell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>176</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1680</sb:first-page>
                              <sb:last-page>1699</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/bph.14622</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">Qiu, J.; Li, Q.; Bell, K. A.; Yao, X.; Du, Y.; Zhang, E.; Yu, J. J.; Yu, Y.; Shi, Z.; Jiang, J., Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth. Br J Pharmacol 2019, 176 (11), 1680-1699. DOI: 10.1111/bph.14622</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Prostaglandin E2 increases migration and proliferation of human glioblastoma cells by activating transient receptor potential melastatin 7 channels</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cell Mol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6327</sb:first-page>
                              <sb:last-page>6337</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/jcmm.13931</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">Tian, Y.; Yang, T.; Yu, S.; Liu, C.; He, M.; Hu, C., Prostaglandin E2 increases migration and proliferation of human glioblastoma cells by activating transient receptor potential melastatin 7 channels. J Cell Mol Med 2018, 22 (12), 6327-6337. DOI: 10.1111/jcmm.13931</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ochs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Rauschenbach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Deumelandt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Sahm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Opitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>von Deimling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Platten</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Neurochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>136</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1142</sb:first-page>
                              <sb:last-page>1154</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/jnc.13503</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">Ochs, K.; Ott, M.; Rauschenbach, K. J.; Deumelandt, K.; Sahm, F.; Opitz, C. A.; von Deimling, A.; Wick, W.; Platten, M., Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. J Neurochem 2016, 136 (6), 1142-1154. DOI: 10.1111/jnc.13503</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Dingledine</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharmacol. Exp. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>344</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>360</sb:first-page>
                              <sb:last-page>367</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1124/jpet.112.200444</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">Jiang, J.; Dingledine, R., Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther 2013, 344 (2), 360-367. DOI: 10.1124/jpet.112.200444</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Palumbo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Lombardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.R.</ce:given-name>
                                 <ce:surname>Augello</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Giusti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Dolo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Leocata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Cifone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Cinque</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biological effects of selective COX-2 inhibitor NS398 on human glioblastoma cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell Int.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>167</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1186/s12935-020-01250-7</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">Palumbo, P.; Lombardi, F.; Augello, F. R.; Giusti, I.; Dolo, V.; Leocata, P.; Cifone, M. G.; Cinque, B., Biological effects of selective COX-2 inhibitor NS398 on human glioblastoma cell lines. Cancer Cell Int 2020, 20, 167. DOI: 10.1186/s12935-020-01250-7</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.J.T.</ce:given-name>
                                 <ce:surname>Tadahisa Shono</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Janet M.</ce:given-name>
                                 <ce:surname>Bruner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Olubunmi</ce:given-name>
                                 <ce:surname>Owolabi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Frederick F.</ce:given-name>
                                 <ce:surname>Lang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4375</sb:first-page>
                              <sb:last-page>4381</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">Tadahisa Shono, P. J. T., Janet M. Bruner, Olubunmi Owolabi, and Frederick F. Lang, Cyclooxygenase-2 Expression in Human Gliomas: Prognostic Significance and Molecular Correlations. CANCER RESEARCH 2001, 61, 4375-4381.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Cook</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Kingsley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Shimizu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Montrose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Marnett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.S.</ce:given-name>
                                 <ce:surname>Tabar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Dannenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Benezra</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuro Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1379</sb:first-page>
                              <sb:last-page>1389</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/neuonc/now049</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">Cook, P. J.; Thomas, R.; Kingsley, P. J.; Shimizu, F.; Montrose, D. C.; Marnett, L. J.; Tabar, V. S.; Dannenberg, A. J.; Benezra, R., Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma. Neuro Oncol 2016, 18 (10), 1379-1389. DOI: 10.1093/neuonc/now049</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Greenhough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Smartt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Paraskeva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kaidi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Carcinogenesis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>377</sb:first-page>
                              <sb:last-page>386</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/carcin/bgp014</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">Greenhough, A.; Smartt, H. J.; Moore, A. E.; Roberts, H. R.; Williams, A. C.; Paraskeva, C.; Kaidi, A., The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30 (3), 377-386. DOI: 10.1093/carcin/bgp014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zelenay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>van der Veen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Bottcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Snelgrove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Rogers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Acton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chakravarty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Girotti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Marais</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Quezada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sahai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Reis e Sousa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclooxygenase-dependent tumor growth through evasion of immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>162</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1257</sb:first-page>
                              <sb:last-page>1270</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.cell.2015.08.015</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">Zelenay, S.; van der Veen, A. G.; Bottcher, J. P.; Snelgrove, K. J.; Rogers, N.; Acton, S. E.; Chakravarty, P.; Girotti, M. R.; Marais, R.; Quezada, S. A.; Sahai, E.; Reis e Sousa, C., Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 2015, 162 (6), 1257-1270. DOI: 10.1016/j.cell.2015.08.015</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Megan Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Chris</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Simon</ce:given-name>
                                 <ce:surname>Gunter</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aberrantly activated Cox-2 and Wnt signaling interact to maintain cancer stem cells in glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>47</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>82217</sb:first-page>
                              <sb:last-page>82230</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.18632/oncotarget.19283</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">Megan Wu, J. G., Chris Li, Simon Gunter, et al., Aberrantly activated Cox-2 and Wnt signaling interact to maintain cancer stem cells in glioblastoma. Oncotarget 2017, 8 (47), 82217-82230. DOI: 10.18632/oncotarget.19283</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.T.</ce:given-name>
                                 <ce:surname>Chiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Chow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.T.</ce:given-name>
                                 <ce:surname>Shia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Contribution of reactive oxygen species to migration/invasion of human glioblastoma cells U87 via ERK-dependent COX-2/PGE(2) activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neurobiol. Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>118</sb:first-page>
                              <sb:last-page>129</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.nbd.2009.09.015</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">Chiu, W. T.; Shen, S. C.; Chow, J. M.; Lin, C. W.; Shia, L. T.; Chen, Y. C., Contribution of reactive oxygen species to migration/invasion of human glioblastoma cells U87 via ERK-dependent COX-2/PGE(2) activation. Neurobiol Dis 2010, 37 (1), 118-129. DOI: 10.1016/j.nbd.2009.09.015</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Qiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclooxygenase-2 in glioblastoma multiforme</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>148</sb:first-page>
                              <sb:last-page>156</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.drudis.2016.09.017</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">Qiu, J.; Shi, Z.; Jiang, J., Cyclooxygenase-2 in glioblastoma multiforme. Drug Discov Today 2017, 22 (1), 148-156. DOI: 10.1016/j.drudis.2016.09.017</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.D.V.</ce:given-name>
                                 <ce:surname>Marco Tafani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Alessandro</ce:given-name>
                                 <ce:surname>Frati</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Neuroinflammation</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>32</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1186/1742-2094-8-32</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">Marco Tafani, M. D. V., Alessandro Frati,et al, Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. Journal of Neuroinflammation 2011, 8, 32. DOI: 10.1186/1742-2094-8-32</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Amaradhi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ganesh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Dingledine</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An agonist dependent allosteric antagonist of prostaglandin EP2 receptors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1436</sb:first-page>
                              <sb:last-page>1446</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acschemneuro.0c00078</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">Jiang, C.; Amaradhi, R.; Ganesh, T.; Dingledine, R., An Agonist Dependent Allosteric Antagonist of Prostaglandin EP2 Receptors. ACS Chem Neurosci 2020, 11 (10), 1436-1446. DOI: 10.1021/acschemneuro.0c00078</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sever</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Altintop</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Kus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ozkurt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ozdemir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.A.</ce:given-name>
                                 <ce:surname>Kaplancikli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Indomethacin based new triazolothiadiazine derivatives: synthesis, evaluation of their anticancer effects on T98 human glioma cell line related to COX-2 inhibition and docking studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>113</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>179</sb:first-page>
                              <sb:last-page>186</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2016.02.036</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">Sever, B.; Altintop, M. D.; Kus, G.; Ozkurt, M.; Ozdemir, A.; Kaplancikli, Z. A., Indomethacin based new triazolothiadiazine derivatives: Synthesis, evaluation of their anticancer effects on T98 human glioma cell line related to COX-2 inhibition and docking studies. Eur J Med Chem 2016, 113, 179-186. DOI: 10.1016/j.ejmech.2016.02.036</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Huo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Hou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKbeta kinase activity and interrupting NF-kappaB/COX-2-mediated signaling cascades</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>93</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1186/s13046-017-0563-8</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">Wang, X.; Yu, Z.; Wang, C.; Cheng, W.; Tian, X.; Huo, X.; Wang, Y.; Sun, C.; Feng, L.; Xing, J.; Lan, Y.; Sun, D.; Hou, Q.; Zhang, B.; Ma, X.; Zhang, B., Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKbeta kinase activity and interrupting NF-kappaB/COX-2-mediated signaling cascades. J Exp Clin Cancer Res 2017, 36 (1), 93. DOI: 10.1186/s13046-017-0563-8</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.L.</ce:given-name>
                                 <ce:surname>Lan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Lou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Isoalantolactone inhibits IKKbeta kinase activity to interrupt the NF-kappaB/COX-2-mediated signaling cascade and induces apoptosis regulated by the mitochondrial translocation of cofilin in glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1655</sb:first-page>
                              <sb:last-page>1670</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/cam4.2013</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">Xing, J. S.; Wang, X.; Lan, Y. L.; Lou, J. C.; Ma, B.; Zhu, T.; Zhang, H.; Wang, D.; Yu, Z.; Yuan, Z.; Li, X. Y.; Zhang, B., Isoalantolactone inhibits IKKbeta kinase activity to interrupt the NF-kappaB/COX-2-mediated signaling cascade and induces apoptosis regulated by the mitochondrial translocation of cofilin in glioblastoma. Cancer Med 2019, 8 (4), 1655-1670. DOI: 10.1002/cam4.2013</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Qiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Prostaglandin E2 signaling: alternative target for glioblastoma?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>75</sb:first-page>
                              <sb:last-page>78</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.trecan.2016.12.002</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">Jiang, J.; Qiu, J.; Li, Q.; Shi, Z., Prostaglandin E2 Signaling: Alternative Target for Glioblastoma? Trends Cancer 2017, 3 (2), 75-78. DOI: 10.1016/j.trecan.2016.12.002</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tuettenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Grobholz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Korn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Wenz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Erber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Vajkoczy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Canc. Res. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>131</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>31</sb:first-page>
                              <sb:last-page>40</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s00432-004-0620-5</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">Tuettenberg, J.; Grobholz, R.; Korn, T.; Wenz, F.; Erber, R.; Vajkoczy, P., Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 2005, 131 (1), 31-40. DOI: 10.1007/s00432-004-0620-5</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Santosh Kesari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>John W.</ce:given-name>
                                 <ce:surname>Henson</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuro Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>300</sb:first-page>
                              <sb:last-page>308</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1215/15228517-2008-005</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">Santosh Kesari, D. S., John W. Henson, et al., Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-Oncology 2008, 10 (3), 300-308. DOI: 10.1215/15228517-2008-005</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mullard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Arvinas's PROTACs pass first safety and PK analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>895</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1038/d41573-019-00188-4</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">Mullard, A., Arvinas's PROTACs pass first safety and PK analysis. Nat Rev Drug Discov 2019, 18 (12), 895. DOI: 10.1038/d41573-019-00188-4</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Luwor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Stylli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.</ce:given-name>
                                 <ce:surname>Kaye</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of Stat3 in glioblastoma multiforme</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>907</sb:first-page>
                              <sb:last-page>911</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.jocn.2013.03.006</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">Luwor, R. B.; Stylli, S. S.; Kaye, A. H., The role of Stat3 in glioblastoma multiforme. J Clin Neurosci 2013, 20 (7), 907-911. DOI: 10.1016/j.jocn.2013.03.006</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Iwamaru</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Szymanski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Iwado</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Aoki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yokoyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Fokt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hess</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Conrad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Madden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sawaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kondo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Priebe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kondo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>17</sb:issue-nr>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2435</sb:first-page>
                              <sb:last-page>2444</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/sj.onc.1210031</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">Iwamaru, A.; Szymanski, S.; Iwado, E.; Aoki, H.; Yokoyama, T.; Fokt, I.; Hess, K.; Conrad, C.; Madden, T.; Sawaya, R.; Kondo, S.; Priebe, W.; Kondo, Y., A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007, 26 (17), 2435-2444. DOI: 10.1038/sj.onc.1210031</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Huynh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ernst</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>82</sb:first-page>
                              <sb:last-page>96</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41568-018-0090-8</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">Huynh, J.; Chand, A.; Gough, D.; Ernst, M., Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer 2019, 19 (2), 82-96. DOI: 10.1038/s41568-018-0090-8</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.Y.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sandanaraj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.K.</ce:given-name>
                                 <ce:surname>Chong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.W.H.</ce:given-name>
                                 <ce:surname>Koh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Ng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.T.</ce:given-name>
                                 <ce:surname>Ang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A STAT3-based gene signature stratifies glioma patients for targeted therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3601</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41467-019-11614-x</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">Tan, M. S. Y.; Sandanaraj, E.; Chong, Y. K.; Lim, S. W.; Koh, L. W. H.; Ng, W. H.; Tan, N. S.; Tan, P.; Ang, B. T.; Tang, C., A STAT3-based gene signature stratifies glioma patients for targeted therapy. Nat Commun 2019, 10 (1), 3601. DOI: 10.1038/s41467-019-11614-x</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3: a key signaling molecule for converting cold to hot tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>489</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>29</sb:first-page>
                              <sb:last-page>40</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.canlet.2020.05.035</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">Hu, R.; Han, Q.; Zhang, J., STAT3: A key signaling molecule for converting cold to hot tumors. Cancer Lett 2020, 489, 29-40. DOI: 10.1016/j.canlet.2020.05.035</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dalwadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Krysan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Heuze-Vourc'h</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dohadwala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Elashoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Cacalano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lichtenstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dubinett</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>21</sb:issue-nr>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7674</sb:first-page>
                              <sb:last-page>7682</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1078-0432.CCR-05-1205</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">Dalwadi, H.; Krysan, K.; Heuze-Vourc'h, N.; Dohadwala, M.; Elashoff, D.; Sharma, S.; Cacalano, N.; Lichtenstein, A.; Dubinett, S., Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 2005, 11 (21), 7674-7682. DOI: 10.1158/1078-0432.CCR-05-1205</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Lo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ali-Osman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>232</sb:first-page>
                              <sb:last-page>245</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1541-7786.MCR-09-0391</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">Lo, H. W.; Cao, X.; Zhu, H.; Ali-Osman, F., Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res 2010, 8 (2), 232-245. DOI: 10.1158/1541-7786.MCR-09-0391</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Koppikar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATe-of-the-art approach: using oligonucleotide decoys to target the "undruggable</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>670</sb:first-page>
                              <sb:last-page>672</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/2159-8290.CD-12-0310</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">Koppikar, P.; Bromberg, J., STATe-of-the-art approach: using oligonucleotide decoys to target the "undruggable". Cancer Discov 2012, 2 (8), 670-672. DOI: 10.1158/2159-8290.CD-12-0310</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chinnaswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Meagher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>511</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ccell.2019.10.002</ce:doi>
                        </sb:host>
                        <sb:comment>e17</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0250">Bai, L.; Zhou, H.; Xu, R.; Zhao, Y.; Chinnaswamy, K.; McEachern, D.; Chen, J.; Yang, C. Y.; Liu, Z.; Wang, M.; Liu, L.; Jiang, H.; Wen, B.; Kumar, P.; Meagher, J. L.; Sun, D.; Stuckey, J. A.; Wang, S., A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell 2019, 36 (5), 498-511 e17. DOI: 10.1016/j.ccell.2019.10.002</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Maitra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bhattacharya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bhattacharya</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Melatonin and its anti-glioma functions: a comprehensive review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Rev. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>527</sb:first-page>
                              <sb:last-page>541</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1515/revneuro-2018-0041</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">Maitra, S.; Bhattacharya, D.; Das, S.; Bhattacharya, S., Melatonin and its anti-glioma functions: a comprehensive review. Rev Neurosci 2019, 30 (5), 527-541. DOI: 10.1515/revneuro-2018-0041</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pineal Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>208</sb:first-page>
                              <sb:last-page>217</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/jpi.12341</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">Chen, X.; Hao, A.; Li, X.; Du, Z.; Li, H.; Wang, H.; Yang, H.; Fang, Z., Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis. J Pineal Res 2016, 61 (2), 208-217. DOI: 10.1111/jpi.12341</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>211</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>113027</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2020.113027</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">Ma, S.; Zhu, L.; Fan, X.; Luo, T.; Liu, D.; Liang, Z.; Hu, X.; Shi, T.; Tan, W.; Wang, Z., Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3. Eur J Med Chem 2021, 211, 113027. DOI: 10.1016/j.ejmech.2020.113027</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>193</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>112217</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2020.112217</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">Fan, X.; Li, J.; Deng, X.; Lu, Y.; Feng, Y.; Ma, S.; Wen, H.; Zhao, Q.; Tan, W.; Shi, T.; Wang, Z., Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation. Eur J Med Chem 2020, 193, 112217. DOI: 10.1016/j.ejmech.2020.112217</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.K.</ce:given-name>
                                 <ce:surname>Hagmann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The many roles for fluorine in medicinal chemistry</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>15</sb:issue-nr>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4360</sb:first-page>
                              <sb:last-page>4369</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm800219f</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">Hagmann, W. K., The Many Roles for Fluorine in Medicinal Chemistry. Journal of Medicinal Chemistry 2008, 51 (15), 4360-4369. DOI: 10.1021/jm800219f</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hambardzumyan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Gutmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kettenmann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of microglia and macrophages in glioma maintenance and progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>20</sb:first-page>
                              <sb:last-page>27</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nn.4185</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">Hambardzumyan, D.; Gutmann, D. H.; Kettenmann, H., The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 2016, 19 (1), 20-27. DOI: 10.1038/nn.4185</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Graeber</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The molecular profile of microglia under the influence of glioma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuro Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>958</sb:first-page>
                              <sb:last-page>978</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/neuonc/nos116</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">Li, W.; Graeber, M. B., The molecular profile of microglia under the influence of glioma. Neuro Oncol 2012, 14 (8), 958-978. DOI: 10.1093/neuonc/nos116</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Marinari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Allard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Gustave</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Widmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Philippin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Merkler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Tsantoulis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Dutoit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.Y.</ce:given-name>
                                 <ce:surname>Dietrich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>OncoImmunology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1779990</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1080/2162402X.2020.1779990</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">Marinari, E.; Allard, M.; Gustave, R.; Widmer, V.; Philippin, G.; Merkler, D.; Tsantoulis, P.; Dutoit, V.; Dietrich, P. Y., Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. Oncoimmunology 2020, 9 (1), 1779990. DOI: 10.1080/2162402X.2020.1779990</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.T.</ce:given-name>
                                 <ce:surname>Oh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Sa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>You</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Son</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Nam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Gwak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yoo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Iavarone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2978</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41467-020-16789-2</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">Yin, J.; Kim, S. S.; Choi, E.; Oh, Y. T.; Lin, W.; Kim, T. H.; Sa, J. K.; Hong, J. H.; Park, S. H.; Kwon, H. J.; Jin, X.; You, Y.; Kim, J. H.; Kim, H.; Son, J.; Lee, J.; Nam, D. H.; Choi, K. S.; Shi, B.; Gwak, H. S.; Yoo, H.; Iavarone, A.; Kim, J. H.; Park, J. B., ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. Nat Commun 2020, 11 (1), 2978. DOI: org/10.1038/s41467-020-16789-2</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front Oncol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>590941</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.3389/fonc.2020.590941</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">Ge, Z.; Ding, S., The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy. Front Oncol 2020, 10, 590941. DOI: 10.3389/fonc.2020.590941</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Qian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Shao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin enhances the radiosensitivity of U87 cells by inducing DUSP-2 up-regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Physiol. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1381</sb:first-page>
                              <sb:last-page>1393</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1159/000373959</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">Qian, Y.; Ma, J.; Guo, X.; Sun, J.; Yu, Y.; Cao, B.; Zhang, L.; Ding, X.; Huang, J.; Shao, J. F., Curcumin enhances the radiosensitivity of U87 cells by inducing DUSP-2 up-regulation. Cell Physiol Biochem 2015, 35 (4), 1381-1393. DOI: 10.1159/000373959</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Pedro J Real</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ana de Juan, et al., Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7611</sb:first-page>
                              <sb:last-page>7618</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/sj.onc</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">Pedro J Real, A. S., Ana de Juan, et al., Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002, 21, 7611 - 7618. DOI: 10.1038/sj.onc</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lalier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.F.</ce:given-name>
                                 <ce:surname>Cartron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Pedelaborde</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Olivier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Loussouarn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Meflah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Menanteau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.M.</ce:given-name>
                                 <ce:surname>Vallette</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>34</sb:issue-nr>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4999</sb:first-page>
                              <sb:last-page>5009</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/sj.onc.1210303</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">Lalier, L.; Cartron, P. F.; Pedelaborde, F.; Olivier, C.; Loussouarn, D.; Martin, S. A.; Meflah, K.; Menanteau, J.; Vallette, F. M., Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme. Oncogene 2007, 26 (34), 4999-5009. DOI: 10.1038/sj.onc.1210303</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gorrini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.S.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Mak</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Modulation of oxidative stress as an anticancer strategy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>931</sb:first-page>
                              <sb:last-page>947</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrd4002</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">Gorrini, C.; Harris, I. S.; Mak, T. W., Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013, 12 (12), 931-947. DOI: 10.1038/nrd4002</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hambardzumyan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bergers</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Glioblastoma: defining tumor niches</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>252</sb:first-page>
                              <sb:last-page>265</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.trecan.2015.10.009</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">Hambardzumyan, D.; Bergers, G., Glioblastoma: Defining Tumor Niches. Trends Cancer 2015, 1 (4), 252-265. DOI: 10.1016/j.trecan.2015.10.009</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.H.</ce:given-name>
                                 <ce:surname>Xiaoming Rong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Shuwei</ce:given-name>
                                 <ce:surname>Qiu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>51</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>83976</sb:first-page>
                              <sb:last-page>83986</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.18632/oncotarget.6930</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">Xiaoming Rong , B. H., Shuwei Qiu,et al., Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation. Oncotarget 2016, 7 (51), 83976-83986. DOI: 10.18632/oncotarget.6930</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>389</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>23</sb:first-page>
                              <sb:last-page>32</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.canlet.2016.12.031</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">Tong, D.; Liu, Q.; Liu, G.; Xu, J.; Lan, W.; Jiang, Y.; Xiao, H.; Zhang, D.; Jiang, J., Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis. Cancer Lett 2017, 389, 23-32. DOI: 10.1016/j.canlet.2016.12.031</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>O'Callaghan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Houston</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>172</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>22</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5239</sb:first-page>
                              <sb:last-page>5250</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/bph.13331</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">O'Callaghan, G.; Houston, A., Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol 2015, 172 (22), 5239-5250. DOI: 10.1111/bph.13331</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Tabouret</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Boudouresque</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Farina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Barrie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Bequet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sanson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Chinot</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuro Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1174</sb:first-page>
                              <sb:last-page>1176</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/neuonc/nov094</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">Tabouret, E.; Boudouresque, F.; Farina, P.; Barrie, M.; Bequet, C.; Sanson, M.; Chinot, O., MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. Neuro Oncol 2015, 17 (8), 1174-1176. DOI: 10.1093/neuonc/nov094</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Mu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evaluation of a tumor electric field treatment system in a rat model of glioma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>CNS Neurosci. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1168</sb:first-page>
                              <sb:last-page>1177</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/cns.13441</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0350">Wu, H.; Wang, C.; Liu, J.; Zhou, D.; Chen, D.; Liu, Z.; Wu, A.; Yang, L.; Chang, J.; Luo, C.; Cheng, W.; Shen, S.; Bai, Y.; Mu, X.; Li, C.; Wang, Z.; Chen, L., Evaluation of a tumor electric field treatment system in a rat model of glioma. CNS Neurosci Ther 2020, 26 (11), 1168-1177. DOI: 10.1111/cns.13441</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Appolloni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Barilari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Caviglia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gambini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Reisoli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Malatesta</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A cadherin switch underlies malignancy in high-grade gliomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>15</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1991</sb:first-page>
                              <sb:last-page>2002</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/onc.2014.122</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0355">Appolloni, I.; Barilari, M.; Caviglia, S.; Gambini, E.; Reisoli, E.; Malatesta, P., A cadherin switch underlies malignancy in high-grade gliomas. Oncogene 2015, 34 (15), 1991-2002. DOI: 10.1038/onc.2014.122</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>[69]</ce:label>
                     <sb:reference id="sref69">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sitarz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Leguit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>de Leng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.H.</ce:given-name>
                                 <ce:surname>Morsink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.P.</ce:given-name>
                                 <ce:surname>Polkowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Maciejewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Offerhaus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.N.</ce:given-name>
                                 <ce:surname>Milne</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>475</sb:first-page>
                              <sb:last-page>485</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.3233/CLO-2009-0496</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0360">Sitarz, R.; Leguit, R. J.; de Leng, W. W.; Morsink, F. H.; Polkowski, W. P.; Maciejewski, R.; Offerhaus, G. J.; Milne, A. N., Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines. Cell Oncol 2009, 31 (6), 475-485. DOI: 10.3233/CLO-2009-0496</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>[70]</ce:label>
                     <sb:reference id="sref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Junyang Lia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Gaoa</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AVNP2 protects against cognitive impairments induced by C6 glioma by suppressing tumour associated inflammation in rats</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Brain Behav. Immun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>87</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>645</sb:first-page>
                              <sb:last-page>659</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bbi.2020.02.009</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0365">Junyang Lia, M. L., Jin Gaoa, et al, AVNP2 protects against cognitive impairments induced by C6 glioma by suppressing tumour associated inflammation in rats. Brain, Behavior, and Immunity 2020, 87, 645-659. DOI: 10.1016/j.bbi.2020.02.009</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>[71]</ce:label>
                     <sb:reference id="sref71">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.H.</ce:given-name>
                                 <ce:surname>Goradel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Asghari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Moloudizargari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Negahdari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Haghi-Aminjan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Abdollahi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Melatonin as an angiogenesis inhibitor to combat cancer: mechanistic evidence</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Toxicol. Appl. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>335</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>56</sb:first-page>
                              <sb:last-page>63</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.taap.2017.09.022</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0370">Goradel, N. H.; Asghari, M. H.; Moloudizargari, M.; Negahdari, B.; Haghi-Aminjan, H.; Abdollahi, M., Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence. Toxicol Appl Pharmacol 2017, 335, 56-63. DOI: 10.1016/j.taap.2017.09.022</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>[72]</ce:label>
                     <sb:reference id="sref72">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:collaboration>OECD</sb:collaboration>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Test No. 425: Acute Oral Toxicity: Up-And-Down Procedure</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2008</sb:date>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0375">OECD, Test no. 425: Acute oral toxicity: Up-and-down procedure. 2008.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>